US20200407721A1 - Compounds of chemically modified oligonucleotides and methods of use thereof - Google Patents
Compounds of chemically modified oligonucleotides and methods of use thereof Download PDFInfo
- Publication number
- US20200407721A1 US20200407721A1 US16/985,779 US202016985779A US2020407721A1 US 20200407721 A1 US20200407721 A1 US 20200407721A1 US 202016985779 A US202016985779 A US 202016985779A US 2020407721 A1 US2020407721 A1 US 2020407721A1
- Authority
- US
- United States
- Prior art keywords
- microrna
- nucleic acid
- seq
- acid sequence
- mir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 title claims abstract description 64
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title description 14
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 165
- 230000014509 gene expression Effects 0.000 claims abstract description 143
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 140
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 93
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 90
- 108700009124 Transcription Initiation Site Proteins 0.000 claims abstract description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 51
- 108020004707 nucleic acids Proteins 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 29
- 206010020880 Hypertrophy Diseases 0.000 claims description 24
- 230000001434 glomerular Effects 0.000 claims description 21
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 21
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 9
- 210000002744 extracellular matrix Anatomy 0.000 claims description 9
- 108091046869 Telomeric non-coding RNA Proteins 0.000 claims description 8
- 238000009825 accumulation Methods 0.000 claims description 7
- 108091007685 MIR541 Proteins 0.000 claims description 5
- 108091007700 MIR543 Proteins 0.000 claims description 5
- 108091008053 gene clusters Proteins 0.000 claims description 5
- 230000034994 death Effects 0.000 claims description 4
- 210000001282 glomerular podocyte Anatomy 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 108700011259 MicroRNAs Proteins 0.000 description 190
- 108091079015 miR-379 Proteins 0.000 description 139
- 108091086215 miR-379 stem-loop Proteins 0.000 description 139
- 241000699670 Mus sp. Species 0.000 description 112
- 108090000623 proteins and genes Proteins 0.000 description 108
- 206010012601 diabetes mellitus Diseases 0.000 description 97
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 59
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 59
- 102100029145 DNA damage-inducible transcript 3 protein Human genes 0.000 description 55
- 101710156077 DNA damage-inducible transcript 3 protein Proteins 0.000 description 55
- 241000282414 Homo sapiens Species 0.000 description 50
- 239000000203 mixture Substances 0.000 description 48
- 239000003795 chemical substances by application Substances 0.000 description 45
- 241000699666 Mus <mouse, genus> Species 0.000 description 44
- 210000003584 mesangial cell Anatomy 0.000 description 39
- 108091034117 Oligonucleotide Proteins 0.000 description 38
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 34
- 102100032443 ER degradation-enhancing alpha-mannosidase-like protein 3 Human genes 0.000 description 34
- 101001016391 Homo sapiens ER degradation-enhancing alpha-mannosidase-like protein 3 Proteins 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 34
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 29
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 108020004459 Small interfering RNA Proteins 0.000 description 27
- 108020004999 messenger RNA Proteins 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 150000003839 salts Chemical class 0.000 description 26
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 26
- -1 ATF3 Proteins 0.000 description 25
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 25
- 210000003734 kidney Anatomy 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 24
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 24
- 108020005004 Guide RNA Proteins 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 239000002585 base Substances 0.000 description 22
- 230000035882 stress Effects 0.000 description 22
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 21
- 229960001052 streptozocin Drugs 0.000 description 21
- 238000011144 upstream manufacturing Methods 0.000 description 21
- 239000002679 microRNA Substances 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 20
- 230000002206 pro-fibrotic effect Effects 0.000 description 19
- 238000001727 in vivo Methods 0.000 description 17
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 16
- 230000000692 anti-sense effect Effects 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 16
- 238000013518 transcription Methods 0.000 description 16
- 230000035897 transcription Effects 0.000 description 16
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 16
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 230000004761 fibrosis Effects 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 206010016654 Fibrosis Diseases 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 230000014616 translation Effects 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- 108020005198 Long Noncoding RNA Proteins 0.000 description 12
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 150000004713 phosphodiesters Chemical group 0.000 description 12
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical class OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 12
- 108020005345 3' Untranslated Regions Proteins 0.000 description 11
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 11
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 208000017169 kidney disease Diseases 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 108091023040 Transcription factor Proteins 0.000 description 10
- 102000040945 Transcription factor Human genes 0.000 description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 101150084233 ago2 gene Proteins 0.000 description 10
- 230000002238 attenuated effect Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 108091089775 miR-200b stem-loop Proteins 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 210000000557 podocyte Anatomy 0.000 description 10
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 101800000733 Angiotensin-2 Proteins 0.000 description 9
- 102400000345 Angiotensin-2 Human genes 0.000 description 9
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 9
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 9
- 102100039315 Cytoplasmic polyadenylation element-binding protein 4 Human genes 0.000 description 9
- 101000745636 Homo sapiens Cytoplasmic polyadenylation element-binding protein 4 Proteins 0.000 description 9
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 9
- 229950006323 angiotensin ii Drugs 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 102100033210 CUGBP Elav-like family member 2 Human genes 0.000 description 8
- 102100037362 Fibronectin Human genes 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 101000944442 Homo sapiens CUGBP Elav-like family member 2 Proteins 0.000 description 8
- 210000000585 glomerular basement membrane Anatomy 0.000 description 8
- 201000001421 hyperglycemia Diseases 0.000 description 8
- 108091086591 miR-882 stem-loop Proteins 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108091033409 CRISPR Proteins 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 108091031190 miR-495 stem-loop Proteins 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000001243 protein synthesis Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 6
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 6
- 101000579354 Homo sapiens PHD finger protein 21A Proteins 0.000 description 6
- 102100028222 PHD finger protein 21A Human genes 0.000 description 6
- 108091034057 RNA (poly(A)) Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 108091055954 miR-377 stem-loop Proteins 0.000 description 6
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 6
- 229920001184 polypeptide Chemical group 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108090000765 processed proteins & peptides Chemical group 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 150000003212 purines Chemical class 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 150000003230 pyrimidines Chemical class 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 5
- 238000012156 HITS-CLIP Methods 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 206010027525 Microalbuminuria Diseases 0.000 description 5
- 102100027352 Pumilio homolog 2 Human genes 0.000 description 5
- 101710087309 Pumilio homolog 2 Proteins 0.000 description 5
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 5
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 5
- 230000003278 mimic effect Effects 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- 201000001474 proteinuria Diseases 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229940113082 thymine Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 229940035893 uracil Drugs 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 208000035657 Abasia Diseases 0.000 description 4
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 4
- 102100022145 Collagen alpha-1(IV) chain Human genes 0.000 description 4
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 4
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 4
- 101000901150 Homo sapiens Collagen alpha-1(IV) chain Proteins 0.000 description 4
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010459 TALEN Methods 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000001668 ameliorated effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000012155 cross-linking immunoprecipitation Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 238000010199 gene set enrichment analysis Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003290 ribose derivatives Chemical group 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000003001 serine protease inhibitor Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 229940126585 therapeutic drug Drugs 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 108091032955 Bacterial small RNA Proteins 0.000 description 3
- 102100032765 Chordin-like protein 1 Human genes 0.000 description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 3
- 101710089250 Heat shock 70 kDa protein 5 Proteins 0.000 description 3
- 101000941971 Homo sapiens Chordin-like protein 1 Proteins 0.000 description 3
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 102100031775 Leptin receptor Human genes 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- LYNKVJADAPZJIK-UHFFFAOYSA-H P([O-])([O-])=O.[B+3].P([O-])([O-])=O.P([O-])([O-])=O.[B+3] Chemical compound P([O-])([O-])=O.[B+3].P([O-])([O-])=O.P([O-])([O-])=O.[B+3] LYNKVJADAPZJIK-UHFFFAOYSA-H 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000003559 RNA-seq method Methods 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 3
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000000523 end stage renal failure Diseases 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 229960005102 foscarnet Drugs 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 108010019813 leptin receptors Proteins 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000009437 off-target effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108091007428 primary miRNA Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- XBCXJKGHPABGSD-UHFFFAOYSA-N 1-methyluracil Chemical compound CN1C=CC(=O)NC1=O XBCXJKGHPABGSD-UHFFFAOYSA-N 0.000 description 2
- NEEVCWPRIZJJRJ-LWRDCAMISA-N 5-(benzylideneamino)-6-[(e)-benzylideneamino]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound C=1C=CC=CC=1C=NC=1C(=O)NC(=S)NC=1\N=C\C1=CC=CC=C1 NEEVCWPRIZJJRJ-LWRDCAMISA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 208000022461 Glomerular disease Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 101000899240 Homo sapiens Endoplasmic reticulum chaperone BiP Proteins 0.000 description 2
- 101000735365 Homo sapiens Poly(rC)-binding protein 4 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108091030146 MiRBase Proteins 0.000 description 2
- 108091027977 Mir-200 Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 2
- 102100039419 Plasminogen activator inhibitor 2 Human genes 0.000 description 2
- 102100034956 Poly(rC)-binding protein 4 Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 229940122055 Serine protease inhibitor Drugs 0.000 description 2
- 101710102218 Serine protease inhibitor Proteins 0.000 description 2
- 102000008847 Serpin Human genes 0.000 description 2
- 108050000761 Serpin Proteins 0.000 description 2
- 238000012167 Small RNA sequencing Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008721 basement membrane thickening Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 206010061989 glomerulosclerosis Diseases 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000012405 in silico analysis Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000011862 kidney biopsy Methods 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 108091090026 miR-3072 stem-loop Proteins 0.000 description 2
- 108091036633 miR-370 stem-loop Proteins 0.000 description 2
- 108091024722 miR822 stem-loop Proteins 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000013059 nephrectomy Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GKMIDMKPBOUSBQ-UHFFFAOYSA-N 1,5-dimethyluracil Chemical compound CC1=CN(C)C(=O)NC1=O GKMIDMKPBOUSBQ-UHFFFAOYSA-N 0.000 description 1
- UJUHACUYECLPGK-UHFFFAOYSA-N 2-amino-6-hydroxyaminopurine Chemical compound NC1=NC(NO)=C2NC=NC2=N1 UJUHACUYECLPGK-UHFFFAOYSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VPLZGVOSFFCKFC-UHFFFAOYSA-N 3-methyluracil Chemical compound CN1C(=O)C=CNC1=O VPLZGVOSFFCKFC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- BLQMCTXZEMGOJM-UHFFFAOYSA-N 5-carboxycytosine Chemical compound NC=1NC(=O)N=CC=1C(O)=O BLQMCTXZEMGOJM-UHFFFAOYSA-N 0.000 description 1
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 1
- FHSISDGOVSHJRW-UHFFFAOYSA-N 5-formylcytosine Chemical compound NC1=NC(=O)NC=C1C=O FHSISDGOVSHJRW-UHFFFAOYSA-N 0.000 description 1
- OHAMXGZMZZWRCA-UHFFFAOYSA-N 5-formyluracil Chemical compound OC1=NC=C(C=O)C(O)=N1 OHAMXGZMZZWRCA-UHFFFAOYSA-N 0.000 description 1
- FFKUHGONCHRHPE-UHFFFAOYSA-N 5-methyl-1h-pyrimidine-2,4-dione;7h-purin-6-amine Chemical compound CC1=CNC(=O)NC1=O.NC1=NC=NC2=C1NC=N2 FFKUHGONCHRHPE-UHFFFAOYSA-N 0.000 description 1
- XZWMZFQOHTWGQE-UHFFFAOYSA-N 6-azathymine Chemical compound CC1=NNC(=O)NC1=O XZWMZFQOHTWGQE-UHFFFAOYSA-N 0.000 description 1
- SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical compound O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 description 1
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000008682 Argonaute Proteins Human genes 0.000 description 1
- 108010088141 Argonaute Proteins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XPEOTKCGRNUVSY-XFCJVXKSSA-N B[C@@H]1O[C@@]2(COC)COC1[C@H]2OC.B[C@H]1C[C@@H](OC)[C@@H](COP(=O)([O-])O[C@@H]2C[C@H](B)O[C@@H]2COC)O1.B[C@H]1C[C@@H](OC)[C@@H](COP([O-])(=S)O[C@@H]2C[C@H](B)O[C@@H]2COC)O1.[H+].[H+] Chemical compound B[C@@H]1O[C@@]2(COC)COC1[C@H]2OC.B[C@H]1C[C@@H](OC)[C@@H](COP(=O)([O-])O[C@@H]2C[C@H](B)O[C@@H]2COC)O1.B[C@H]1C[C@@H](OC)[C@@H](COP([O-])(=S)O[C@@H]2C[C@H](B)O[C@@H]2COC)O1.[H+].[H+] XPEOTKCGRNUVSY-XFCJVXKSSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101150072801 COL1A2 gene Proteins 0.000 description 1
- 101150066399 COL4A1 gene Proteins 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108091035710 E-box Proteins 0.000 description 1
- 102000055765 ELAV-Like Protein 1 Human genes 0.000 description 1
- 108700015856 ELAV-Like Protein 1 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 230000006782 ER associated degradation Effects 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108091093094 Glycol nucleic acid Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000979347 Homo sapiens Nuclear factor 1 X-type Proteins 0.000 description 1
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 1
- 101000611194 Homo sapiens Trinucleotide repeat-containing gene 6A protein Proteins 0.000 description 1
- 101000611192 Homo sapiens Trinucleotide repeat-containing gene 6B protein Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 206010022530 Intercapillary glomerulosclerosis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 101150046735 LEPR gene Proteins 0.000 description 1
- 101150063827 LEPROT gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940113306 Ligase inhibitor Drugs 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 238000012179 MicroRNA sequencing Methods 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 101100500623 Mus musculus Edem3 gene Proteins 0.000 description 1
- 101100350635 Mycoplasma gallisepticum (strain R(low / passage 15 / clone 2)) mgc2 gene Proteins 0.000 description 1
- WIFHSKZDPZUSLN-UHFFFAOYSA-N N(6)-carbamoylmethyladenine Chemical compound NC(=O)CNC1=NC=NC2=C1NC=N2 WIFHSKZDPZUSLN-UHFFFAOYSA-N 0.000 description 1
- CBCQWVQNMGNYEO-UHFFFAOYSA-N N(6)-hydroxyadenine Chemical compound ONC1=NC=NC2=C1NC=N2 CBCQWVQNMGNYEO-UHFFFAOYSA-N 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 102100023049 Nuclear factor 1 X-type Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010007544 Protease Nexins Proteins 0.000 description 1
- 102000007324 Protease Nexins Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 206010038468 Renal hypertrophy Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- DXIOFHTULAODLN-UHFFFAOYSA-N S.S=S.S=S=S.S=S=S=S Chemical compound S.S=S.S=S=S.S=S=S=S DXIOFHTULAODLN-UHFFFAOYSA-N 0.000 description 1
- 101150035628 Serpine1 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102000007374 Smad Proteins Human genes 0.000 description 1
- 108010007945 Smad Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108091046915 Threose nucleic acid Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100040241 Trinucleotide repeat-containing gene 6A protein Human genes 0.000 description 1
- 102100040244 Trinucleotide repeat-containing gene 6B protein Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000007495 abnormal renal function Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- KFEPVFJQVOMODD-SCDVKCJHSA-N chembl467192 Chemical compound C1=C(Br)C(C)=C(Br)C=C1NCC(=O)N\N=C/C1=CC([N+]([O-])=O)=CC=C1O KFEPVFJQVOMODD-SCDVKCJHSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010209 gene set analysis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 231100000853 glomerular lesion Toxicity 0.000 description 1
- 210000002601 glomerular mesangium Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 201000008627 kidney hypertrophy Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000436 ligase inhibitor Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 108091086416 miR-192 stem-loop Proteins 0.000 description 1
- 108091090395 miR-239b stem-loop Proteins 0.000 description 1
- 108091007431 miR-29 Proteins 0.000 description 1
- 108091092564 miR-494 stem-loop Proteins 0.000 description 1
- 108091063861 miR397 stem-loop Proteins 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 108700005673 mouse S1 Proteins 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 230000002580 nephropathic effect Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000007859 posttranscriptional regulation of gene expression Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 229950000329 thiouracil Drugs 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Definitions
- Diabetic nephropathy is one of the most common complications of diabetes and a major cause of renal failure, which requires painful dialysis. Although key therapeutic interventions have been implemented to treat DN, diabetic patients continue to reach end-stage renal disease at alarming proportions. It is therefore imperative to identify new targets. Key features of DN include the expansion and hypertrophy of glomerular mesangial cells (MCs), increased accumulation of extracellular matrix (ECM) proteins such as collagen 1 alpha1 (Col1 ⁇ 1), Col1 ⁇ 2, Col4 ⁇ 1 and fibronectin, and tubulointerstitial fibrosis, podocyte dysfunction and proteinuria.
- MCs glomerular mesangial cells
- ECM extracellular matrix proteins
- tubulointerstitial fibrosis tubulointerstitial fibrosis
- the current disclosure provides, inter alia, an isolated compound including a nucleic acid sequence capable of hybridizing to an RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript; method of treating diabetic nephropathy in a subject with the compound; method of inhibiting expression of a mammalian microRNA-379 megacluster with the compound.
- the compound includes a nucleic acid sequence having a nucleobase analog.
- the nucleic acid sequence includes Locked Nucleic Acid (LNA), 2′-O-alkyl, 2′ O-Methyl, 2′-deoxy-2′fluoro, 2′-deoxy, a universal base, 5-C-methyl, an inverted deoxy abasic residue incorporation, or any combination thereof.
- the nucleic acid sequence may include analogs with positive backbones; non-ionic backbones, modified sugars, and non-ribose backbones (e.g. phosphorodiamidate morpholino oligos).
- the current disclosure provides an isolated compound including a nucleic acid sequence having at least 90% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24.
- the current disclosure further provides a pharmaceutical composition including a compound of this disclosure, and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.
- FIG. 1 depicts an alignment of the upstream sequences of mouse and human microRNA-379 region. Sequence legend: mouse (SEQ ID NO:49); human (SEQ ID NO:50); consensus (SEQ ID NO:51). The transcript of mouse miR-379 is SEQ ID NO: 118, and that of human miR-379 is SEQ ID NO: 119.
- FIGS. 2A-2B are a diagram ( 2 A) and a histogram ( 2 B).
- FIG. 2A is a diagram showing the mega cluster of microRNAs (miRNAs) and their upstream promoter region.
- FIG. 2B depicts bar graphs showing up-regulation of cluster miRNAs and the host long noncoding RNA (lnc-RNA) in glomerular mesangial cells (MC) obtained from glomeruli of diabetic and control mice.
- FIG. 3 is a bar graph showing key cluster miRNAs and the host IncRNA-MGC induced in MC treated with high glucose (HG) or transforming growth factor beta (TGF ⁇ 1).
- FIG. 4 is a diagram showing 5′RACE (Rapid Amplification of cDNA Ends) to clone the cluster and LncRNA-MGC (lncMGC) upstream region.
- FIG. 5 is a bar graph showing that the expression of key indicated targets of miRNAs of the cluster is down-regulated in glomeruli of diabetic mice.
- FIG. 6 is a bar graph showing that Tnrc6b and ER (endoplasmic reticulum) degredation-enhancing alpha-mannosidase-like 3 (EDEM) expression levels are decreased by miR-379 mimic (M) and increased by miR-379 inhibitor (I) oligos in MMCs.
- Tnrc6b and ER endoplasmic reticulum
- EDEM degredation-enhancing alpha-mannosidase-like 3
- FIG. 7 is a bar graph showing that the expression levels of lnc-MGC and key cluster miRNAs are reduced in MMC transfected with an siRNA mixture targeting the lncMGC (silnc-MGC).
- FIG. 8 is a bar graph depicting that diabetes induced increase in expression of key miRNAs and the lnc-MGC in mice glomeruli is ameliorated in CHOP knockout (KO) mice relative to wild type (WT).
- FIG. 9 is a bar graph depicting that expression levels of key miRNA target genes are higher in the glomeruli of CHOP KO mice versus WT mice.
- FIG. 10 is a diagram showing the scheme by which microRNA mega cluster and lnc-MGC can promote the progression of diabetic nephropathy (DN).
- DN diabetic nephropathy
- FIG. 11A is a schematic of genome editing using the RNA-guided Cas9 nucleases from the microbial CRISPR (clustered regularly interspaced short palindromic repeat)-Cas systems for generating miR-379 knock-out mouse.
- FIG. 11B depicts the miR-379 genomic region (SEQ ID NO: 45) complementary regions of five guide RNAs. S1, S2, and S3 are sense guide RNAs; and AS1 and AS2 are antisense guide RNAs.
- FIGS. 12A-12F are bar graphs of normalized expression of microRNAs in the Lnc-MGC, the host of microRNA-379 cluster, under normal (CTR, db/+) and diabetic conditions (db/db or streptozotocin (STZ)).
- FIGS. 12G-12J are bar graphs of normalized expression of Linc-MGC, Mirg (another lncRNA located in the locus of miRNA-379 cluster) under normal (CTR, db/+) and diabetic conditions (db/db or streptozotocin (STZ)).
- FIGS. 12K-12L are bar graphs of Mirg expression under when treated with normal glucose (NG), serum depletion (SD), TGF ⁇ , or high glucose (HG) conditions.
- FIGS. 13A-13D are graphs of normalized mRNA expression of the putative target genes under different treatment conditions.
- FIGS. 14A-14B are bar graphs of normalized Luciferase (Luc) activity of the EDEM3 expression vectors after cotransfection to MMC with miR-379 mimic.
- the data suggests that miR200 family and miR-379 cluster may collaborate to inhibit EDEM3 expression.
- the data also suggests that miR-379 cluster and miR-200b upregulated in diabetic conditions induces DN through hypertrophy and fibrosis mediated by EDEM3 (ER stress).
- FIGS. 15A-15W are bar graphs of normalized RNA expression.
- TM tunicamycin
- FIGS. 16A-16B depict schematics of representative Gapmer designs.
- the basic design of the Gapmers is three LNAs at both 5′ and 3′ ends of oligonucleotides and backbone is phosphorothioated.
- Sequence legend ( FIG. 16B , in order of appearance): SEQ ID NOS: 52-54.
- FIGS. 16C-16L are bar graphs of normalized RNA expression.
- MGC10 transfection inhibited expression of lnc-MGC significantly at 48 hours after MGC10 transfection.
- MCG10 also reduced the expression of lnc-MGC even after TGF ⁇ treatment.
- Some miRNAs in miR-379 cluster were reduced by MCG10 in MMC.
- Several targets (EDEME3, Tnrc6b, and Phf21a) of miR-379 cluster were also upregulated by MGC10, suggesting that downregulation of miR-379 cluster restores the target expression.
- FIGS. 17A-17F demonstrates that MGC10 inhibits miR-379 cluster miRNAs in the mouse kidney in vivo.
- FIG. 17A is a diagram of mouse receiving subcutaneous injection of 5 mg/kg MGC10.
- FIGS. 17B-17F are bar graphs of normalized RNA expression after subcutaneous injection of 5 mg/kg MGC10, which consistently inhibited the expression of lnc-MGC in kidney cortex at 24-72 hours after injection. Three mice in each group were injected. The expression of lnc-MGC ( FIG. 17B ) and miRNAs in the miR-379 cluster, miR-379 ( FIG. 17C ), miR-495 ( FIG. 17D ), miR-377 ( FIG.
- FIG. 18A shows PAS staining images of WT-NS, WT-STZ, STZ-C and STZ-MGC10.
- PAS staining showed mesangial expression and increased glomerular size in diabetic mice compared to that in non-diabetic mice and those were reduced in diabetic mice injected with MGC10.
- FIG. 18B is a bar graph of PAS positive area.
- FIG. 18C is a bar graph of glomerular area.
- FIG. 18D is an image of NS, STZ, STZ+C and STZ+MGC10.
- FIG. 18E is a bar graph of percent area.
- FIGS. 19A-19F are bar graphs of normalized RNA expression showing HMGC10 inhibiting the effects of HG or TGF ⁇ .
- FIG. 19C depicts HMGC10 mediated restoration of miR-370 cluster targets, EDEM3, ATF3, CUGBP2 and CPEB4 which were inhibited by TGF- ⁇ 1 in HMC.
- FIG. 19D depicts significant increase of pro-fibrotic genes, TGF- ⁇ 1, COL1A2, COL4A1, F1 and CTGF in HMC treated with TGF-B1 and their significant inhibition ion HMC transfected with HMGC10.
- FIG. 19E depicts HMGC10 mediated restoration of miR-379 cluster targets, EDEM3, ATF3, CGBP2 and CPEB4 which were inhibited by HG in HMC.
- 19F depicts significant increase of pro-fibrotic genes, TGF- ⁇ 1, COL1A2, COL4A1, FN1 and CTGF in HMC treated with HG which was significantly inhibited by HMGC10. Result are mean+SE in triplicate PCRs from three-four independent culture experiments. *, P ⁇ 0.05.
- FIGS. 20A-20D are depictions of genomic region of mouse with a 36 base pair deletion in the miR-379 locus, generated using the CRISPR/CAS9 system as described in FIG. 11 .
- FIG. 20A represents SEQ ID NO: 46;
- FIG. 20B represents SEQ ID NO: 47;
- FIG. 20C represents SEQ ID NO: 47 with the guide RNAs; and
- FIG. 20D represents SEQ ID NO: 48.
- FIGS. 21A-21B are bar graphs depicting expression levels of miR-379 ( FIG. 21A ) and EDEM3 ( FIG. 21B ) from miR-379 knockout (miR-379KO) mice.
- FIG. 21A depicts relative expression of miR-379 in kidney mesangial cells from three miR-379KO mice compared to wild type mice.
- FIG. 21B depicts relative protein expression of EDEM3 (western blot (left panel) and bar graph (right panel)), a target of miR-379, from miR-379KO mice compared to wild type mice.
- FIG. 22 depicts a schematic of the strategy for replacing a human miR-379 region with a poly(A) signal to terminate transcription of the human miR-379.
- FIG. 23A depicts a bar graph of glomerular basement membrane (GBM) thickness, showing that the GBM thickness was significantly increased in diabetic mice (STZ and STZ-C) compared to non-diabetic mice (NS), and this was attenuated in diabetic mice injected with MGC10 (STZ-MGC10). *, P ⁇ 0.05.
- GBM glomerular basement membrane
- TdT Terminal deoxynucleotidyl transferase
- TUNEL dUTP Nick-End Labeling
- an isolated compound including a nucleic acid sequence capable of hybridizing to an RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript; method of treating diabetic nephropathy in a subject with the compound; method of inhibiting expression of a mammalian microRNA-379 megacluster.
- the compound includes a nucleic acid sequence having a nucleobase analog.
- the nucleic acid sequence includes Locked Nucleic Acid (LNA), 2′-O-alkyl, 2′ O-Methyl, 2′-deoxy-2′fluoro, 2′-deoxy, a universal base, 5-C-methyl, an inverted deoxy abasic residue incorporation, or any combination thereof.
- the nucleic acid sequence may include analogs with positive backbones; non-ionic backbones, modified sugars, and non-ribose backbones (e.g. phosphorodiamidate morpholino oligos).
- the current disclosure provides an isolated compound including a nucleic acid sequence having at least 90% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24.
- the current disclosure further provides a pharmaceutical composition including a compound of this disclosure, and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.
- Nucleic acid or “oligonucleotide” or “polynucleotide” or grammatical equivalents used herein means at least two nucleotides covalently linked together.
- nucleic acid includes single-, double-, multiple-stranded or branched DNA, RNA and analogs (derivatives) thereof.
- modified internucleotide linkage or “internucleotide linkage analogue” and the like refers, in the usual and customary sense, to a non-physiologic linkage between nucleotides.
- phosphorothioate nucleic acid refers to a nucleic acid in which one or more internucleotide linkages are through a phosphorothioate moiety (thiophosphate) moiety.
- the phosphorothioate moiety may be a monothiophosphate (—P(O) 3 (S) 3 ⁇ —) or a dithiophosphate (—P(O) 2 (S) 2 3 ⁇ —).
- one or more of the nucleosides of a phosphorothioate nucleic acid are linked through a phosphorothioate moiety (e.g. monothiophosphate) moiety, and the remaining nucleosides are linked through a phosphodiester moiety (—P(O) 4 3 ⁇ —).
- one or more of the nucleosides of a phosphorothioate nucleic acid are linked through a phosphorothioate moiety (e.g. monothiophosphate) moiety, and the remaining nucleosides are linked through a methylphosphonate linkage.
- all the nucleosides of a phosphorothioate nucleic acid are linked through a phosphorothioate moiety (e.g. a monothiophosphate) moiety.
- phosphorothioate oligonucleotides are from about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length.
- the phosphorothioate nucleic acids herein contain one or more phosphodiester bonds.
- the phosphorothioate nucleic acids include alternate backbones (e.g., mimics or analogs of phosphodiesters as known in the art, such as, boranophosphate, methylphosphonate, phosphoramidate, or O-methylphosphoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press).
- alternate backbones e.g., mimics or analogs of phosphodiesters as known in the art, such as, boranophosphate, methylphosphonate, phosphoramidate, or O-methylphosphoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press).
- the phosphorothioate nucleic acids may include one or more nucleic acid analog monomers known in the art, such as, peptide nucleic acid monomer or polymer, locked nucleic acid monomer or polymer, morpholino monomer or polymer, glycol nucleic acid monomer or polymer, or threose nucleic acid monomer or polymer.
- nucleic acid analog monomers known in the art, such as, peptide nucleic acid monomer or polymer, locked nucleic acid monomer or polymer, morpholino monomer or polymer, glycol nucleic acid monomer or polymer, or threose nucleic acid monomer or polymer.
- Other analog nucleic acids include those with positive backbones; non-ionic backbones, and nonribose backbones, including those described in U.S. Pat. Nos.
- nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.
- Phosphorothioate nucleic acids and phosphorothioate polymer backbones can be linear or branched.
- the branched nucleic acids are repetitively branched to form higher ordered structures such as dendrimers and the like.
- nucleic acid bases refer, in the usual and customary sense, to chemical moieties that can substitute for normal (i.e., physiological) nucleobases (i.e., A, T, G, C and U) in nucleic acids.
- Nucleobase analogs can be categorized as purine analogs and pyrimidine analogs. Purine analogs have a core purine ring structure which is substituted to form a purine analog. Pyrimidine analogs have a core pyrimidine ring structure which is substituted to form a pyrimidine analog.
- nucleobase analogs include, but are not limited to: 1,5-dimethyluracil, 1-methyluracil, 2-amino-6-hydroxyaminopurine, 2-aminopurine, 3-methyluracil, 5-(hydroxymethyl)cytosine, 5-bromouracil, 5-carboxycytosine, 5-fluoroorotic acid, 5-fluorouracil, 5-formylcytosine, 5-formyluracil, 6-azathymine, 6-azauracil, 8-azaadenine, 8-azaguanine, N6-carbamoylmethyladenine, N6-hydroxyadenine, allopurinol, hypoxanthine, thiouracil, locked nucleic acid (LNA), 2′-O-alkyl nucleobase, 2′
- locked nucleic acid is a modified RNA nucleotide.
- LNAs are RNA molecules which possess an extra bridge connecting the 2′ oxygen and 4′ carbon of the ribose moiety.
- the ribose becomes locked in the 3′-endo (North) conformation. Base stacking and backbone pre-organization are enhanced by the locked ribose conformation.
- LNA modification has several advantages, including reduced toxicity, lower dosing, higher affinity and efficient targeting.
- nucleobases refers to the naturally occurring compounds, which form the differentiating component of nucleotides; five bases occur in nature, three of which are common to RNA and DNA (uracil replaces thymine in RNA). Bases are divided into two groups, purines and pyrimidines, based on their chemical structure. Purines are larger, double-ring molecules comprising adenine and guanine, whereas pyrimidines have only a single-ring structure and comprise cytosine and thymine/uracil. Because of the different size of the two types of nucleobases, purines can only base pair with pyrimidines in order to preserve the DNA molecule's constant width. More specifically, the only base pairs that will fit the structure of the particular molecule are adenine-thymine and cytosine-guanine.
- cell as used herein also refers to individual cells, cell lines, or cultures derived from such cells.
- a “culture” refers to a composition comprising isolated cells of the same or a different type.
- Diabetic nephropathy is typically defined by macroalbuminuria—that is, a urinary albumin excretion of more than 300 mg in a 24-hour collection—or macroalbuminuria and abnormal renal function as represented by an abnormality in serum creatinine, calculated creatinine clearance, or glomerular filtration rate (GFR).
- macroalbuminuria that is, a urinary albumin excretion of more than 300 mg in a 24-hour collection
- macroalbuminuria and abnormal renal function as represented by an abnormality in serum creatinine, calculated creatinine clearance, or glomerular filtration rate (GFR).
- GFR glomerular filtration rate
- diabetic nephropathy is characterized by a progressive increase in proteinuria and decline in GFR, hypertension, and a high risk of cardiovascular morbidity and mortality.
- “early stage DN” or “incipient DN” is characterized by microalbuminuria, which is defined as levels of albumin ranging from 30 to 300 mg in a 24-h urine collection.
- Microalbuminuria progresses to overt nephropathy. Renal disease is suspected to be secondary to diabetes in the clinical setting of long-standing diabetes. This is supported by the history of diabetic retinopathy, particularly in type 1 diabetics, in whom there is a strong correlation. The natural history of diabetic nephropathy is a process that progresses gradually over years.
- Renal biopsy findings consistent with diabetic nephropathy in the early stages of DN are mesangial expansion and glomerular basement membrane thickening. Eventual progression of diabetic nephropathy can lead to nodular glomerulosclerosis, also referred to as Kimmelstiel-Wilson disease.
- glomerular hyperfiltration and an increase in GFR. This is believed to be related to increased cell growth and expansion in the kidneys, possibly mediated by hyperglycemia itself.
- Microalbuminuria typically occurs after 5 years in type 1 diabetes.
- Overt nephropathy with urinary protein excretion higher than 300 mg/day, often develops after 10 to 15 years.
- ESRD develops in 50% of type 1 diabetics, with overt nephropathy within 10 years.
- Type 2 diabetes has a more variable course. Patients often present at diagnosis with microalbuminuria because of delays in diagnosis and other factors affecting protein excretion. Fewer patients with microalbuminuria progress to advanced renal disease. Without intervention, approximately 30% progress to overt nephropathy and, after 20 years of nephropathy, approximately 20% develop ESRD. Because of the high prevalence of type 2 compared with type 1 diabetes, however, most diabetics on dialysis are type 2 diabetics.
- Hyperglycemia is known to be a significant risk factor for the development of diabetic nephropathy.
- Hyperglycemia may directly result in mesangial expansion and injury by an increase in the mesangial cell glucose concentration.
- the glomerular mesangium expands initially by cell proliferation and then by cell hypertrophy. Increased mesangial stretch and pressure can stimulate this expansion, as can high glucose levels.
- Transforming growth factor ⁇ TGF- ⁇
- Glucose can also bind reversibly and eventually irreversibly to proteins in the kidneys and circulation to form advanced glycosylation end products (AGEs).
- AGEs can form complex cross-links over years of hyperglycemia and can contribute to renal damage by stimulation of growth and fibrotic factors via receptors for AGEs.
- mediators of proliferation and expansion including platelet-derived growth factor, TGF- ⁇ , and vascular endothelial growth factor (VEGF) that are elevated in diabetic nephropathy can contribute to further renal and microvascular complications.
- VEGF vascular endothelial growth factor
- Proteinuria a marker and potential contributor to renal injury, accompanies diabetic nephropathy. Increased glomerular permeability will allow plasma proteins to escape into the urine. Some of these proteins will be taken up by the proximal tubular cells, which can initiate an inflammatory response that contributes to interstitial scarring eventually leading to fibrosis. Tubulointerstitial fibrosis is seen in advanced stages of diabetic nephropathy and is a better predictor of renal failure than glomerular sclerosis. Hyperglycemia, angiotensin II, TGF- ⁇ , and likely proteinuria itself all play roles in stimulating this fibrosis. There is an epithelial-mesenchymal transition that takes place in the tubules, with proximal tubular cell conversion to fibroblast-like cells. These cells can then migrate into the interstitium and produce collagen and fibronectin.
- ATII Angiotensin II
- ATII itself contributes to the progression of diabetic nephropathy.
- ATII is stimulated in diabetes despite the high-volume state typically seen with the disease, and the intrarenal level of ATII is typically high, even in the face of lower systemic concentrations.
- ATII preferentially constricts the efferent arteriole in the glomerulus, leading to higher glomerular capillary pressures.
- ATII also stimulates renal growth and fibrosis through ATII type 1 receptors, which secondarily upregulate TGF- ⁇ and other growth factors.
- Control of hypertension has clearly shown to be an important and powerful intervention in decreasing the progression of diabetic nephropathy.
- diabetics who have disordered autoregulation at the level of the kidney, systemic hypertension can contribute to endothelial injury.
- Human studies of type 2 diabetics have shown that blood pressure lowering, regardless of the agent used, retards the onset and progression of diabetic nephropathy.
- the degree and severity of the diabetic nephropathy were strongly linked to systemic blood pressure.
- DN diabetic nephropathy
- Diabetic nephropathy include the expansion and hypertrophy of glomerular mesangial cells (MCs), increased accumulation of extracellular matrix (ECM) proteins such as collagen 1alpha1 (Col1 ⁇ 1), Col1 ⁇ 2, Col4 ⁇ 1 and fibronectin, and tubulointerstitial fibrosis, podocyte dysfunction and proteinuria.
- ECM extracellular matrix
- TGF- ⁇ 1 transforming growth factor-beta1
- TGF- ⁇ 1 Factors relevant to the pathogenesis of DN such as angiotensin II, and high glucose (HG), increase TGF- ⁇ 1 expression in MCs in vitro and in vivo.
- Signals from the activated TGF- ⁇ 1 receptor complex are transduced to the nucleus by Smad proteins, including Smad2/3/4, which regulate TGF- ⁇ -induced genes, including PAI-1, collagen and p21cip1/waf1.
- Smad proteins including Smad2/3/4
- TGF- ⁇ -induced genes including PAI-1, collagen and p21cip1/waf1.
- a few microRNAs are involved in mediating the pro-fibrotic effects of TGF- ⁇ 1 in MCs in vitro and diabetic conditions in vivo.
- microRNAs are endogenously produced, short single-stranded non-coding RNAs ( ⁇ 20-23 nucleotides) that play key roles in post-transcriptional regulation of gene expression to silence genes by repressing the translation or inducing the degradation of target mRNAs.
- miRNAs There are more than 1000 mammalian miRNAs that can target nearly 60% of mRNAs in the genome, and therefore, they regulate many key cellular functions.
- miRNA miRNA
- miRNA miRNAs
- LncRNAs Long ncRNAs
- mRNAs messenger RNAs
- TFs transcription factors
- LncRNAs also serve as hosts for miRNAs and/or a miRNA megacluster. LncRNAs have cell-specific expression, and function in various biological processes including transcription, differentiation, and the immune response.
- the microRNA megacluster is a region of the genome where more than 10 microRNA genes are encoded. In embodiments, 35-60 microRNAs are encoded in the region. In embodiments, some of these clustered miRNA genes may be encoded by a single-copy DNA sequence. Alternatively, the miRNA genes may be arranged in tandem arrays of closely related sequences.
- the microRNA-379 transcript is a RNA sequence transcribed from a microRNA-379 gene of a mammalian genome, e.g., a human genome.
- a “transcript” in molecular biology or similar context is a product of transcription.
- miRNAs are transcribed as much larger primary transcripts (pri-miRNAs).
- the vast majority of mature miRNAs are produced from primary transcripts of microRNAs (pri-miRNAs) by a multi-step pathway.
- miRNAs are first transcribed as longer primary transcripts called primary miRNA (pri-miRNA).
- the transcript may contain multiple miRNA stem loops and is capped at the 5′ end through polyadenylation.
- Drosha a nuclear RNase III
- pre-miRNA precursor-miRNA
- This cleavage event is critical and site-specific, as it determines the mature miRNA sequence.
- the pre-miRNA is then exported out of the nucleus for further cleavage into a 22 nt duplex.
- the complementary strand becomes degraded leaving one fully mature miRNA strand.
- Mature miRNA then associate with several members of the Argonaute protein family to form the RNA-induced silencing complex which then binds to specific protein-coding mRNA transcripts, directing mRNA inactivation by translational repression, deadenylation, or degradation.
- plasminogen activator inhibitor-1 is an endothelial plasminogen activator inhibitor or serpin E1 is a protein that in humans is encoded by the SERPINE1 gene.
- PAI-1 is a serine protease inhibitor (serpin) that functions as the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), the activators of plasminogen and hence fibrinolysis (the physiological breakdown of blood clots). It is a serine protease inhibitor (serpin) protein (SERPINE1).
- Other PAI, plasminogen activator inhibitor-2 (PAI-2) is secreted by the placenta and only present in significant amounts during pregnancy.
- protease nexin acts as an inhibitor of tPA and urokinase.
- PAI-1 is the main inhibitor of the plasminogen activators.
- CTGF connective-tissue growth factor
- nucleic acids or polypeptide sequences refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher identity over a specified region when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see,
- sequences are then said to be “substantially identical.”
- This definition also refers to, or may be applied to, the compliment of a test sequence.
- the definition also includes sequences that have deletions and/or additions, as well as those that have substitutions.
- the preferred algorithms can account for gaps and the like.
- identity exists over a region that is at least about 10 amino acids or 20 nucleotides in length, or more preferably over a region that is 10-50 amino acids or 20-50 nucleotides in length.
- percent (%) amino acid sequence identity is defined as the percentage of amino acids in a candidate sequence that are identical to the amino acids in a reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.
- Alignment for purposes of determining percent sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared can be determined by known methods.
- sequence comparisons typically one sequence acts as a reference sequence, to which test sequences are compared.
- test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated.
- sequence algorithm program parameters Preferably, default program parameters can be used, or alternative parameters can be designated.
- sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
- “Patient,” “subject,” “patient in need thereof,” and “subject in need thereof” are herein used interchangeably and refer to a living organism suffering from or prone to a disease or condition that can be treated by administration using the methods and compositions provided herein.
- Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals.
- a patient is human.
- Tissues, cells and their progeny of a biological entity obtained in vitro or cultured in vitro are also contemplated.
- treat include alleviating, abating, ameliorating, or preventing a disease, condition or symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition, and are intended to include prophylaxis.
- the terms further include achieving a therapeutic benefit and/or a prophylactic benefit.
- therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
- a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder.
- prevent include to keep from developing, occur, hinder or avert a disease or condition symptoms as well as to decrease the occurrence of symptoms.
- the prevention may be complete (i.e., no detectable symptoms) or partial, so that fewer symptoms are observed than would likely occur absent treatment.
- the terms further include a prophylactic benefit.
- the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
- inhibitor also means reducing an effect (disease state or expression level of a gene/protein/mRNA) relative to the state in the absence of a compound or composition of the present disclosure.
- test compound refers to an experimental compound used in a screening process to identify activity, non-activity, or other modulation of a particularized biological target or pathway.
- Control or “control experiment” is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is the measurement of the activity of a protein in the absence of a compound as described herein (including embodiments and examples).
- Disease or “condition” refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein. In some instances, “disease” or “condition” refers to diabetes nephropathy (DN).
- DN diabetes nephropathy
- Contacting is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including biomolecules or cells) to become sufficiently proximal to react, interact or physically touch. It should be appreciated; however, the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents which can be produced in the reaction mixture. In some embodiments contacting includes allowing a compound described herein to interact with a protein or enzyme.
- phenotype and “phenotypic” as used herein refer to an organism's observable characteristics such as onset or progression of disease symptoms, biochemical properties, or physiological properties.
- expression means the transcriptional and/or translational product of that sequence.
- the level of expression of a DNA molecule in a cell may be determined on the basis of either the amount of corresponding mRNA that is present within the cell or the amount of protein encoded by that DNA produced by the cell (Sambrook et al., 1989 Molecular Cloning: A Laboratory Manual, 18.1-18.88).
- expression includes any step involved in the production of a polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).
- gene means the segment of DNA involved in producing a protein; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).
- the leader, the trailer as well as the introns include regulatory elements that are necessary during the transcription and the translation of a gene.
- a “protein gene product” is a protein expressed from a particular gene.
- promoter and the like in the usual and customary sense, is a region of DNA that initiates transcription of a particular gene. Promoters are located near the transcription start sites of genes, on the same strand and upstream on the DNA (towards the 5′ region of the sense strand). Upstream and downstream in the usual and customary sense both refer to a relative position in DNA or RNA. Each strand of DNA or RNA has a 5′ end and a 3′ end, so named for the carbon position on the deoxyribose (or ribose) ring. By convention, upstream and downstream relate to the 5′ to 3′ direction in which RNA transcription takes place. Upstream is toward the 5′ end of the RNA molecule and downstream is toward the 3′ end.
- upstream is toward the 5′ end of the coding strand for the gene in question and downstream is toward the 3′ end. Due to the anti-parallel nature of DNA, this means the 3′ end of the template strand is upstream of the gene and the 5′ end is downstream.
- an amount of in reference to a polynucleotide or polypeptide refers to an amount at which a component or element is detected. The amount may be measured against a control, for example, wherein an increased level of a particular polynucleotide or polypeptide in relation to the control, demonstrates enrichment of the polynucleotide or polypeptide.
- the term refers to quantitative measurement of the enrichment as well as qualitative measurement of an increase or decrease relative to a control.
- a derivative is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical agent that is structurally similar to another agent (i.e., a so-called “reference” agent) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of a chiral center of the reference agent.
- a derivative may be a conjugate with a pharmaceutically acceptable agent, for example, phosphate or phosphonate.
- salt refers to acid or base salts of the agents used herein.
- acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid, and the like) salts, and quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts.
- salts are meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
- pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
- inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge et al., Journal of Pharmaceutical Science 66:1-19 (1977)).
- Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present disclosure. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms.
- the preparation may be a lyophilized powder in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5, which is combined with buffer prior to use.
- the compounds of the present disclosure may exist as salts, such as with pharmaceutically acceptable acids.
- the present disclosure includes such salts.
- examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates, ( ⁇ )-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid.
- These salts may be prepared by methods known to those skilled in the art.
- an “adjuvant” (from Latin, adiuvare: to aid) is a pharmacological and/or immunological agent that modifies the effect of other agents.
- a “diluent” (also referred to as a filler, dilutant or thinner) is a diluting agent. Certain fluids are too viscous to be pumped easily or too dense to flow from one particular point to the other. This can be problematic, because it might not be economically feasible to transport such fluids in this state. To ease this restricted movement, diluents are added. This decreases the viscosity of the fluids, thereby also decreasing the pumping/transportation costs.
- administering refer to the act of providing an agent of the current embodiments or pharmaceutical composition including an agent of the current embodiments to the individual in need of treatment.
- co-administer it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of additional therapies.
- the compound or the composition of the disclosure can be administered alone or can be co-administered to the patient.
- Co-administration is meant to include simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent).
- the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation).
- sequential administration includes that the administration of two agents (e.g., the compounds or compositions described herein) occurs separately on the same day or do not occur on a same day (e.g., occurs on consecutive days).
- “concurrent administration” includes overlapping in duration at least in part.
- two agents e.g., any of the agents or class of agents described herein that has bioactivity
- their administration occurs within a certain desired time.
- the agents' administration may begin and end on the same day.
- the administration of one agent can also precede the administration of a second agent by day(s) as long as both agents are taken on the same day at least once.
- the administration of one agent can extend beyond the administration of a second agent as long as both agents are taken on the same day at least once.
- the bioactive agents/agents do not have to be taken at the same time each day to include concurrent administration.
- “intermittent administration” includes the administration of an agent for a period of time (which can be considered a “first period of administration”), followed by a time during which the agent is not taken or is taken at a lower maintenance dose (which can be considered “off-period”) followed by a period during which the agent is administered again (which can be considered a “second period of administration”).
- first period of administration a period of time
- second period of administration a period during which the agent is administered again
- the dosage level of the agent will match that administered during the first period of administration but can be increased or decreased as medically necessary.
- administering means oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject.
- Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal).
- Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and.
- Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
- compositions disclosed herein can be delivered transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
- Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
- the compositions of the present disclosure may additionally include components to provide sustained release and/or comfort.
- Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes.
- the compositions disclosed herein can also be delivered as microspheres for slow release in the body.
- microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, J. Bioniater Sci. Polym. Ed. 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Phann. Res. 12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, J. Phann. Pharmacol. 49:669-674, 1997).
- an “effective amount” or “therapeutically effective amount” is that amount sufficient to affect a desired biological effect, such as beneficial results, including clinical results. As such, an “effective amount” depends upon the context in which it is being applied. An effective amount may vary according to factors known in the art, such as the disease state, age, sex, and weight of the individual being treated. Several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. In addition, the compositions/formulations of this disclosure can be administered as frequently as necessary to achieve a therapeutic amount.
- compositions may include compositions wherein the therapeutic drug (e.g., agents described herein, including embodiments or examples) is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose.
- a therapeutically effective amount i.e., in an amount effective to achieve its intended purpose.
- the actual amount effective for a particular application will depend, inter alia, on the condition being treated.
- compositions When administered in methods to treat a disease, such compositions will contain an amount of therapeutic drug effective to achieve the desired result, e.g., modulating the activity of a target molecule, and/or reducing, eliminating, or slowing the progression of disease symptoms.
- the dosage and frequency (single or multiple doses) administered to a mammal can vary depending upon a variety of factors, for example, whether the mammal suffers from another disease, and its route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated, kind of concurrent treatment, complications from the disease being treated or other health-related problems.
- Other therapeutic regimens or agents can be used in conjunction with the methods and agents of this disclosure. Adjustment and manipulation of established dosages (e.g., frequency and duration) are well within the ability of those skilled in the art.
- the therapeutically effective amount can be initially determined from cell culture assays.
- Target concentrations will be those concentrations of therapeutic drug(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.
- therapeutically effective amounts for use in humans can also be determined from animal models.
- a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals.
- the dosage in humans can be adjusted by monitoring agent's effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.
- Dosages may be varied depending upon the requirements of the patient and the therapeutic drug being employed.
- the dose administered to a patient should be sufficient to effects a beneficial therapeutic response in the patient over time.
- the size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the agent. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. Dosage amounts and intervals can be adjusted individually to provide levels of the administered agent effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
- a weight percent of a component is based on the total weight of the formulation or composition in which the component is included.
- Excipient is used herein to include any other agent that may be contained in or combined with a disclosed agent, in which the excipient is not a therapeutically or biologically active agent/agent. As such, an excipient should be pharmaceutically or biologically acceptable or relevant (for example, an excipient should generally be non-toxic to the individual). “Excipient” includes a single such agent and is also intended to include a plurality of excipients. For the purposes of the present disclosure the term “excipient” and “carrier” are used interchangeably in some embodiments of the present disclosure and said terms are defined herein as, “ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition.”
- the term “about” refers to any minimal alteration in the concentration or amount of an agent that does not change the efficacy of the agent in preparation of a formulation and in treatment of a disease or disorder.
- concentration range of the agents (e.g., therapeutic/active agents) of the current disclosure also refers to any variation of a stated amount or range which would be an effective amount or range.
- Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it is understood that the particular value forms another aspect. It is further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself.
- data are provided in a number of different formats and that this data represent endpoints and starting points and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
- the present disclosure includes an isolated compound including a nucleic acid sequence capable of hybridizing to an RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript or a microRNA-379 megacluster transcript.
- the present disclosure includes an isolated compound including a nucleic acid sequence capable of hybridizing to at least one nucleic acid base of a downstream region of the transcription start site of a mammalian microRNA-379 transcript or a microRNA-379 megacluster transcript.
- the transcript is as exists immediately after transcription, e.g., primary transcript mRNA or pre-mRNA.
- the compound includes a nucleic acid sequence having a nucleobase analog or modified internucleotide linkage.
- the compound includes a nucleic acid sequence having a nucleobase analog.
- the nucleic acid sequence includes Locked Nucleic Acid (LNA), 2′-O-alkyl, 2′ O-Methyl, 2′-deoxy-2′fluoro, 2′-deoxy, a universal base, 5-C-methyl, an inverted deoxy abasic residue incorporation, or any combination thereof.
- the nucleic acid sequence may include analogs with positive backbones; non-ionic backbones, modified sugars, and non-ribose backbones (e.g. phosphorodiamidate morpholino oligos), including those described in U.S. Pat. Nos.
- nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids.
- the nucleic acid sequence includes at least one nucleic acid analog.
- the nucleic acid sequence includes at least one nucleic acid analog having an alternate backbone (e.g. phosphodiester derivative (e.g. phosphoramidate, phosphorodiamidate, phosphorothioate, phosphorodithioate, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phosphonate, boron phosphonate, or O-methylphosphoroamidite), peptide nucleic acid backbone(s), LNA, or linkages).
- a nucleic acid sequence includes or is DNA.
- a nucleic acid sequence includes or is RNA.
- a nucleic acid sequence includes or is a nucleic acid having internucleotide linkages selected from phosphodiesters and phosphodiester derivatives (e.g., phosphoramidate, phosphorodiamidate, phosphorothioate, phosphorodithioate, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phosphonate, boron phosphonate, O-methylphosphoroamidite, or combinations thereof).
- phosphodiesters and phosphodiester derivatives e.g., phosphoramidate, phosphorodiamidate, phosphorothioate, phosphorodithioate, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phosphonate, boron phosphonate, O-methylphosphoroami
- a nucleic acid sequence consists of a nucleic acid having internucleotide linkages selected from phosphodiesters and phosphorothioates.
- a nucleic acid sequence includes or is a nucleic acid having backbone linkages selected from phosphodiesters and phosphorodithioates.
- a nucleic acid sequence includes or is a nucleic acid having phosphodiester backbone linkages.
- a nucleic acid sequence includes or is a nucleic acid having phosphorothioate backbone linkages.
- a nucleic acid sequence includes or is a nucleic acid having phosphorodithioate backbone linkages.
- a nucleic acid sequence in the compound includes a nucleic acid analog (e.g. LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleobases.
- a nucleic acid analog e.g. LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)
- the compound includes a nucleic acid sequence capable of hybridizing to an RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript, where the nucleic acid sequence has an analog (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleobases.
- the compound includes a nucleic acid sequence with an analog (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at 3 nucleobases.
- the nucleobase analog is at the 5′-end or the 3′-end of the nucleic acid sequence.
- the nucleobase analog e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)
- the nucleobase analog e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′-OMe
- the nucleobase analog is at the 5′-end and the 3′-end of the nucleic acid sequence.
- the nucleic acid sequence includes three, four or five nucleobase analogs (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at the 5′-end or the 3′-end of the nucleic acid sequence.
- the nucleic acid sequence includes three, four or five nucleobase analogs (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at the 5′-end and the 3′-end of the nucleic acid sequence.
- the nucleic acid sequence includes three nucleobase analogs (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at the 5′-end or the 3′-end of the nucleic acid sequence.
- the nucleic acid sequence includes three nucleobase analogs (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at the 5′-end and the 3′-end of the nucleic acid sequence
- the compound includes a nucleic acid sequence with a modified internucleotide linkage.
- the modified internucleotide linkage is a phosphorothioate (also known as phosphothioate) linkage.
- nucleic acid analogs are included that may have alternate backbones (e.g.
- phosphodiester derivatives including, e.g., phosphoramidate, phosphorodiamidate, phosphorodithioate, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phosphonate, boron phosphonate, or O-methylphosphoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip.
- the internucleotide linkages in DNA are phosphodiester, phosphodiester derivatives, or a combination of both.
- the compound includes a nucleic acid sequence with internal modified internucleotide linkage between nucleobases at one or more positions. In embodiments, the compound includes a nucleic acid sequence with internal modified internucleotide linkage between nucleobases at one or more positions, and one, two, three, or four nucleobase analogs at the 5′- or the 3′-ends of the nucleic acid sequence. In embodiments, the compound includes a nucleic acid sequence with internal internucleotide phosphorothioate linkage between nucleobases at one or more positions, and one, two, three, or four nucleobase LNA analogs at the 5′- or the 3′-ends of the nucleic acid sequence.
- the compound includes a nucleic acid sequence with internal modified internucleotide linkage between nucleobases at one or more positions, and one, two, three, or four nucleobase analogs at the 5′- and the 3′-ends of the nucleic acid sequence.
- the compound includes a nucleic acid sequence with internal internucleotide phosphorothioate linkage between nucleobases at one or more positions, and one, two, three, or four nucleobase LNA analogs at the 5′- and the 3′-ends of the nucleic acid sequence.
- internucleotide analogyes such as an LNA monomer
- internucleotide linkages such as phosphodiester linkage and phosphorothioate linkage
- the RNA sequence to which a nucleic acid sequence of the present disclosure hybridizes to includes 11 to 27, 61 to 93, 115 to 139, or 246 to 265 nucleobases downstream of the transcription start site of the gene.
- the target site on the RNA sequence to which a nucleic acid sequence of the present disclosure hybridizes to is listed in Table 1.
- the target site range listed in Table 1 (middle column) reflects the nucleobase positions counting from the transcription start site at +1 of a target RNA.
- compound includes, e.g., GATTTGGCATTGGAAG (SEQ ID NO: 21) with internal internucleotide phosphorothioate linkage between one or more nucleobases, and one, two, three, or four nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- the LNA analogs at the 5′ and/or the 3′-ends of the sequence are underlined, e.g., GAT TTGGCATTGG AAG (SEQ ID NO: 21).
- the remaining internal internucleotide linkages between nucleobases are phosphorothioate linkages.
- a compound is, e.g., GATTTGGCATTGGAAG (SEQ ID NO: 21), with internal internucleotide phosphorothioate linkage between one or more nucleobases.
- the compound includes a nucleic acid that binds to the mouse miR-379 transcript including the upstream region of mouse miR-379 and the mouse miR-379 sequence.
- the sequence of the mouse miR-379 transcript including the upstream region of mouse miR-379 and the mouse miR-379 sequence is shown in SEQ ID NO: 118.
- the nucleic acid sequences of SEQ ID NOs: 1-20 hybridize to a region of mouse miR-379 transcript of SEQ ID NO: 25 (the transcription start site indicated with “+1”), i.e., SEQ ID NO: 118; in SEQ ID NO: 118, a uracil (“U”) replaces each thymine (“T”) of SEQ ID NO: 25.
- the compound includes a nucleic acid that binds to the human miR-379 transcript including the upstream region of human miR-379 and the human miR-379 sequence.
- the sequence of the human miR-379 transcript including the upstream region of human miR-379 and the human miR-379 sequence is shown in SEQ ID NO: 119.
- the nucleic acid sequences of SEQ ID NOs: 21-24 hybridize to a region of human miR-379 transcript of SEQ ID NO: 26 (the transcription start site indicated with “+1”), i.e., SEQ ID NO: 119; in SEQ ID NO: 119, a uracil (“U”) replaces each thymine (“T”) of SEQ ID NO: 26.
- the consensus sequence of the mouse and human miR-379 transcript corresponds to a transcript of the consensus sequence provided in SEQ ID NO: 51.
- the compound includes a nucleic acid sequence that is 10 to 30 nucleobases in length. In embodiments, the compound includes a nucleic acid sequence capable of hybridizing at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases within a RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript. In embodiments, the mammalian microRNA-379 transcript is a human microRNA-379 transcript.
- the compound includes a nucleic acid sequence capable of hybridizing at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases within the sequence of SEQ ID NO: 118 or 119.
- the compound includes a nucleic acid sequence capable of hybridizing at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases within 10-20, 10-30, 20-40, 20-50, 40-60, 40-70, 60-80, 60-90, 80-100, 80-110, 100-120, 100-130, 120-140, 120-150, 140-160, 140-170, 160-180, 160-190, 180-200, 180-210, 200-220, 200-230, 220-240, 220-230, 240-260, or 240-270 nucleobases downstream of the transcription start site (indicated with “+1”) of the transcript sequence of SEQ ID NO: 25 or 26 (i.e., transcript sequence SEQ ID NO: 118 or 119), a sequence including the transcript of SEQ ID NO: 25 or 26 (i.e., transcript sequence SEQ ID NO: 118 or 119), or a variation thereof.
- the transcription start site indicated with “+1”
- the compound includes a nucleic acid sequence capable of hybridizing at least 5 nucleobases within the sequence of 10-20, 10-30, 20-40, 20-50, 40-60, 40-70, 60-80, 60-90, 80-100, 80-110, 100-120, 100-130, 120-140, 120-150, 140-160, 140-170, 160-180, 160-190, 180-200, 180-210, 200-220, 200-230, 220-240, 220-230, 240-260, or 240-270 nucleobases downstream of the transcription start site (indicated with “+1”) of the transcript of SEQ ID NO: 25 or 26 (i.e., transcript sequence SEQ ID NO: 118 or 119).
- the compound includes a nucleic acid sequence capable of hybridizing at least 5 nucleobases within a RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript. In embodiments, the compound includes a nucleic acid sequence capable of hybridizing at least 5 nucleobases within a RNA sequence 10-20, 10-30, 20-40, 20-50, 40-60, 40-70, 60-80, 60-90, 80-100, 80-110, 100-120, 100-130, 120-140, 120-150, 140-160, 140-170, 160-180, 160-190, 180-200, 180-210, 200-220, 200-230, 220-240, 220-230, 240-260, or 240-270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript.
- the present disclosure includes a compound including a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, or analogues or derivatives thereof.
- the compound includes a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal modified internucleotide linkage between nucleobases and/or terminal nucleobase analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- the compound includes a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or terminal nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- the nucleobase analogs at the 5′- and/or the 3′ ends may be 2′-O-alkyl nucleobase, 2′-Fluoro nucleobase, or 2′-OMe nucleobase.
- the present disclosure includes a compound including a nucleic acid sequence having at least 90% sequence identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24.
- the compound includes a nucleic acid sequence having at least 90% sequence identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal modified internucleotide linkage between nucleobases and/or terminal nucleobase analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- the compound includes a nucleic acid sequence having at least 90% sequence identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- the nucleobase analogs at the 5′- and the 3′ ends may be 2′-O-alkyl nucleobase, 2′-Fluoro nucleobase, or 2′-OMe nucleobase, and any combination thereof.
- the present disclosure includes a compound including a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24.
- the compound includes a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal modified internucleotide linkage between nucleobases and/or terminal nucleobase analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- the compound includes a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- the nucleobase analogs at the 5′- and/or the 3′ ends may be 2′-O-alkyl nucleobase, 2′-Fluoro nucleobase, or 2′-OMe nucleobase, and any combination thereof.
- the present disclosure provides a complex of a compound including a nucleic acid sequence described in this disclosure hybridized to an RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript or a microRNA-379 megacluster transcript.
- the present disclosure includes a nucleic acid sequence of SEQ ID NOs: 1-20 hybridized to a region of mouse miR-379 transcript of SEQ ID NO: 25 (i.e., transcript sequence SEQ ID NO: 118) to form a complex.
- the present disclosure includes a nucleic acid sequence of SEQ ID NOs: 21-24 hybridized to a region of human miR-379 transcript of SEQ ID NO: 26 (i.e., transcript sequence SEQ ID NO: 119) to form a complex.
- the present disclosure includes a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, or 98-99% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or analogues thereof, hybridized to a region of human miR-379 transcript of SEQ ID NO: 26 (i.e., transcript sequence SEQ ID NO: 119) to form a complex.
- a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, or 98-99% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or analogues thereof, hybridized to a region of human miR-379 transcript of
- the present disclosure includes a complex of a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10, 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence, hybridized to a RNA sequence 10 to 270 nucleobase downstream of the transcription start site of microRNA-379 transcript.
- the present disclosure includes a complex of a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10, 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence, hybridized to a RNA sequence transcript at 10-20, 10-30, 20-40, 20-50, 40-60, 40-70, 60-80, 60-90, 80-100, 80-110, 100-120, 100-130, 120-140, 120-150, 140-160, 140-170, 160-180, 160-190, 180-200, 180
- the present disclosure provides a method of treating diabetic nephropathy in a subject in need thereof, the method including administering to the subject an effective amount of a compound of the present disclosure.
- the present disclosure includes a method of treating diabetic nephropathy in a subject by administering to the subject about 0.001 mg/kg to about 100 mg/kg of a compound of the present disclosure.
- a compound of the present disclosure inhibits renal glomerular podocyte death, glomerular mesangial expansion, glomerular hypertrophy, glomerular extracellular matrix accumulation, thereby treating DN.
- the method of treating diabetic nephropathy in a subject includes administering to the subject a compound or a pharmaceutical composition including a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10, 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, or analogues thereof.
- the method of treating diabetic nephropathy in a subject includes administering to the subject a compound or a pharmaceutical composition including a nucleic acid sequence having a nucleobase analog.
- the nucleic acid sequence includes Locked Nucleic Acid (LNA), 2′-O-alkyl, 2′ O-Methyl, 2′-deoxy-2′fluoro, 2′-deoxy, a universal base, 5-C-methyl, an inverted deoxy abasic residue incorporation, or any combination thereof.
- the nucleic acid sequence may include analogs with positive backbones; non-ionic backbones, modified sugars, and non-ribose backbones (e.g. phosphorodiamidate morpholino oligos).
- the present disclosure includes a method of treating diabetic nephropathy by administering a compound to a subject in need of such treatment, where the compound inhibits expression of a long non-coding RNA (lncMGC) in the subject.
- the method of treating diabetic nephropathy is by administering a compound to a subject in need of such treatment, where the compound inhibits expression of a long non-coding RNA (lncMGC) in the subject, which includes microRNA-376a, microRNA-299, microRNA-376c, microRNA-410, microRNA-494, microRNA-380-5p, microRNA-369-3p, microRNA-300, microRNA-541, microRNA-329, microRNA-381, microRNA-411, microRNA-134, microRNA-379, microRNA-154, microRNA-382, microRNA-376b, microRNA-496, microRNA-409-5p, microRNA-543, microRNA-377, microRNA-380-3p, and/or microRNA-495.
- lncMGC long
- the present disclosure includes a method of treating diabetic nephropathy by administering a compound to a subject, where the compound inhibits expression of a microRNA gene cluster.
- expression of the microRNA gene cluster that is inhibited for treating diabetic nephropathy is microRNA-379 gene cluster.
- the microRNA gene cluster expression of which is inhibited expresses microRNAs such as microRNA-376a, microRNA-299, microRNA-376c, microRNA-410, microRNA-494, microRNA-380-5p, microRNA-369-3p, microRNA-300, microRNA-541, microRNA-329, microRNA-381, microRNA-411, microRNA-134, microRNA-379, microRNA-154, microRNA-382, microRNA-376b, microRNA-496, microRNA-409-5p, microRNA-543, microRNA-377, microRNA-380-3p, and/or microRNA-495.
- microRNAs such as microRNA-376a, microRNA-299, microRNA-376c, microRNA-410, microRNA-494, microRNA-380-5p, microRNA-369-3p, microRNA-300, microRNA-541, microRNA-329, microRNA-381, microRNA-411, microRNA-134, microRNA-379, microRNA-154, microRNA-382, microRNA-376b, microRNA-496, micro
- the sequence of the nucleic acid that inhibits the microRNA for treating diabetic nephropathy is complementary to the microRNA sequence, or complementary to a transcript that includes the targeted microRNA and binds downstream of the transcription start site.
- mouse microRNA targeted for inhibition are listed in Table 3.
- the present disclosure includes a method of treating diabetic nephropathy by administering a compound of the present disclosure, which upregulates microRNA target genes and down-regulates expression of profibrotic genes.
- the compound of the present disclosure up-regulates and down-regulates in kidney mesangial cells.
- the compound of the present disclosure up-regulates target genes, for example, Tnrc6, CUGBP2, CPEB4, Pumillio2, BHC80 EDEM3, and any combination(s) thereof.
- the compound of the present disclosure down-regulates profibrotic genes, for example, pro-fibrotic genes Col1 ⁇ 2, TGF- ⁇ 1, Col1 ⁇ 4, Plasminogen activator inhibitor-1 (PAI-1), fibronectin, connective tissue growth factor (CTGF), and any combination(s) thereof.
- PAI-1 Plasminogen activator inhibitor-1
- fibronectin fibronectin
- CTGF connective tissue growth factor
- the compound of the present disclosure treats diabetic nephropathy at an early stage of the disease.
- the diabetic nephropathy is characterized as having glomerular lesions including glomerular basement membrane thickening, mild mesangial expansion, severe mesangial expansion, nodular sclerosis (Kimmelstiel-Wilson lesions), or advanced diabetic glomerulosclerosis.
- the present disclosure provides a method of inhibiting expression of a mammalian microRNA-379, the method includes hybridizing a compound of the present disclosure to an RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript.
- the method of inhibiting expression of a mammalian microRNA-370 cluster includes contacting a cell or tissue with a nucleic acid sequence of SEQ ID NOs: 1-24.
- the method of inhibiting expression of a mammalian microRNA-370 cluster includes contacting a cell or tissue with a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10, 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- the method of inhibiting expression of a mammalian microRNA-370 cluster includes contacting a kidney mesangial cell with a nucleic acid sequence of SEQ ID NOs: 1-24. In embodiments, the method of inhibiting expression of a mammalian microRNA-370 cluster includes contacting a kidney mesangial cell with a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10, 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- the present disclosure provides a pharmaceutical composition including a compound of the present disclosure and a pharmaceutically acceptable diluent, carrier, salt, and/or adjuvant.
- the pharmaceutical composition of the present disclosure includes a nucleic acid sequence of SEQ ID NOs: 1-24.
- the pharmaceutical composition of the present disclosure includes a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10, 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- the present disclosure includes administering to an individual, a composition of a therapeutically effective amount of a compound including a nucleic acid sequence of SEQ ID NOs: 1-24, alone or in combination with a diabetic and/or diabetic nephropathic agent.
- the effective dose of the composition may be between about 0.001 mg/kg to about 100 mg/kg of compound.
- the compositions may have between about 0.1% to about 20% of the pharmaceutical composition.
- the compositions may include pharmaceutically acceptable diluent(s), excipient(s), and/or carrier(s).
- composition of a compound including a nucleic acid sequence of SEQ ID NOs: 1-24 may be administered with a suitable pharmaceutical carrier.
- the administration can be local or systemic, including oral, parenteral, intraperitoneal, intrathecal or topical application.
- the release profiles of such composition may be rapid release, immediate release, controlled release or sustained release.
- the composition may comprise a sustained release matrix and a therapeutically effective amount.
- a composition of a compound including a nucleic acid sequence of SEQ ID NOs: 1-24 can be secreted by genetically modified cells that are implanted, either free or in a capsule, at the gut of a subject.
- a composition of a compound including a nucleic acid sequence of SEQ ID NOs: 1-24 may be administered to a subject via subcutaneous route.
- the composition may be administered as an oral nutritional supplement.
- Oral compositions may include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral administration, a composition of a compound including a nucleic acid sequence of SEQ ID NOs: 1-24 can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the agent in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or agents of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, primogel, or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, primogel, or corn starch
- a lubricant such as magnesium stearate or sterotes
- a glidant such as colloidal silicon dioxide
- parenteral including subcutaneous, intramuscular, and intravenous
- parenteral including subcutaneous, intramuscular, and intravenous
- inhalation buccal, sublingual, nasal, rectal, topical, or oral administration for treating a viral infection, for inducing immune response, for treating neuroinflammation.
- parenteral including subcutaneous, intramuscular, and intravenous
- inhalation including subcutaneous, intramuscular, and intravenous
- buccal sublingual
- nasal rectal
- topical topical
- oral administration for treating a viral infection, for inducing immune response, for treating neuroin
- composition of the present disclosure may be formulated in dosage unit form for ease of administration and uniformity of dosage.
- Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the individual to be treated; each unit containing a predetermined quantity of agent calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms are dictated by and directly dependent on the unique characteristics of the agent and the particular therapeutic effect to be achieved.
- Example 1 Small RNA (miRNA)-Sequencing Revealed Mega Cluster of miRNAs was Up-Regulated Under Diabetic Conditions
- RNA obtained from the glomeruli of streptozotocin (STZ) diabetic and control mice was profiled by miRNA-sequence and the Illumina sequencing data analyzed.
- a significant increase in the expression of several miRNAs was found (e.g. miR-379, -495, -377) ( FIG. 2B ) that are among the mega cluster of miRNAs within mouse Chr12 ( FIG. 2A ).
- Genome organization showed that the miRNA mega cluster is hosted downstream of the lncRNA termed lnc-MGC, with another reported lncRNA, Mirg, present in this locus ( FIG. 2A ).
- Lnc-MGC expression (5′ and 3′) was also increased under these diabetic conditions ( FIG. 2B ), p ⁇ 0.05. Furthermore, apart from the region upstream of lnc-MGC, no clear putative promoter was evident throughout the cluster, indicating that the miRNA cluster and lncRNA may be co-transcribed together as one unit, i.e., lnc-MGC may be induced under diabetic conditions and this up-regulates key miRNAs of the, cluster as one transcript, which encompasses a long ncRNA that functionally serves as host for the mega miRNA cluster.
- Mouse MC was treated with high glucose (HG, 25 mM), mannitol or TGF- ⁇ 1 and several miRNAs within the cluster, (and lnc-MGC), was examined by amplifying these regions with specific PCR primers.
- miR-882 outside the cluster was unaffected.
- Small RNA (sm-RNA) sequencing was performed as previously described. Scatter plot of miRNAs in kidney glomeruli from control (CTR) and diabetic mice (STZ) were generated. The expression of each detectable miRNA in the form of log scaled reads was plotted with x-axis for CTR and y-axis for STZ. Each dot represents one miRNA. All the miRNAs in the miR-379 cluster were presented in red. Among them, the upregulated miRNAs with fold change ⁇ 2) were highlighted with bigger size dots and labeled with the corresponding miRNA names. miR-882 was plotted in blue as a negative control (outside of miR-379 cluster).
- each detectable miRNA within the miR-379 cluster in the two samples were ordered by log 2 fold change from low to high, mean-centered and shown in the heatmap. Green represents lower than average expression in the 2 samples and red presents higher than average expression level. The expression of the detected miRNAs in this cluster was higher in STZ than CTR.
- the mouse miR-379 megacluster is located within the largest miRNA cluster currently identified in the genome. It maps within the DLK-DIO 3 genomic region (mouse chr 12, human chr14), which is home to several miRNAs and lncRNAs. TSS, transcription start site. miR-882 is located far-upstream of miR-379 cluster and not covered by lnc-MGC.
- All the miRNAs detected by smRNA-seq with at least 5 scaled reads in at least one sample are ranked by log 2 fold change between STZ and CTR samples to generate ranked list and all the detectable miRNAs in cluster are considered as a gene set.
- CHOP Protein Levels are Up-Regulated in the Glomeruli of Diabetic Db/Db and STZ-Injected Mice
- Chromatin immunoprecipitation (ChIP) assays were performed to evaluate CHOP enrichment at the miR379 promoter.
- CHOP occupancy at the CHOP binding site of the miR-379 promoter arrows
- NG normal glucose
- SD serum-depleted
- CHOP siRNA significantly attenuated HG- and TGF- ⁇ 1-induced expression of miR-379 and lnc-MGC. Mir-495 and -377 expression were also inhibited. In addition to these miRNAs, similar trends were observed for 29 other cluster miRNAs that were tested, i.e. these 29 were significantly up-regulated in diabetic mice glomeruli and in response to TGF- ⁇ 1, and increases of the most of them were inhibited by CHOP siRNA in MC. Cumulatively, these results indicate that CHOP is a key transcriptional regulator of the miRNA cluster and related lncRNA-MGC.
- miRNA target prediction algorithms predicted that numerous miRNAs in the mega cluster collectively targeted similar genes. Therefore, the 3′ UTRs of at least 25 genes were similarly targeted by 8-13 cluster miRNAs, with some genes having more than two miRNA target sites. Furthermore, it was found that these target genes had functions already related to DN, namely protein synthesis, ER stress, RNA binding proteins and protein translation (as determined by in silico GSEA (Gene Set Enrichment Analysis), IPA (Ingenuity Pathway Analysis), as well as Gene ontology analyses). This indicated that miRNAs in the mega cluster work in unison to alter the expression of groups of similar genes that can functionally modulate DN progression.
- GSEA Gene Set Enrichment Analysis
- IPA Ingenuity Pathway Analysis
- RNA binding proteins and translational regulators included RNA binding proteins and translational regulators (CUGBP2), Pumilio2, Tnrc6b, CPEB4, HuR, TFs and co-factors (Arid2, BHC80), Nf1a/b), an ER stress modulator (EDEM3), and the cell growth gene phosphatase and tensin homolog (Pten).
- CUGBP2 RNA binding proteins and translational regulators
- Pumilio2, Tnrc6b include HuR, TFs and co-factors (Arid2, BHC80), Nf1a/b), an ER stress modulator (EDEM3)
- EDEM3 ER stress modulator
- Pten cell growth gene phosphatase and tensin homolog
- TGF- ⁇ 1 or HG can reduce the mRNA expression levels of Tnrc6, CUGBP2, CPEB4, Pumilio2, BHC80 and EDEM3 in MCs in vitro, and in the glomeruli of diabetic mice in vivo (db/db and STZ), relative to controls ( FIG. 5 ; *p ⁇ 0.05).
- These genes are known to regulate protein translation, protein synthesis, mRNA stability (e.g., CUGBP2) and miRNA processing (Tnrc6b).
- BHC80 interacts with histone deacetylases (HDACs) and the Ets TFs to promote chromatin condensation (86). Therefore, it is indicated that these targets mediate the downstream effects of the corresponding miRNAs in a cooperative and synergistic manner, to augment renal hypertrophy and fibrosis, and thereby enhance renal dysfunction in DN ( FIG. 10 ).
- CHOP siRNA treatment significantly prevented a key miRNA target (TNRC6) from being down-regulated by HG and TGF- ⁇ . Furthermore, in parallel, transfection of CHOP siRNA into MMCs also prevented increases in the TGF- ⁇ 1 induced expression of key pro-fibrotic genes Col1 ⁇ 2, TGF- ⁇ 1, Col1 ⁇ 4 and PAI-1 which are associated with DN. Consistently, CHOP siRNA also prevented TGF- ⁇ 1 induced MC hypertrophy and protein content. These data indicate that inducing key mega cluster miRNAs can regulate MC genes and functions associated with DN pathogenesis through CHOP.
- Oligonucleotide mimics and inhibitors of miRNAs, and siRNAs and corresponding control oligos were obtained from Integrated DNA technologies (IDT) or Thermo Fisher Scientific Inc. (Waltham, Mass.), as described. Wild-type (WT) MMCs (from WT C57BL/6 mice), MMC transfected with CHOP siRNA, and MMCs from CHOP-KO mice were treated with HG, mannitol and TGF- ⁇ 1 as described. Briefly, cells ( ⁇ 10 6 /transfection) were transfected with siRNA or miRNA oligonucleotides using an Amaxa Nucleofector (Lonza, Basel, Switzerland) according to the manufacturer's protocols as described previously. siRNAs (double-stranded oligos of three pairs of sense (S) and antisense (AS) synthesized oligos,
- Non-targeting siRNA controls were obtained from Thermo Fisher Scientific Inc. MMC were trypsinized and resuspended in Basic Nucleofection Solution at 1 ⁇ 10 7 /ml. Subsequently, 100 ⁇ l of cell suspension (1 ⁇ 10 6 cells) was mixed with miRNA mimic, hairpin inhibitor oligonucleotides, or ON-TARGET plus siRNA or negative controls (Thermo Fischer Scientific Inc., Waltham, Mass.). Transfected cells were harvested for RNA and protein extraction. RNA was extracted from the cells and the expression of lncRNA-MGC, and all 40 miRNAs within the cluster were systematically examined using primers designed for each of the mature miRNAs.
- MMCs were transfected with oligonucleotide mimics, siRNAs of candidate miRNAs or negative control (NC) oligos to determine if manipulating their levels can influence TGF- ⁇ 1 and HG responses.
- oligonucleotide mimics siRNAs of candidate miRNAs or negative control (NC) oligos to determine if manipulating their levels can influence TGF- ⁇ 1 and HG responses.
- NC negative control
- EDEM3 is a direct target of miR-379 was tested.
- 3′UTR of mouse EDEM3 gene was cloned into psiCheck2 vector and co-transfected to MMC with miR-379 mimic.
- miR-379 inhibited luciferase activity of this reporter, which suggested EDEM3 is a direct target of miR-379.
- a potential target site of miR-200b/c was found in the 3′UTR of EDEM3.
- miR-200b inhibited the reporter activity. Because miR-200b/c are also known to be upregulated in glomeruli from diabetic mouse and MMC treated with TGF- ⁇ 1, miR200 family and miR-379 cluster may collaborate to inhibit EDEM3 expression.
- miR-379 and miR-200b had no effect on the reporter with partial deletion of region which includes miR-379 and miR-200b/c sites from 3′UTR of EDEM3, those sites are real targets of miR-379 and miR-200b. Those results also suggest that miR-379 cluster and miR-200b upregulated in diabetic conditions induces DN through hypertrophy and fibrosis mediated by EDEM3 (ER stress).
- TM tunicamycin
- HSPA5 heat shock 70 kDa protein 5
- GRP78 glycose-regulated protein, 78 kDa
- FIGS. 15D-15I The expression of lncMGC and miRNAs in the cluster was increased by the TM ( ⁇ 50 ng/ml) ( FIGS. 15D-15I ), suggesting that TM (ER stress) induces this cluster expression in MMC.
- Faster migrating isoform of EDEM3 protein was detected in TM-treated cells by western blot while no such isoform was detected in MMC treated with TGF- ⁇ ( FIG. 15K ).
- TM ER stress
- DN phenotypes hypertrophy and fibrosis
- siRNAs to target lnc-MGC which are located upstream of miR-379 were designed.
- transfecting this silnc-MGC into MMCs decreased both basal and TGF- ⁇ -induced expression not only of lncRNA-MGC, but also of the key cluster miRNAs 379, -495 and -377, without affecting miR-882, located outside the cluster ( FIG. 7 p ⁇ 0.05).
- silnc-MGC RNAs down-regulate lnc-MGC, and thereby down-regulate the component cluster miRNAs and their functions.
- MCs were serum starved and tested with or without TGF- ⁇ 1 for 24 hours. Cells were then UV crosslinked, sonicated and immunoprecipitated using an Ago2 antibody. Ago-associated RNA was purified then sequenced for RNA and miRNA on the Illumina Hiseq platform. The levels of 3′ UTR RNAs of the Col1 ⁇ 1 gene, which were enriched in control Ago2-IP samples (CTR), were decreased by TGF- ⁇ 1. The results indicate that, under CTR conditions, Ago2 miRNA complexes bind to the 3′ UTR of Col1 ⁇ 1 RNAs. This is attenuated by TGF- ⁇ , which decreases specific miRNAs such as miR-29 to up-regulate Col1 ⁇ 1. These data suggest the feasibility of CLIP-seq experiments.
- Example 5 Inhibition of lncMGC by Gapmers In Vivo
- GapmeRs were synthesized and obtained from Exiqon (Vedbaek, Denmark) according to the following design strategy: MGC1, TCAaaaacataacGCC [SEQ ID NO:55]; MGC5, CACggtgctgaaaGAG [SEQ ID NO:56]; MGC8, TGAaggccacactAAC [SEQ ID NO:57]; MGC10, ATTtggcagtgggAAG [SEQ ID NO: 58], (uppercase: LNA; lowercase: DNA, full phosphorothioate).
- LNA modification has several advantages, including less toxicity, lower dosing and efficient targeting.
- Basic design of these Gapmers is three LNAs at both 5′ and 3′ ends of oligonucleotides and backbone is phosphorothioated ( FIG. 16B ).
- MMC were transfected with those Gapmers and the expression of lnc-MGC was examined.
- MGC10 consistently inhibited expression of lnc-MGC significantly at 48 hours after MGC10 transfection in two independent experiments although others did not with that consistency ( FIGS. 16C-16D ).
- MGC10 also reduced the expression of lnc-MGC even after TGF- ⁇ treatment ( FIG. 16E ).
- miRNAs in miR-379 cluster were confirmed to be reduced by MGC10 in MMC ( FIGS. 16F-16H ).
- targets EAEME3, Tnrc6b and Phf21a
- FIGS. 16I-16L show that down-regulation of miR-379 cluster restores the target expression.
- MGC10 was effective to reduce the expression of miR-379 cluster in MMC in vitro, it was also tested in mouse kidney in vivo ( FIGS. 17A-17F ).
- miRNAs in the cluster miR-379, miR-495, and miR-377) were also reduced in the same samples ( FIGS. 17C-F ).
- Those results suggest that MGC10 is effective in vivo in mouse kidney to reduce the expression of lnc-MGC and miR-379 cluster.
- the antisense in situ LNA modified probe was designed.
- MGC10 Clear accumulation of MGC10 was observed in the kidney injected with MGC10 although very week background in the kidney injected with vehicle (PBS). Phosphorothioated oligonucleotides can be transported into nucleus by a protein complex (TCP1 complex). Because MGC10 is fully phosphorothioated, it may be efficiently transported into nucleus and cleaved lncMGC RNA and suppressed the expression of miR-379 cluster.
- TCP1 complex protein complex
- MGC10 was tested in STZ injected diabetic mice. Five non-diabetic mice, five diabetic without injection, six diabetic mice with injection of negative control oligonucleotides and six diabetic mice with MGC10 injection were examined. lnc-MGC expression was higher in the kidney from diabetic mice than that from non-diabetic mice and interestingly, its expression was reduced in kidney from diabetic mice injected with MGC10, suggesting that MGC10 is effective even in diabetic mice. miRNAs in the miR-379 cluster behaved the similar patterns to lnc-MGC while no significant change of the expression of miR-882 (outside of miR-379 cluster) was observed.
- Targets (EDEM3, TRNC6B, CPEB4, Pumilio2) of miR-379 cluster were reduced in kidney from diabetic mice and it was restored in the kidney from diabetic mice injected with MGC10.
- PAS staining showed mesangial expansion and increased glomerular size in diabetic mice compared to that in non-diabetic mice and those were reduced in diabetic mice injected with MGC10 ( FIGS. 18A-18C ).
- MGC10 can prevent glomerular fibrosis and hypertrophy in diabetic mice.
- IHC of EDEM3, a target of miR-379 showed the significant decrease in kidney glomeruli from diabetic mice and that was restored in that from diabetic mice injected with MGC10 ( FIGS. 18D-18E ).
- Those results demonstrate that MGC10 inhibits miR-379 and restore the EDEM3 and suppress the ER-stress in diabetic kidney. Serum profiling of those mice showed no significant difference in liver or kidney toxicity by MGC10 injection.
- Example 6 Human Version of lncMGC and miRNA-379 Cluster and the Inhibition by Humanized Gapmer HMGC10
- HMC human mesangial cells
- HMGC10 human version of MGC10
- Basic chemistry was the same as mouse version of MGC10.
- D33 was the best (regarding viability and transfection efficiency).
- hlnc-MGC and miR-379 cluster miRNAs were reduced by transfection of HMGC10 in HMC, suggesting that the same strategy can be useful to suppressed cluster miRNAs in human cells and may be useful to treat DN patients.
- HMGC10 can inhibit the effects by HG or TGF- ⁇ in HMC.
- Human lncMGC expression was significantly inhibited by HMGC10 even after TGF- ⁇ treatment ( FIG. 19A ). Similar trends were observed in the expression of miR-379, miR-495 and miR-377 but not miR-822 which is out of miR-379 cluster, suggesting that inhibition of hlncMGC (host RNA) by HMGC10 resulted in reduction of the expression of miRNAs in the cluster in HMC treated with TGF- ⁇ ( FIGS. 19A-19B ).
- Targets (EDEM3, CPEB4, Pumilio2 and CUGBP2) of the cluster miRNAs were also examined and reduction of target expression was attenuated by HMGC10 treatment in HMC treated with TGF- ⁇ ( FIGS. 19C and 19E ).
- Those results suggest that reduction of hlncMGC by HMGC10 suppressed the expression of miR-379 cluster miRNAs and restored the expression of targets and also inhibited the expression of profibrotic genes in HMC even after treatment of TGF- ⁇ .
- HMGC10 Similar to TGF- ⁇ results, hlncMGC expression was significantly inhibited by HMGC10 in HMC treated with HG.
- the reduction of target expression (EDEM3, CPEB4 and CUGBP2) was attenuated by HMGC10 treatment in HMC treated with HG.
- Induction of profibrotic genes (TGF-b1, COL1A2, COL4A1, FN1 and CTGF) by HG was also attenuated by HMGC10 in HMC.
- RNA isolated from micro-dissected glomeruli of kidney biopsies from 46 Scios with documented type-2 diabetes Total RNA was isolated using spin-columns; miRNA expression was quantified using qRT-PCR performed using TaqMan Array Human MicroRNA Card (Applied Biosystems) and small RNA-sequencing. Samples were normalized to geometric mean of reference RNAs. Expression of miRNA precursors was determined in micro-dissected glomeruli of nephrectomy samples using Affymetrix Human Gene 2.1 ST 24-Array. The cluster miRNAs were expressed robustly in these diabetic patient samples with read frequency comparable to miR-192, which are highly enriched in the kidney and mediate important mechanisms in diabetic nephropathy (DN).
- DN diabetic nephropathy
- DN is associated with glomerular hypertrophy, mesangial expansion and loss of podocytes leading to glomerulosclerosis.
- increased expression of the precursors of some of the cluster miRNAs is associated with morphometric parameters of increased glomerular damage in micro-dissected glomeruli of human nephrectomy tissue samples that showed various stages of glomerular pathology similar to early stages diabetic glomerulopathy. These include decreased podocyte density and increased podocyte and glomerular volume as well as mesangial index, suggesting that cluster miRNA expression increases with glomerular damage.
- These associations suggest that inhibition of cluster miRNAs may also ameliorate human glomerular diseases including DN.
- HG diabetic conditions
- TGF- ⁇ 1 which upregulates miR-379 cluster targeting ER stress regulators and protein synthesis that resulted in hypertrophy and ER stress in mouse kidney related to DN
- lnc-MGC host noncoding RNA
- CHOP CHOP siRNA inhibited the induction of lnc-MGC and miR-379 cluster miRNAs and the early features (ECM expression and cellular hypertrophy) of DN.
- miRNAs in this cluster target several groups of genes, transcription factors, RNA binding proteins regulating gene expression and protein synthesis and ER stress, which results in hypertrophy by increased protein synthesis and fibrosis by accumulation of ECM (profibrotic genes). Induction of those miRNAs was inhibited in the kidney from diabetic CHOPKO mice compared to those from WT mice. Similarly induction of those miRNAs and profibrotic genes by TGF- ⁇ was prevented in MMC from CHOPKO mice. A known ER stress inducer TM also induces lnc-MGC and miR-379 cluster miRNAs in MMC through reduction of N-glycosylation of EDEM3. Therefore, induction of lnc-MGC in diabetes may also be mediated by ER stress.
- Gapmer inhibiting lnc-MGC can be developed as new drugs to prevent or treat the early stage of DN.
- TGF- ⁇ or diabetic conditions induce glomerular podocyte dysfunction and death.
- MGC10 podocyte effacement and glomerular basement membrane (GBM) thickness using electron microscopy was assessed (summarized in the bar graph depicted in FIG. 23A ). Clear protection from diabetes induced podocyte effacement and GBM thickening was observed in diabetic mice treated with the MGC10 compared to control oligo.
- TdT Terminal deoxynucleotidyl transferase
- TUNEL dUTP Nick-End Labeling
- CHOP KO mice developed diabetes at the same rates as WT mice.
- mice Four weeks after diabetes induction, mice were sacrificed. Diabetes-induced mice increased in the key cluster miRNAs, as well as in the lnc-MGC, which occurred in the glomeruli of WT mice, were abrogated in the glomeruli of diabetic CHOP KO mice ( FIG. 8 ).
- the expression of profibrotic genes Col1 ⁇ 2, Col4 ⁇ 1 and TGF- ⁇ 1 were also attenuated in glomeruli from diabetic CHOP KO mice compared to diabetic WT mice.
- MMCs were cultured from non-diabetic WT and CHOP KO mice, with or without TGF- ⁇ 1.
- TGF- ⁇ 1 induced increases in cellular hypertrophy were also ameliorated in MMCs from CHOP KO compared to WT mice.
- both the basal and TGF- ⁇ 1 induced expression of fibrotic genes, Col1 ⁇ 1, Col4 ⁇ 1 and TGF- ⁇ 1 were significantly decreased in MMC from the CHOP KO mice compared to WT.
- both the basal and TGF- ⁇ 1-induced increases in tree key cluster miRNAs and the lnc-RNA-MGC were also ameliorated in MMC derived from CHOP KO mice, compared to MMCs from WT mice.
- TALENs Transcription Activator-Like Effector Nuclease
- TALENs designed and generated to target and delete two genomic regions in the miRNA cluster are used. The first is knockout of miR-379 and the upstream promoter, aimed to interrupt both miR-379 and lnc-MGC expression. The second is to delete the entire mega cluster region. These TALENs are tested in vitro for their readiness to inject directly into mouse embryos, for the rapid and efficient generation of KO mice.
- Example: 8 Identify the Molecular Mechanisms by which Diabetic Conditions (HG and TGF- ⁇ 1) Upregulate the miRNA Mega Cluster and its Host Transcript, lncRNA-MGC
- the CHOP binding sites are cloned and nearby regions of the promoter into luciferase reporters. These constructs are transfected into MMC and treated with or without HG (25 mM), mannitol (19.5 mM) and incubated for 24-72 hours; TGF- ⁇ (10 ng/mL is added, and is incubated for 6-24 hours). MMCs pre-treated with or without CHOP specific siRNAs or negative control siRNAs, or MMC from WT versus CHOP KO mice is treated with HG, mannitol or TGF- ⁇ 1 to determine if losing CHOP reduces promoter transactivation.
- Chromatin immunoprecipitation (ChIP) assays with a CHOP antibody are used to evaluate CHOP occupancy at the promoter regions in response to TGF- ⁇ 1 and HG in MMCs.
- ChIP-qPCRs amplify the desired promoter genomic region and an unrelated control region.
- Western blots are used to determine CHOP protein levels.
- Wild type (WT) MMCs, MMC transfected with CHOP siRNA and MMCs from CHOP KO mice are treated with HG, mannitol and TGF- ⁇ 1.
- RNA is extracted from the cells and the expression of lncRNA-MGC, and all 40 miRNAs within the cluster are systematically examined using primers designed for each of the mature miRNAs. This is supported by data indicating nearly 30 of the cluster miRNAs were induced in MMCs by TGF- ⁇ 1 but inhibited by CHOP siRNAs.
- RNA-seq can be identified by combining RNA-seq with ChIP-seq to identify domains marked with H3K4me3 (promoter mark), H3K36me3 (gene body), and enhancers (H3K4me1). Therefore, antibodies for these three chromatin marks are used to perform ChIP, and then use the ChIP-enriched DNA to sequence (ChIP-seq) this specific genomic region. The results verify whether the lncRNA and miRNAs within the cluster have their own promoters, or if they are transcribed as one unit.
- MMCs are pre-treated with a mixture of siRNAs designed to target the lnc-MGC, and then treat them ⁇ TGF- ⁇ 1 or HG. Determining expression levels for all 40 miRNAs reveals if some or all are down regulated by the siRNAs.
- Example 9 Determine the Functional Significance of MCs Up-Regulating Key Component miRNAs of the Mega Cluster and Down-Regulating their Key Targets in Response to HG and TGF- ⁇ 1
- Putative target genes that are targeted by multiple miRNAs within the cluster and have functions related to DN include TNRC6B, CUGBP2, CPEB4, Pumilio2 (RNA binding proteins that regulate translation) and BHC80 (a transcription factor) and are common targets of multiple miRNAs including miR-379.
- Others, including HuR (RNA binding proteins), FoxP2, NF1A, Arid2 (TFs and co-factors) have binding sites in their 3′ UTRs for 9 to 18 of the cluster miRNAs.
- EDEM3 a protein related to ER-associated degradation, is a miR-379 target with interesting functions. Decreasing EDEM3 through miR-379 will cause unfolded proteins to accumulate resulting in glomerular hypertrophy. Hence ER stress may induce further ER stress through the miR-379-EDEM3 pathway ( FIG. 10 ).
- 3′UTRs of the genes listed above are cloned downstream of a luciferase reporter gene.
- MMCs are transfected with the constructs (sense and antisense), and negative control oligos, and treated with or without TGF- ⁇ 1, or with mimics or inhibitors of key selected miRNAs that target the genes discussed above (including miR-379, -377 and -495). It is expected that miRNA mimics will decrease, and inhibitors will increase, the luciferase activity of reporters that contain 3′-UTRs from bona fide target genes.
- the miRNA binding sites in the 3′ UTRs of targets identified experimentally are mutated to verify that the inhibitory effects of the mimics are lost.
- the protein and mRNA levels of these genes are also determined by Western blotting and RT-qPCR, respectively, as described.
- Select candidate megacluster miRNAs is selected, whose expression, according to miRNA-seq, is increased at least 1.5-2-fold under diabetic conditions, e.g., the 28-30 miRNAs identified in the studies.
- mRNA expression profiles induced by TGF- ⁇ 1 in MMCs is compared (transcriptome profiling by RNA-seq) with the micro RNA profiles, to identify genes whose mRNA expression patterns inversely correlate with miRNA expression.
- the 3′-UTRs of these mRNAs (in the USCS and ENSEMBLE genome browsers) is aligned with the differentially expressed miRNAs to identify potential targets.
- TargetScan The results are compared with publically available miRNA target prediction sites in TargetScan, miRBase, PicTar and DIANA-microT 3.0.
- Targets predicted by two or more databases and conserved among rat, human and mouse species are pooled. Particular attention is paid to those miRNA, whose predicted targets have functions related to MC dysfunction and DN.
- IPA Pathway analyses software
- GSEA GSEA
- the ClIP-seq (HITS-CLIP) method can generate sequencing data for both miRNAs and their complementary (target) mRNAs bound to Ago2 in RISCs (RNA-inducing silencing complex), genome-wide.
- Ago2-CLIP-Seq coupled with bioinformatics is used to identify specific megacluster miRNAs and their targets bound to Ago2 in control and TGF- ⁇ 1-treated MMC.
- the results reveal mechanisms of action and the in vivo functional roles of the miRNA cluster.
- MMCs are treated with and without TGF- ⁇ 1 for 24 hours, then UV crosslinked and immunoprecipitated with Ago2 antibody.
- Ago2 associated mRNAs and miRNAs are isolated, transcribed into cDNAs, and libraries prepared for small and regular RNAs for sequencing (Iluminia). From the smRNA-seq CLIP data, the abundance of each mouse miRNA (miRBase v20) in each sample is determined by processing the raw reads. For target mRNA-seq CLIP data, reads in each sample are first aligned to the mouse genome assembly (NCBI GRCm38) using TopHat2.
- Ago2-binding clusters (containing reads that are significantly greater than background signal) are identified using the pooled, uniquely-aligned reads from all samples. Reads are summarized and normalized to obtain Ago2-binding cluster levels in each sample. Ago2 binding clusters across all the samples and replicates for each condition, and regions that differentially bind Ago2 between the two conditions are identified.
- the CLIP data and potential miRNA target sites predicted using base pair searches and existing tools like TargetScan are analyzed together to identify bona fide miRNA-mRNA interactions in control and TGF- ⁇ 1-treated MCs.
- each Refseq mRNA is determined by regular RNA-seq of the MC samples without IP, summarized, normalized and compared between the two conditions using Bioconductor package “edgeR.”
- the miRNA-mRNA interactions are integrated and identified by CLIP assays with the related changes in gene expression to further verify the interactions and reveal the potential effects of up-regulating cluster miRNAs on target gene expression levels.
- the potential functions of target mRNAs is determined with respect to DN using in silico analyses, including GO, WA, network and motif analysis of the identified targets. Mega cluster miRNAs whose expression was co-modulated, or mega cluster target genes that contain multiple, closely related miRNA binding sites, are also identified by comparing data obtained under the two conditions. The expression levels of target mRNAs and corresponding proteins is assessed by qPCR and Western blots respectively.
- MMCs are transfected with oligonucleotide mimics, inhibitors of candidate miRNAs (miR-379, -495, -377), or NC oligos to determine whether manipulating the levels of their putative target genes can influence TGF- ⁇ 1 and HG responses.
- miRNA target genes fibrosis and hypertrophy related genes and proteins induced by TGF- ⁇ 1/HG is determined by RT-qPCR and Western blotting. Cellular hypertrophy, oxidant and ER stress markers are assayed.
- the gain and loss of function of key target genes including EDEM3, CUGB2, Tnrc6, BHC80 are tested.
- Example 10 Functional Roles of the miRNA Cluster and Lnc-MGC in DN Progression In Vivo
- miRNAs and their targets identified in MCs in vitro are regulated in mouse models of T1D- and T2D-associated DN in vivo using: 1) STZ-injected T1D mouse models of DN in which increases in expression f 30 of the cluster miRNAs was observed, 2) Male T2D leptin receptor deficient db/db mice (Strain BKS. CG-m+/+lepr db/J) at 10-14 weeks of age (101-103). db/db mice are obese, insulin resistant and diabetic by 6-8 weeks, and develop renal dysfunction by 10-12.
- db/db mice are compared with age-matched controls (db/+, glucose ⁇ 150 mg/dL).
- age-matched controls db/+, glucose ⁇ 150 mg/dL.
- Akita T1D mice in the DBA2J background which develop features of DN that are more overt than the STZ model.
- Mice diet-induced obese (DIO) mice C57BL/6J) on 14 week high fat diets (60 kcal percent fat), and controls on standard diets. DIO mice are insulin resistant, have mild hyperglycemia, elevated triglycerides and fibrosis/inflammation in glomeruli.
- Blood pressure, changes in physiology (blood glucose, urinary protein, albumin, creatinine), and the histology and morphology of the renal cortex are monitored regularly and at sacrifice.
- kidneys are dissected from all the mice, and cortical tissues and glomeruli isolated, then either flash frozen for RNA/protein extraction, or used to prepare MMCs.
- RT-QPCR is used to compare the basal levels of the miRNAs and their candidate target genes in glomeruli.
- CHOP KO mice and their controls are made diabetic by STZ injections. At 4, 12 and 16-20 weeks post-diabetes development, key features of DN are assessed in these mice.
- the expression levels of fibrotic genes, TGF- ⁇ 1, 40 of the mega cluster miRNAs, and lnc-MGC, in glomeruli are determined at each time point. At least 10 mice per group are studied per time point and experiments are performed in triplicate.
- LNA modification has several advantages, including less toxicity, lower dosing and efficient targeting.
- LNA-modified anti-miR-379 is designed, and the control LNAs target miR-239b, which is expressed in Caenorhabditis elegans .
- To target lnc-MGC in vivo Gapmer technology is adopted/used.
- LNATM longRNA GapmeRs are newly available antisense oligos that are used to functionally analyze mRNAs and lncRNAs. They contain a central stretch (gap) of DNA monomers flanked by blocking of LNA-modified nucleotides (http://www.exiqon.com/gamper).
- LNA blocks increase the oligos' target affinity and nuclease resistance and the DNA gap induces RNase H cleavage of the target RNA after binding.
- the gapmers are 14-16 nucleotides in length and are fully phosphorothioated.
- Exiqon's advanced design algorithms design the most potent LNATM longRNA GapmeRs that have minimal off-target effects and high success rates.
- LNA-anti-miR-379 or LNA-anti-lnc-MGC are injected subcutaneously twice weekly into control and STZ-injected DBA2J mice, which develop more sever DN than C57BL6 mice. The progression of key structural, histological and molecular features of DN is followed for up to 20 weeks as described.
- the anti-miR-379 and anti-lnc-MGC are evaluated in these in vivo translational studies.
- miR-379 knockout (KO) mouse was generated.
- the genome editing using the RNA-guided Cas9 nucleases from the microbial CRISPR (clustered regularly interspaced short palindromic repeat)-Cas systems was used to generate gene knockout mouse.
- a paired nickase strategy was used for engineering a system to ameliorate off-target activity. Paired nicking method can reduce off-target activity by 50- to 1,500-fold in cell lines and to facilitate gene knockout in mouse zygotes without sacrificing on-target cleavage efficiency.
- a double nickase strategy was used to delete mouse miR-379 genomic region with less off-target.
- Five guide RNAs, three sense (S1, S2, and S3) and two antisense (AS1 and AS2) were designed (shown in FIG. 11B ). Positions and actual sequences of oligonucleotides to construct expression vectors (e.g., PX461, EGFP; PX462, or Puromycine (PX461 and PX462 are plasmid names; the double strand DNA made from designed and synthesized sense and antisense oligos were cloned into the plasmid vectors.
- the guide RNAs are expressed from the plasmids.
- PX461 has EGFP gene to monitor the transfection by GFP.
- PX462 has Puromycine resistance gene to select the cells by drug (Puromycine) resistance) are listed below.
- S1 is one of the target sequences.
- S15 is synthesized oligonucleotides for sense strand with extra 5′ overhang (CACC) for cloning.
- S1AS is synthesized oligonucleotides for antisense strand with extra 5′ overhang (AAAC) for cloning.
- S1S and S1AS are complimentary and annealed double strand DNA (S1S/S1AS) has 5′ overhang for cloning.
- Small “g” is transcription start site in the expression vector. Likewise, in the remaining target sequences listed above.
- TCMK cells human kidney cell line
- activity of genome editing at miR-370 locus was tested with several combinations of those guide RNAs (sense and antisense). Since the combination S2 and AS1 showed the best activity, this combination was injected into fertilized eggs to make mutant mice.
- guide RNAs Two strategies are used to inject guide RNAs.
- guide RNAs are injected into pronuclei of fertilized eggs with plasmids expressing guide RNAs and nickase.
- the guide RNA is transcribed in vitro and nickase RNA is injected into cytoplasm of fertilized eggs.
- the first strategy required injecting the same plasmids used for cell line transfection in vitro.
- T7-transcribed guide RNAs were made.
- guide RNA part in the plasmids was amplified with primers with T7-promoter and reverse primer for guide RNA (below).
- T7-S2 (SEQ ID NO: 42) TTAATACGACTCACTATAGGGATGGTAGACTATGGAACGT T7-AS1 (SEQ ID NO: 43) TTAATACGACTCACTATAGGGTTAGTGGACCATGTTACAT gRNA-R (SEQ ID NO: 44) AAAAGCACCGACTCGGTGCC
- the amplified PCR products were used as template for in vitro transcription of guide RNAs using T7 in vitro transcription kit. Seven mice were obtained from plasmid injection and fourteen mice were obtained from RNA injection experiments. The short deletion of miR-379 genomic region was tested by fragment analysis in the PCR fragment amplified from tail DNA.
- FIG. 20A-B shows the 36 base-pair deletion in the miR-379 locus of a mouse generated using the CRISPR/CAS9 system described in this disclosure.
- a colony of mice possessing the 8F deletion was generated by crossing heterozygotes to produce homozygotes.
- the colony was expanded and mice were used for characterization of miR-379 knockout as well as for experiments of type 1 diabetes (STZ-induced) and high fat diet (HFD).
- Kidney mesangial cells (MC) from three miR-379 KO mice were cultured in vitro and expression of miR-379 was significantly reduced compared to MC from wild type mice ( FIG. 21A ).
- One of the targets of miR-379 was confirmed significantly increased in miR-370K0 mice compared to MC from wild type mice ( FIG. 21B ). These mice were also used for in vitro experiments in diabetic conditions (high glucose, TGF- ⁇ , and other treatments.
- miR-379 cluster Another method to stop the transcription of lnc-MGC (miR-379 cluster) was also established, as depicted in FIG. 22 .
- miR-379 region For replacement of miR-379 region with poly(A) signal sequence, ⁇ 200 bases oligonucleotide was designed (below) which includes 5′ and 3′ homologous sequences to miR-379 region (underline) and minimum BGH poly(A) sequence in the middle (italics).
- DNA ligase inhibitor (SCR7) was also used to enhance recombination.
- ⁇ 100 eggs were injected with Cas9 nickase mRNA, two guide RNAs (S2 & AS1) and SCR7 (ligase inhibitor inhibiting end joining and enhancing replacement). Twenty two (22) mice were born and twenty-one (21) mice survived. By PCR screening, five founders were identified as four full insertion (7F, 9M, 10M, 18M) and one partial insertion (8F). These mice were crossed with wild-type B6 mice and confirmed replacement. The line with partial insertion was designated as 51536 and full insertion was S1543. These lines were expanded for further experiment.
- the method to insert poly(A) signal are applicable to stop any kinds of transcripts (coding or noncoding) if guide RNAs are designed for specific targets.
- sequences of potential targets e.g., 51 below
- sequences of oligos for cloning e.g., S1S and S1AS
- S1S and S1AS sequences of oligos for cloning
- S1 TTCCGTGGTTCCTGAAGAGATGG [SEQ ID NO: 120]
- S1S CACCgTTCCGTGGTTCCTGAAGAGA [SEQ ID NO: 121]
- S1AS AAACTCTCTTCAGGAACCACGGAAc [SEQ ID NO: 27]
- S2 CCTGAAGAGATGGTAGACTATGG (same as mouse S1)
- SEQ ID NO: 28 S2S: CACCgCCTGAAGAGATGGTAGACTA
- S2AS AAACTAGTCTACCATCTCTTCAGGc [SEQ ID NO: 30]
- S3S CACCgGATGGTAGACTATGGAACGT
- S3AS AAACACGTTCCATAGTCTACCATCc [SEQ ID NO: 82]
- S4 GATTTCTGACCTATGTAACAT
- S1, S2, S3, S4, AS1, and AS2 are sequences of potential targets. Sequences of oligos for cloning are under the each target sequences.
- S1S is sequence of sense oligo for S1
- S1AS is sequence of antisense oligo for S1.
- They are designed for constructing expression vectors for miR-379 target genes (e.g., PX461, EGFP; PX462, or Puromycine (PX461 and PX462 are plasmid names; the double strand DNA made from designed and synthesized sense and antisense oligos were cloned into the plasmid vectors.
- the guide RNAs are expressed from the plasmids.
- PX461 has EGFP gene to monitor the transfection by GFP.
- PX462 has Puromycine resistance gene to select the cells by drug (Puromycine) resistance).
- Possible combinations include: S1-AS2, S2-AS1, S3-AS1, S3-AS2, and S4-AS2. Additional sets of possible combinations include S1S-S1AS, S4S-S4AS, AS1S-AS1AS, AS2S-AS2AS. Delivery of plasmids expressing these guide RNAs and CAS9 nickase (or other CAS9 derivatives, for example, fusion with repressor) into human kidney reduces human lnc-MGC and miRNA-379 cluster and prevents DN.
Abstract
Description
- This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/166,533, filed May 26, 2015 which is incorporated herein by reference in its entirety for all purposes.
- This invention was made with Government support under Grant No. NIH R01 DK081705 awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The Government has certain rights to this invention.
- The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is entitled 48440-565001US_ST25.txt, was created on May 23, 2016, and is 30,720 bytes in size. The information in the electronic format of the Sequence Listing is part of the present application and is incorporated herein by reference in its entirety.
- Diabetic nephropathy (DN) is one of the most common complications of diabetes and a major cause of renal failure, which requires painful dialysis. Although key therapeutic interventions have been implemented to treat DN, diabetic patients continue to reach end-stage renal disease at alarming proportions. It is therefore imperative to identify new targets. Key features of DN include the expansion and hypertrophy of glomerular mesangial cells (MCs), increased accumulation of extracellular matrix (ECM) proteins such as
collagen 1 alpha1 (Col1α1), Col1α2, Col4α1 and fibronectin, and tubulointerstitial fibrosis, podocyte dysfunction and proteinuria. - The current disclosure provides, inter alia, an isolated compound including a nucleic acid sequence capable of hybridizing to an
RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript; method of treating diabetic nephropathy in a subject with the compound; method of inhibiting expression of a mammalian microRNA-379 megacluster with the compound. - In embodiments, the compound includes a nucleic acid sequence having a nucleobase analog. In embodiments, the nucleic acid sequence includes Locked Nucleic Acid (LNA), 2′-O-alkyl, 2′ O-Methyl, 2′-deoxy-2′fluoro, 2′-deoxy, a universal base, 5-C-methyl, an inverted deoxy abasic residue incorporation, or any combination thereof. In embodiments, the nucleic acid sequence may include analogs with positive backbones; non-ionic backbones, modified sugars, and non-ribose backbones (e.g. phosphorodiamidate morpholino oligos).
- The current disclosure provides an isolated compound including a nucleic acid sequence having at least 90% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24. The current disclosure further provides a pharmaceutical composition including a compound of this disclosure, and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.
- Other features and advantages of the disclosure will be apparent from the following detailed description and claims.
- Unless noted to the contrary, all publications, references, patents and/or patent applications reference herein are hereby incorporated by reference in their entirety for all purposes.
-
FIG. 1 depicts an alignment of the upstream sequences of mouse and human microRNA-379 region. Sequence legend: mouse (SEQ ID NO:49); human (SEQ ID NO:50); consensus (SEQ ID NO:51). The transcript of mouse miR-379 is SEQ ID NO: 118, and that of human miR-379 is SEQ ID NO: 119. -
FIGS. 2A-2B are a diagram (2A) and a histogram (2B).FIG. 2A is a diagram showing the mega cluster of microRNAs (miRNAs) and their upstream promoter region.FIG. 2B depicts bar graphs showing up-regulation of cluster miRNAs and the host long noncoding RNA (lnc-RNA) in glomerular mesangial cells (MC) obtained from glomeruli of diabetic and control mice. -
FIG. 3 is a bar graph showing key cluster miRNAs and the host IncRNA-MGC induced in MC treated with high glucose (HG) or transforming growth factor beta (TGFβ1). -
FIG. 4 is a diagram showing 5′RACE (Rapid Amplification of cDNA Ends) to clone the cluster and LncRNA-MGC (lncMGC) upstream region. -
FIG. 5 is a bar graph showing that the expression of key indicated targets of miRNAs of the cluster is down-regulated in glomeruli of diabetic mice. -
FIG. 6 is a bar graph showing that Tnrc6b and ER (endoplasmic reticulum) degredation-enhancing alpha-mannosidase-like 3 (EDEM) expression levels are decreased by miR-379 mimic (M) and increased by miR-379 inhibitor (I) oligos in MMCs. -
FIG. 7 is a bar graph showing that the expression levels of lnc-MGC and key cluster miRNAs are reduced in MMC transfected with an siRNA mixture targeting the lncMGC (silnc-MGC). -
FIG. 8 is a bar graph depicting that diabetes induced increase in expression of key miRNAs and the lnc-MGC in mice glomeruli is ameliorated in CHOP knockout (KO) mice relative to wild type (WT). -
FIG. 9 is a bar graph depicting that expression levels of key miRNA target genes are higher in the glomeruli of CHOP KO mice versus WT mice. -
FIG. 10 is a diagram showing the scheme by which microRNA mega cluster and lnc-MGC can promote the progression of diabetic nephropathy (DN). -
FIG. 11A is a schematic of genome editing using the RNA-guided Cas9 nucleases from the microbial CRISPR (clustered regularly interspaced short palindromic repeat)-Cas systems for generating miR-379 knock-out mouse.FIG. 11B depicts the miR-379 genomic region (SEQ ID NO: 45) complementary regions of five guide RNAs. S1, S2, and S3 are sense guide RNAs; and AS1 and AS2 are antisense guide RNAs. -
FIGS. 12A-12F are bar graphs of normalized expression of microRNAs in the Lnc-MGC, the host of microRNA-379 cluster, under normal (CTR, db/+) and diabetic conditions (db/db or streptozotocin (STZ)).FIGS. 12G-12J are bar graphs of normalized expression of Linc-MGC, Mirg (another lncRNA located in the locus of miRNA-379 cluster) under normal (CTR, db/+) and diabetic conditions (db/db or streptozotocin (STZ)).FIGS. 12K-12L are bar graphs of Mirg expression under when treated with normal glucose (NG), serum depletion (SD), TGFβ, or high glucose (HG) conditions. -
FIGS. 13A-13D are graphs of normalized mRNA expression of the putative target genes under different treatment conditions. -
FIGS. 14A-14B are bar graphs of normalized Luciferase (Luc) activity of the EDEM3 expression vectors after cotransfection to MMC with miR-379 mimic. The data suggests that miR200 family and miR-379 cluster may collaborate to inhibit EDEM3 expression. The data also suggests that miR-379 cluster and miR-200b upregulated in diabetic conditions induces DN through hypertrophy and fibrosis mediated by EDEM3 (ER stress). -
FIGS. 15A-15W are bar graphs of normalized RNA expression.FIGS. 15C, 15K, and 15O depict western blots. MMC was treated with tunicamycin (TM), a known ER stress inducer, and the expression of miR-379 cluster was tested. -
FIGS. 16A-16B depict schematics of representative Gapmer designs. The basic design of the Gapmers is three LNAs at both 5′ and 3′ ends of oligonucleotides and backbone is phosphorothioated. Sequence legend (FIG. 16B , in order of appearance): SEQ ID NOS: 52-54.FIGS. 16C-16L are bar graphs of normalized RNA expression. MGC10 transfection inhibited expression of lnc-MGC significantly at 48 hours after MGC10 transfection. MCG10 also reduced the expression of lnc-MGC even after TGFβ treatment. Some miRNAs in miR-379 cluster were reduced by MCG10 in MMC. Several targets (EDEME3, Tnrc6b, and Phf21a) of miR-379 cluster were also upregulated by MGC10, suggesting that downregulation of miR-379 cluster restores the target expression. -
FIGS. 17A-17F demonstrates that MGC10 inhibits miR-379 cluster miRNAs in the mouse kidney in vivo.FIG. 17A is a diagram of mouse receiving subcutaneous injection of 5 mg/kg MGC10.FIGS. 17B-17F are bar graphs of normalized RNA expression after subcutaneous injection of 5 mg/kg MGC10, which consistently inhibited the expression of lnc-MGC in kidney cortex at 24-72 hours after injection. Three mice in each group were injected. The expression of lnc-MGC (FIG. 17B ) and miRNAs in the miR-379 cluster, miR-379 (FIG. 17C ), miR-495 (FIG. 17D ), miR-377 (FIG. 17E ) were inhibited by subcutaneous injection of 5 mg/kg MGC10, while miR-882 outside of the cluster was not (FIG. 17F ). Three mice were injected for each condition and each time point. Gene expression quantified in cortical samples are shown. Results are mean+SE in triplicate PCRs from each mouse, *, P<0.05. These results suggest that MGC10 is effective to reduce the expression of lnc-MGC and miR-379 cluster miRNAs. -
FIG. 18A shows PAS staining images of WT-NS, WT-STZ, STZ-C and STZ-MGC10. PAS staining showed mesangial expression and increased glomerular size in diabetic mice compared to that in non-diabetic mice and those were reduced in diabetic mice injected with MGC10.FIG. 18B is a bar graph of PAS positive area.FIG. 18C is a bar graph of glomerular area.FIG. 18D is an image of NS, STZ, STZ+C and STZ+MGC10.FIG. 18E is a bar graph of percent area. These results showed that MGC10 inhibits miR-379 and restore the EDEM3 and suppress the ER-stress in diabetic kidney. -
FIGS. 19A-19F are bar graphs of normalized RNA expression showing HMGC10 inhibiting the effects of HG or TGFβ.FIGS. 19A and 19B depict Human homologue of lnc-MGC (hlnc-MGC) and its inhibition by HMGC10 in human MC. Significant increase of hlnc-MGC, miR-379, miR-494, miR495, miR-377 in human MC (HMC) treated with TGF-β1 (FIG. 19A ) or HG (FIG. 19B ) relative to respective controls (SD or NG), but not miR-882 (outside of miR-379 cluster). These increases were significantly reduced in HMC transfected with HMGC10 compared to control oligo.FIG. 19C depicts HMGC10 mediated restoration of miR-370 cluster targets, EDEM3, ATF3, CUGBP2 and CPEB4 which were inhibited by TGF-β1 in HMC.FIG. 19D depicts significant increase of pro-fibrotic genes, TGF-β1, COL1A2, COL4A1, F1 and CTGF in HMC treated with TGF-B1 and their significant inhibition ion HMC transfected with HMGC10.FIG. 19E depicts HMGC10 mediated restoration of miR-379 cluster targets, EDEM3, ATF3, CGBP2 and CPEB4 which were inhibited by HG in HMC.FIG. 19F depicts significant increase of pro-fibrotic genes, TGF-β1, COL1A2, COL4A1, FN1 and CTGF in HMC treated with HG which was significantly inhibited by HMGC10. Result are mean+SE in triplicate PCRs from three-four independent culture experiments. *, P<0.05. -
FIGS. 20A-20D are depictions of genomic region of mouse with a 36 base pair deletion in the miR-379 locus, generated using the CRISPR/CAS9 system as described inFIG. 11 .FIG. 20A represents SEQ ID NO: 46;FIG. 20B represents SEQ ID NO: 47;FIG. 20C represents SEQ ID NO: 47 with the guide RNAs; andFIG. 20D represents SEQ ID NO: 48. -
FIGS. 21A-21B are bar graphs depicting expression levels of miR-379 (FIG. 21A ) and EDEM3 (FIG. 21B ) from miR-379 knockout (miR-379KO) mice.FIG. 21A depicts relative expression of miR-379 in kidney mesangial cells from three miR-379KO mice compared to wild type mice.FIG. 21B depicts relative protein expression of EDEM3 (western blot (left panel) and bar graph (right panel)), a target of miR-379, from miR-379KO mice compared to wild type mice. -
FIG. 22 depicts a schematic of the strategy for replacing a human miR-379 region with a poly(A) signal to terminate transcription of the human miR-379. Sequence legend: SEQ ID NO: 117. -
FIG. 23A depicts a bar graph of glomerular basement membrane (GBM) thickness, showing that the GBM thickness was significantly increased in diabetic mice (STZ and STZ-C) compared to non-diabetic mice (NS), and this was attenuated in diabetic mice injected with MGC10 (STZ-MGC10). *, P<0.05.FIG. 23B depicts a bar graph of cell death measured by Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay, showing that cell death was significantly increased (increase in TUNEL positive cells) in diabetic mice (STZ and STZ-C) compared to non-diabetic mice (NS), and this was attenuated in diabetic mice injected with MGC10 (STZ-MGC10). *, P<0.05. - Provided herein is, inter alia, an isolated compound including a nucleic acid sequence capable of hybridizing to an
RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript; method of treating diabetic nephropathy in a subject with the compound; method of inhibiting expression of a mammalian microRNA-379 megacluster. - In embodiments, the compound includes a nucleic acid sequence having a nucleobase analog. In embodiments, the nucleic acid sequence includes Locked Nucleic Acid (LNA), 2′-O-alkyl, 2′ O-Methyl, 2′-deoxy-2′fluoro, 2′-deoxy, a universal base, 5-C-methyl, an inverted deoxy abasic residue incorporation, or any combination thereof. In embodiments, the nucleic acid sequence may include analogs with positive backbones; non-ionic backbones, modified sugars, and non-ribose backbones (e.g. phosphorodiamidate morpholino oligos).
- The current disclosure provides an isolated compound including a nucleic acid sequence having at least 90% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24. The current disclosure further provides a pharmaceutical composition including a compound of this disclosure, and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.
- The following definitions are included for the purpose of understanding the present subject matter and for constructing the appended patent claims. Abbreviations used herein have their conventional meaning within the chemical and biological arts.
- Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art. See, e.g., Singleton et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY 2nd ed., J. Wiley & Sons (New York, N.Y. 1994); Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, Cold Springs Harbor Press (Cold Springs Harbor, N.Y. 1989). Any methods, devices and materials similar or equivalent to those described herein can be used in the practice of this disclosure. The following definitions are provided to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the present disclosure.
- “Nucleic acid” or “oligonucleotide” or “polynucleotide” or grammatical equivalents used herein means at least two nucleotides covalently linked together. The term “nucleic acid” includes single-, double-, multiple-stranded or branched DNA, RNA and analogs (derivatives) thereof.
- The term “modified internucleotide linkage” or “internucleotide linkage analogue” and the like refers, in the usual and customary sense, to a non-physiologic linkage between nucleotides. For example, the term “phosphorothioate nucleic acid” refers to a nucleic acid in which one or more internucleotide linkages are through a phosphorothioate moiety (thiophosphate) moiety. The phosphorothioate moiety may be a monothiophosphate (—P(O)3(S)3−—) or a dithiophosphate (—P(O)2(S)2 3−—). In embodiments, one or more of the nucleosides of a phosphorothioate nucleic acid are linked through a phosphorothioate moiety (e.g. monothiophosphate) moiety, and the remaining nucleosides are linked through a phosphodiester moiety (—P(O)4 3−—). In embodiments, one or more of the nucleosides of a phosphorothioate nucleic acid are linked through a phosphorothioate moiety (e.g. monothiophosphate) moiety, and the remaining nucleosides are linked through a methylphosphonate linkage. In embodiments, all the nucleosides of a phosphorothioate nucleic acid are linked through a phosphorothioate moiety (e.g. a monothiophosphate) moiety.
- As used herein, phosphorothioate oligonucleotides (phosphorothioate nucleic acids) are from about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. In embodiments, the phosphorothioate nucleic acids herein contain one or more phosphodiester bonds. In other embodiments, the phosphorothioate nucleic acids include alternate backbones (e.g., mimics or analogs of phosphodiesters as known in the art, such as, boranophosphate, methylphosphonate, phosphoramidate, or O-methylphosphoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press).
- In embodiments, the phosphorothioate nucleic acids may include one or more nucleic acid analog monomers known in the art, such as, peptide nucleic acid monomer or polymer, locked nucleic acid monomer or polymer, morpholino monomer or polymer, glycol nucleic acid monomer or polymer, or threose nucleic acid monomer or polymer. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and nonribose backbones, including those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, and
Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui & Cook, eds. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made. Phosphorothioate nucleic acids and phosphorothioate polymer backbones can be linear or branched. For example, the branched nucleic acids are repetitively branched to form higher ordered structures such as dendrimers and the like. - The terms “analog,” “nucleobase analog” and the like, in the context of nucleic acid bases refer, in the usual and customary sense, to chemical moieties that can substitute for normal (i.e., physiological) nucleobases (i.e., A, T, G, C and U) in nucleic acids. Nucleobase analogs can be categorized as purine analogs and pyrimidine analogs. Purine analogs have a core purine ring structure which is substituted to form a purine analog. Pyrimidine analogs have a core pyrimidine ring structure which is substituted to form a pyrimidine analog. Substitution may be endocyclic (i.e., within the purine or pyrimidine ring structure) or exocyclic (i.e., attached to the purine or pyrimidine ring structure). Exemplary nucleobase analogs include, but are not limited to: 1,5-dimethyluracil, 1-methyluracil, 2-amino-6-hydroxyaminopurine, 2-aminopurine, 3-methyluracil, 5-(hydroxymethyl)cytosine, 5-bromouracil, 5-carboxycytosine, 5-fluoroorotic acid, 5-fluorouracil, 5-formylcytosine, 5-formyluracil, 6-azathymine, 6-azauracil, 8-azaadenine, 8-azaguanine, N6-carbamoylmethyladenine, N6-hydroxyadenine, allopurinol, hypoxanthine, thiouracil, locked nucleic acid (LNA), 2′-O-alkyl nucleobase, 2′-Fluoro nucleobase, and 2′-OMe nucleobase.
- As used herein, locked nucleic acid (LNA) is a modified RNA nucleotide. LNAs are RNA molecules which possess an extra bridge connecting the 2′ oxygen and 4′ carbon of the ribose moiety. The ribose becomes locked in the 3′-endo (North) conformation. Base stacking and backbone pre-organization are enhanced by the locked ribose conformation. In embodiments, LNA modification has several advantages, including reduced toxicity, lower dosing, higher affinity and efficient targeting.
- As used herein the term “nucleobases” refers to the naturally occurring compounds, which form the differentiating component of nucleotides; five bases occur in nature, three of which are common to RNA and DNA (uracil replaces thymine in RNA). Bases are divided into two groups, purines and pyrimidines, based on their chemical structure. Purines are larger, double-ring molecules comprising adenine and guanine, whereas pyrimidines have only a single-ring structure and comprise cytosine and thymine/uracil. Because of the different size of the two types of nucleobases, purines can only base pair with pyrimidines in order to preserve the DNA molecule's constant width. More specifically, the only base pairs that will fit the structure of the particular molecule are adenine-thymine and cytosine-guanine.
- The term “cell” as used herein also refers to individual cells, cell lines, or cultures derived from such cells. A “culture” refers to a composition comprising isolated cells of the same or a different type.
- Diabetic nephropathy (DN) is typically defined by macroalbuminuria—that is, a urinary albumin excretion of more than 300 mg in a 24-hour collection—or macroalbuminuria and abnormal renal function as represented by an abnormality in serum creatinine, calculated creatinine clearance, or glomerular filtration rate (GFR). Clinically, diabetic nephropathy is characterized by a progressive increase in proteinuria and decline in GFR, hypertension, and a high risk of cardiovascular morbidity and mortality.
- As used herein, “early stage DN” or “incipient DN” is characterized by microalbuminuria, which is defined as levels of albumin ranging from 30 to 300 mg in a 24-h urine collection. Microalbuminuria progresses to overt nephropathy. Renal disease is suspected to be secondary to diabetes in the clinical setting of long-standing diabetes. This is supported by the history of diabetic retinopathy, particularly in
type 1 diabetics, in whom there is a strong correlation. The natural history of diabetic nephropathy is a process that progresses gradually over years. - Renal biopsy findings consistent with diabetic nephropathy in the early stages of DN are mesangial expansion and glomerular basement membrane thickening. Eventual progression of diabetic nephropathy can lead to nodular glomerulosclerosis, also referred to as Kimmelstiel-Wilson disease.
- Early diabetes is heralded by glomerular hyperfiltration and an increase in GFR. This is believed to be related to increased cell growth and expansion in the kidneys, possibly mediated by hyperglycemia itself. Microalbuminuria typically occurs after 5 years in
type 1 diabetes. Overt nephropathy, with urinary protein excretion higher than 300 mg/day, often develops after 10 to 15 years. ESRD develops in 50% oftype 1 diabetics, with overt nephropathy within 10 years. -
Type 2 diabetes has a more variable course. Patients often present at diagnosis with microalbuminuria because of delays in diagnosis and other factors affecting protein excretion. Fewer patients with microalbuminuria progress to advanced renal disease. Without intervention, approximately 30% progress to overt nephropathy and, after 20 years of nephropathy, approximately 20% develop ESRD. Because of the high prevalence oftype 2 compared withtype 1 diabetes, however, most diabetics on dialysis aretype 2 diabetics. - Long-standing hyperglycemia is known to be a significant risk factor for the development of diabetic nephropathy. Hyperglycemia may directly result in mesangial expansion and injury by an increase in the mesangial cell glucose concentration. The glomerular mesangium expands initially by cell proliferation and then by cell hypertrophy. Increased mesangial stretch and pressure can stimulate this expansion, as can high glucose levels. Transforming growth factor β (TGF-β) is particularly important in the mediation of expansion and later fibrosis via the stimulation of collagen and fibronectin. Glucose can also bind reversibly and eventually irreversibly to proteins in the kidneys and circulation to form advanced glycosylation end products (AGEs). AGEs can form complex cross-links over years of hyperglycemia and can contribute to renal damage by stimulation of growth and fibrotic factors via receptors for AGEs. In addition, mediators of proliferation and expansion, including platelet-derived growth factor, TGF-β, and vascular endothelial growth factor (VEGF) that are elevated in diabetic nephropathy can contribute to further renal and microvascular complications.
- Proteinuria, a marker and potential contributor to renal injury, accompanies diabetic nephropathy. Increased glomerular permeability will allow plasma proteins to escape into the urine. Some of these proteins will be taken up by the proximal tubular cells, which can initiate an inflammatory response that contributes to interstitial scarring eventually leading to fibrosis. Tubulointerstitial fibrosis is seen in advanced stages of diabetic nephropathy and is a better predictor of renal failure than glomerular sclerosis. Hyperglycemia, angiotensin II, TGF-β, and likely proteinuria itself all play roles in stimulating this fibrosis. There is an epithelial-mesenchymal transition that takes place in the tubules, with proximal tubular cell conversion to fibroblast-like cells. These cells can then migrate into the interstitium and produce collagen and fibronectin.
- In diabetic nephropathy, the activation of the local renin-angiotensin system occurs in the proximal tubular epithelial cells, mesangial cells, and podocytes. Angiotensin II (ATII) itself contributes to the progression of diabetic nephropathy. ATII is stimulated in diabetes despite the high-volume state typically seen with the disease, and the intrarenal level of ATII is typically high, even in the face of lower systemic concentrations. ATII preferentially constricts the efferent arteriole in the glomerulus, leading to higher glomerular capillary pressures. In addition to its hemodynamic effects, ATII also stimulates renal growth and fibrosis through
ATII type 1 receptors, which secondarily upregulate TGF-β and other growth factors. - Control of hypertension has clearly shown to be an important and powerful intervention in decreasing the progression of diabetic nephropathy. In diabetics who have disordered autoregulation at the level of the kidney, systemic hypertension can contribute to endothelial injury. Human studies of
type 2 diabetics have shown that blood pressure lowering, regardless of the agent used, retards the onset and progression of diabetic nephropathy. In animal studies, the degree and severity of the diabetic nephropathy were strongly linked to systemic blood pressure. - The fact that
most types - Diabetic nephropathy (DN) include the expansion and hypertrophy of glomerular mesangial cells (MCs), increased accumulation of extracellular matrix (ECM) proteins such as collagen 1alpha1 (Col1α1), Col1α2, Col4α1 and fibronectin, and tubulointerstitial fibrosis, podocyte dysfunction and proteinuria. Levels of transforming growth factor-beta1 (TGF-β1) are increased in MCs and other renal cells in diabetics and TGF-β1 mediates many of the adverse effects. Several biochemical mechanisms of action have been reported for TGF-β1. Factors relevant to the pathogenesis of DN such as angiotensin II, and high glucose (HG), increase TGF-β1 expression in MCs in vitro and in vivo. Signals from the activated TGF-β1 receptor complex are transduced to the nucleus by Smad proteins, including Smad2/3/4, which regulate TGF-β-induced genes, including PAI-1, collagen and p21cip1/waf1. However, the molecular mechanisms by which diabetic conditions and TGF-β1 regulate the genes that increase the hypertrophy, protein synthesis and fibrosis associated with DN are not fully clear. A few microRNAs (miRNAs or miRs, in short) are involved in mediating the pro-fibrotic effects of TGF-β1 in MCs in vitro and diabetic conditions in vivo.
- microRNAs (miRNA) are endogenously produced, short single-stranded non-coding RNAs (˜20-23 nucleotides) that play key roles in post-transcriptional regulation of gene expression to silence genes by repressing the translation or inducing the degradation of target mRNAs. There are more than 1000 mammalian miRNAs that can target nearly 60% of mRNAs in the genome, and therefore, they regulate many key cellular functions. The terms microRNA, miRNA, and miR are interchangeable.
- Long ncRNAs (lncRNAs) are long transcripts that range from >200 nucleotides up to ˜100 kb, and are similar to messenger RNAs (mRNAs) but lack protein coding (translation) potential. LncRNAs can regulate the expression of local and distal genes by various mechanisms that include recruiting histone modifying complexes and modulating the activities of transcription factors (TFs). LncRNAs also serve as hosts for miRNAs and/or a miRNA megacluster. LncRNAs have cell-specific expression, and function in various biological processes including transcription, differentiation, and the immune response.
- As used herein, the microRNA megacluster is a region of the genome where more than 10 microRNA genes are encoded. In embodiments, 35-60 microRNAs are encoded in the region. In embodiments, some of these clustered miRNA genes may be encoded by a single-copy DNA sequence. Alternatively, the miRNA genes may be arranged in tandem arrays of closely related sequences.
- As used herein, the microRNA-379 transcript is a RNA sequence transcribed from a microRNA-379 gene of a mammalian genome, e.g., a human genome. In its ordinary meaning, a “transcript” in molecular biology or similar context is a product of transcription. miRNAs are transcribed as much larger primary transcripts (pri-miRNAs). The vast majority of mature miRNAs are produced from primary transcripts of microRNAs (pri-miRNAs) by a multi-step pathway. In mammals, miRNAs are first transcribed as longer primary transcripts called primary miRNA (pri-miRNA). The transcript may contain multiple miRNA stem loops and is capped at the 5′ end through polyadenylation. Drosha, a nuclear RNase III, is recruited to crop the pri-miRNA transcript into a hairpin-shaped structure, about 70 nt long, known as precursor-miRNA (pre-miRNA). This cleavage event is critical and site-specific, as it determines the mature miRNA sequence. The pre-miRNA is then exported out of the nucleus for further cleavage into a 22 nt duplex. The complementary strand becomes degraded leaving one fully mature miRNA strand. Mature miRNA then associate with several members of the Argonaute protein family to form the RNA-induced silencing complex which then binds to specific protein-coding mRNA transcripts, directing mRNA inactivation by translational repression, deadenylation, or degradation.
- As used herein, plasminogen activator inhibitor-1 (PAI-1) is an endothelial plasminogen activator inhibitor or serpin E1 is a protein that in humans is encoded by the SERPINE1 gene. PAI-1 is a serine protease inhibitor (serpin) that functions as the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), the activators of plasminogen and hence fibrinolysis (the physiological breakdown of blood clots). It is a serine protease inhibitor (serpin) protein (SERPINE1). Other PAI, plasminogen activator inhibitor-2 (PAI-2) is secreted by the placenta and only present in significant amounts during pregnancy. In addition, protease nexin acts as an inhibitor of tPA and urokinase. PAI-1, however, is the main inhibitor of the plasminogen activators.
- As used herein, connective-tissue growth factor (CTGF) is a secreted protein implicated in multiple cellular events including angiogenesis, skeletogenesis and wound healing.
- The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher identity over a specified region when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site or the like). Such sequences are then said to be “substantially identical.” This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 10 amino acids or 20 nucleotides in length, or more preferably over a region that is 10-50 amino acids or 20-50 nucleotides in length. As used herein, percent (%) amino acid sequence identity is defined as the percentage of amino acids in a candidate sequence that are identical to the amino acids in a reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared can be determined by known methods.
- For sequence comparisons, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
- “Patient,” “subject,” “patient in need thereof,” and “subject in need thereof” are herein used interchangeably and refer to a living organism suffering from or prone to a disease or condition that can be treated by administration using the methods and compositions provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human. Tissues, cells and their progeny of a biological entity obtained in vitro or cultured in vitro are also contemplated.
- The terms “treat,” “treating” or “treatment,” and other grammatical equivalents as used herein, include alleviating, abating, ameliorating, or preventing a disease, condition or symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition, and are intended to include prophylaxis. The terms further include achieving a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder.
- The terms “prevent,” “preventing,” or “prevention,” and other grammatical equivalents as used herein, include to keep from developing, occur, hinder or avert a disease or condition symptoms as well as to decrease the occurrence of symptoms. The prevention may be complete (i.e., no detectable symptoms) or partial, so that fewer symptoms are observed than would likely occur absent treatment. The terms further include a prophylactic benefit. For a disease or condition to be prevented, the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
- The term “inhibiting” also means reducing an effect (disease state or expression level of a gene/protein/mRNA) relative to the state in the absence of a compound or composition of the present disclosure.
- A “test compound” as used herein refers to an experimental compound used in a screening process to identify activity, non-activity, or other modulation of a particularized biological target or pathway.
- “Control” or “control experiment” is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is the measurement of the activity of a protein in the absence of a compound as described herein (including embodiments and examples).
- “Disease” or “condition” refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein. In some instances, “disease” or “condition” refers to diabetes nephropathy (DN).
- “Contacting” is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including biomolecules or cells) to become sufficiently proximal to react, interact or physically touch. It should be appreciated; however, the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents which can be produced in the reaction mixture. In some embodiments contacting includes allowing a compound described herein to interact with a protein or enzyme.
- The terms “phenotype” and “phenotypic” as used herein refer to an organism's observable characteristics such as onset or progression of disease symptoms, biochemical properties, or physiological properties.
- The word “expression” or “expressed” as used herein in reference to a DNA nucleic acid sequence (e.g. a gene) means the transcriptional and/or translational product of that sequence. The level of expression of a DNA molecule in a cell may be determined on the basis of either the amount of corresponding mRNA that is present within the cell or the amount of protein encoded by that DNA produced by the cell (Sambrook et al., 1989 Molecular Cloning: A Laboratory Manual, 18.1-18.88). When used in reference to polypeptides, expression includes any step involved in the production of a polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).
- The term “gene” means the segment of DNA involved in producing a protein; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons). The leader, the trailer as well as the introns include regulatory elements that are necessary during the transcription and the translation of a gene. Further, a “protein gene product” is a protein expressed from a particular gene.
- The term “promoter” and the like in the usual and customary sense, is a region of DNA that initiates transcription of a particular gene. Promoters are located near the transcription start sites of genes, on the same strand and upstream on the DNA (towards the 5′ region of the sense strand). Upstream and downstream in the usual and customary sense both refer to a relative position in DNA or RNA. Each strand of DNA or RNA has a 5′ end and a 3′ end, so named for the carbon position on the deoxyribose (or ribose) ring. By convention, upstream and downstream relate to the 5′ to 3′ direction in which RNA transcription takes place. Upstream is toward the 5′ end of the RNA molecule and downstream is toward the 3′ end. When considering double-stranded DNA, upstream is toward the 5′ end of the coding strand for the gene in question and downstream is toward the 3′ end. Due to the anti-parallel nature of DNA, this means the 3′ end of the template strand is upstream of the gene and the 5′ end is downstream.
- The term “an amount of” in reference to a polynucleotide or polypeptide, refers to an amount at which a component or element is detected. The amount may be measured against a control, for example, wherein an increased level of a particular polynucleotide or polypeptide in relation to the control, demonstrates enrichment of the polynucleotide or polypeptide. The term refers to quantitative measurement of the enrichment as well as qualitative measurement of an increase or decrease relative to a control.
- Throughout the description and claims of this specification the word “comprise” and other forms of the word, such as “comprising” and “comprises,” means including but not limited to, and is not intended to exclude, for example, other components.
- “Analog,” “analogue,” or “derivative” is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical agent that is structurally similar to another agent (i.e., a so-called “reference” agent) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of a chiral center of the reference agent. In some embodiments, a derivative may be a conjugate with a pharmaceutically acceptable agent, for example, phosphate or phosphonate.
- As used herein, the term “salt” refers to acid or base salts of the agents used herein. Illustrative but non-limiting examples of acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid, and the like) salts, and quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts.
- The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge et al., Journal of Pharmaceutical Science 66:1-19 (1977)). Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present disclosure. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5, which is combined with buffer prior to use.
- Thus, the compounds of the present disclosure may exist as salts, such as with pharmaceutically acceptable acids. The present disclosure includes such salts. Examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates, (−)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in the art.
- An “adjuvant” (from Latin, adiuvare: to aid) is a pharmacological and/or immunological agent that modifies the effect of other agents.
- A “diluent” (also referred to as a filler, dilutant or thinner) is a diluting agent. Certain fluids are too viscous to be pumped easily or too dense to flow from one particular point to the other. This can be problematic, because it might not be economically feasible to transport such fluids in this state. To ease this restricted movement, diluents are added. This decreases the viscosity of the fluids, thereby also decreasing the pumping/transportation costs.
- The terms “administration” or “administering” refer to the act of providing an agent of the current embodiments or pharmaceutical composition including an agent of the current embodiments to the individual in need of treatment.
- By “co-administer” it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of additional therapies. The compound or the composition of the disclosure can be administered alone or can be co-administered to the patient. Co-administration is meant to include simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent). The preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation).
- As used herein, “sequential administration” includes that the administration of two agents (e.g., the compounds or compositions described herein) occurs separately on the same day or do not occur on a same day (e.g., occurs on consecutive days).
- As used herein, “concurrent administration” includes overlapping in duration at least in part. For example, when two agents (e.g., any of the agents or class of agents described herein that has bioactivity) are administered concurrently, their administration occurs within a certain desired time. The agents' administration may begin and end on the same day. The administration of one agent can also precede the administration of a second agent by day(s) as long as both agents are taken on the same day at least once. Similarly, the administration of one agent can extend beyond the administration of a second agent as long as both agents are taken on the same day at least once. The bioactive agents/agents do not have to be taken at the same time each day to include concurrent administration.
- As used herein, “intermittent administration includes the administration of an agent for a period of time (which can be considered a “first period of administration”), followed by a time during which the agent is not taken or is taken at a lower maintenance dose (which can be considered “off-period”) followed by a period during which the agent is administered again (which can be considered a “second period of administration”). Generally, during the second phase of administration, the dosage level of the agent will match that administered during the first period of administration but can be increased or decreased as medically necessary.
- As used herein, the term “administering” means oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
- The compositions disclosed herein can be delivered transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols. Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. The compositions of the present disclosure may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes. The compositions disclosed herein can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, J. Bioniater Sci. Polym. Ed. 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Phann. Res. 12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, J. Phann. Pharmacol. 49:669-674, 1997).
- As used herein, an “effective amount” or “therapeutically effective amount” is that amount sufficient to affect a desired biological effect, such as beneficial results, including clinical results. As such, an “effective amount” depends upon the context in which it is being applied. An effective amount may vary according to factors known in the art, such as the disease state, age, sex, and weight of the individual being treated. Several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. In addition, the compositions/formulations of this disclosure can be administered as frequently as necessary to achieve a therapeutic amount.
- Pharmaceutical compositions may include compositions wherein the therapeutic drug (e.g., agents described herein, including embodiments or examples) is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose. The actual amount effective for a particular application will depend, inter alia, on the condition being treated. When administered in methods to treat a disease, such compositions will contain an amount of therapeutic drug effective to achieve the desired result, e.g., modulating the activity of a target molecule, and/or reducing, eliminating, or slowing the progression of disease symptoms.
- The dosage and frequency (single or multiple doses) administered to a mammal can vary depending upon a variety of factors, for example, whether the mammal suffers from another disease, and its route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated, kind of concurrent treatment, complications from the disease being treated or other health-related problems. Other therapeutic regimens or agents can be used in conjunction with the methods and agents of this disclosure. Adjustment and manipulation of established dosages (e.g., frequency and duration) are well within the ability of those skilled in the art.
- For any therapeutic agent described herein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of therapeutic drug(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.
- As is well known in the art, therapeutically effective amounts for use in humans can also be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring agent's effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.
- Dosages may be varied depending upon the requirements of the patient and the therapeutic drug being employed. The dose administered to a patient should be sufficient to effects a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the agent. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. Dosage amounts and intervals can be adjusted individually to provide levels of the administered agent effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
- A weight percent of a component, unless specifically stated to the contrary, is based on the total weight of the formulation or composition in which the component is included.
- “Excipient” is used herein to include any other agent that may be contained in or combined with a disclosed agent, in which the excipient is not a therapeutically or biologically active agent/agent. As such, an excipient should be pharmaceutically or biologically acceptable or relevant (for example, an excipient should generally be non-toxic to the individual). “Excipient” includes a single such agent and is also intended to include a plurality of excipients. For the purposes of the present disclosure the term “excipient” and “carrier” are used interchangeably in some embodiments of the present disclosure and said terms are defined herein as, “ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition.”
- The term “about” refers to any minimal alteration in the concentration or amount of an agent that does not change the efficacy of the agent in preparation of a formulation and in treatment of a disease or disorder. The term “about” with respect to concentration range of the agents (e.g., therapeutic/active agents) of the current disclosure also refers to any variation of a stated amount or range which would be an effective amount or range.
- Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it is understood that the particular value forms another aspect. It is further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. It is also understood that throughout the application, data are provided in a number of different formats and that this data represent endpoints and starting points and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
- The present disclosure includes an isolated compound including a nucleic acid sequence capable of hybridizing to an
RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript or a microRNA-379 megacluster transcript. In embodiments, the present disclosure includes an isolated compound including a nucleic acid sequence capable of hybridizing to at least one nucleic acid base of a downstream region of the transcription start site of a mammalian microRNA-379 transcript or a microRNA-379 megacluster transcript. In embodiments, the transcript is as exists immediately after transcription, e.g., primary transcript mRNA or pre-mRNA. In embodiments, the compound includes a nucleic acid sequence having a nucleobase analog or modified internucleotide linkage. - In embodiments, the compound includes a nucleic acid sequence having a nucleobase analog. In embodiments, the nucleic acid sequence includes Locked Nucleic Acid (LNA), 2′-O-alkyl, 2′ O-Methyl, 2′-deoxy-2′fluoro, 2′-deoxy, a universal base, 5-C-methyl, an inverted deoxy abasic residue incorporation, or any combination thereof. In embodiments, the nucleic acid sequence may include analogs with positive backbones; non-ionic backbones, modified sugars, and non-ribose backbones (e.g. phosphorodiamidate morpholino oligos), including those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, and
Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui & Cook, eds. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. - In embodiments, the nucleic acid sequence includes at least one nucleic acid analog. In embodiments, the nucleic acid sequence includes at least one nucleic acid analog having an alternate backbone (e.g. phosphodiester derivative (e.g. phosphoramidate, phosphorodiamidate, phosphorothioate, phosphorodithioate, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phosphonate, boron phosphonate, or O-methylphosphoroamidite), peptide nucleic acid backbone(s), LNA, or linkages). In embodiments, a nucleic acid sequence includes or is DNA. In embodiments, a nucleic acid sequence includes or is RNA. In embodiments, a nucleic acid sequence includes or is a nucleic acid having internucleotide linkages selected from phosphodiesters and phosphodiester derivatives (e.g., phosphoramidate, phosphorodiamidate, phosphorothioate, phosphorodithioate, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phosphonate, boron phosphonate, O-methylphosphoroamidite, or combinations thereof). In embodiments, a nucleic acid sequence consists of a nucleic acid having internucleotide linkages selected from phosphodiesters and phosphorothioates. In embodiments, a nucleic acid sequence includes or is a nucleic acid having backbone linkages selected from phosphodiesters and phosphorodithioates. In embodiments, a nucleic acid sequence includes or is a nucleic acid having phosphodiester backbone linkages. In embodiments, a nucleic acid sequence includes or is a nucleic acid having phosphorothioate backbone linkages. In embodiments, a nucleic acid sequence includes or is a nucleic acid having phosphorodithioate backbone linkages.
- In embodiments, a nucleic acid sequence in the compound includes a nucleic acid analog (e.g. LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleobases. In embodiments, the compound includes a nucleic acid sequence capable of hybridizing to an
RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript, where the nucleic acid sequence has an analog (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleobases. In embodiments, the compound includes a nucleic acid sequence with an analog (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at 3 nucleobases. - In embodiments, the nucleobase analog is at the 5′-end or the 3′-end of the nucleic acid sequence. In embodiments, the nucleobase analog (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) is at the 5′-end or the 3′-end of the nucleic acid sequence. In embodiments, the nucleobase analog (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′-OMe) is at the 5′-end and the 3′-end of the nucleic acid sequence.
- In embodiments, the nucleic acid sequence includes three, four or five nucleobase analogs (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at the 5′-end or the 3′-end of the nucleic acid sequence. In embodiments, the nucleic acid sequence includes three, four or five nucleobase analogs (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at the 5′-end and the 3′-end of the nucleic acid sequence. In embodiments, the nucleic acid sequence includes three nucleobase analogs (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at the 5′-end or the 3′-end of the nucleic acid sequence. In embodiments, the nucleic acid sequence includes three nucleobase analogs (e.g., LNA, 2′-O-alkyl, 2′-Fluoro, or 2′ O-Methyl (2′-OMe)) at the 5′-end and the 3′-end of the nucleic acid sequence
- In embodiments, the compound includes a nucleic acid sequence with a modified internucleotide linkage. In embodiments, the modified internucleotide linkage is a phosphorothioate (also known as phosphothioate) linkage. In other embodiments, nucleic acid analogs are included that may have alternate backbones (e.g. phosphodiester derivatives), including, e.g., phosphoramidate, phosphorodiamidate, phosphorodithioate, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phosphonate, boron phosphonate, or O-methylphosphoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made. In embodiments, the internucleotide linkages in DNA are phosphodiester, phosphodiester derivatives, or a combination of both.
- In embodiments, the compound includes a nucleic acid sequence with internal modified internucleotide linkage between nucleobases at one or more positions. In embodiments, the compound includes a nucleic acid sequence with internal modified internucleotide linkage between nucleobases at one or more positions, and one, two, three, or four nucleobase analogs at the 5′- or the 3′-ends of the nucleic acid sequence. In embodiments, the compound includes a nucleic acid sequence with internal internucleotide phosphorothioate linkage between nucleobases at one or more positions, and one, two, three, or four nucleobase LNA analogs at the 5′- or the 3′-ends of the nucleic acid sequence. In embodiments, the compound includes a nucleic acid sequence with internal modified internucleotide linkage between nucleobases at one or more positions, and one, two, three, or four nucleobase analogs at the 5′- and the 3′-ends of the nucleic acid sequence. In embodiments, the compound includes a nucleic acid sequence with internal internucleotide phosphorothioate linkage between nucleobases at one or more positions, and one, two, three, or four nucleobase LNA analogs at the 5′- and the 3′-ends of the nucleic acid sequence.
- Structures of exemplary molecules for internucleotide analogyes, such as an LNA monomer, and internucleotide linkages, such as phosphodiester linkage and phosphorothioate linkage, are depicted below.
- In embodiments, the RNA sequence to which a nucleic acid sequence of the present disclosure hybridizes to includes 11 to 27, 61 to 93, 115 to 139, or 246 to 265 nucleobases downstream of the transcription start site of the gene. In embodiments, the target site on the RNA sequence to which a nucleic acid sequence of the present disclosure hybridizes to is listed in Table 1. The target site range listed in Table 1 (middle column) reflects the nucleobase positions counting from the transcription start site at +1 of a target RNA.
-
TABLE 1 Nu- cleic Acid Iden- Target tity site Nucleic acid sequence MGC8 +11 to +26 TGAAGGCCACACTAAC (SEQ ID NO: 1) MGC12 +12 to +27 ATGAAGGCCACACTAA (SEQ ID NO: 2) MGC15 +11 to +25 GAAGGCCACACTAAC (SEQ ID NO: 3) MGC5 +64 to +79 CACGGTGCTGAAAGAG (SEQ ID NO: 4) MGC6 +63 to +78 ACGGTGCTGAAAGAGA (SEQ ID NO: 5) MGC13 +63 to +77 CGGTGCTGAAAGAGA (SEQ ID NO: 6) MGC14 +78 to +93 TCCTTGAATGGTTGCA (SEQ ID NO: 7) MGC18 +75 to +90 TTGAATGGTTGCACGG (SEQ ID NO: 8) MGC20 +62 to +77 CGGTGCTGAAAGAGAG (SEQ ID NO: 9) MGC10 +117 to +132 ATTTGGCAGTGGGAAG (SEQ ID NO: 10) MGC17 +116 to +131 TTTGGCAGTGGGAAGC (SEQ ID NO: 11) MGC19 +115 to +130 TTGGCAGTGGGAAGCA (SEQ ID NO: 12) MGC1 +246 to +261 TCAAAAACATAACGCC (SEQ ID NO: 13) MGC2 +247 to +262 GTCAAAAACATAACGC (SEQ ID NO: 14) MGC3 +248 to +262 GGTCAAAAACATAACGC (SEQ ID NO: 15) MGC4 +248 to +263 GGTCAAAAACATAACG (SEQ ID NO: 16) MGC7 +249 to +264 AGGTCAAAAACATAAC (SEQ ID NO: 17) MGC9 +249 to +263 AGGTCAAAAACATAACG (SEQ ID NO: 18) MGC11 +251 to +265 TAGGTCAAAAACATA (SEQ ID NO: 19) MGC16 +246 to +260 CAAAAACATAACGCC (SEQ ID NO: 20) HMGC10 +124 to +139 GATTTGGCATTGGAAG (SEQ ID NO: 21) HMGC8 +12 to +27 GGAAGGCCATGTCAAC (SEQ ID NO: 22) HMGC5 +61 to +76 GGCATTGATGGGGGAA (SEQ ID NO: 23) HMGC1 +249 to +265 TCAGAAATCATAACGCC (SEQ ID NO: 24) - In embodiments, compound includes, e.g., GATTTGGCATTGGAAG (SEQ ID NO: 21) with internal internucleotide phosphorothioate linkage between one or more nucleobases, and one, two, three, or four nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence. The LNA analogs at the 5′ and/or the 3′-ends of the sequence are underlined, e.g., GATTTGGCATTGGAAG (SEQ ID NO: 21). In embodiments, the remaining internal internucleotide linkages between nucleobases (italicized in the above sequence) are phosphorothioate linkages. In embodiments, a compound is, e.g., GATTTGGCATTGGAAG (SEQ ID NO: 21), with internal internucleotide phosphorothioate linkage between one or more nucleobases.
- In embodiments, the compound includes a nucleic acid that binds to the mouse miR-379 transcript including the upstream region of mouse miR-379 and the mouse miR-379 sequence. The sequence of the mouse miR-379 transcript including the upstream region of mouse miR-379 and the mouse miR-379 sequence is shown in SEQ ID NO: 118. The nucleic acid sequences of SEQ ID NOs: 1-20 hybridize to a region of mouse miR-379 transcript of SEQ ID NO: 25 (the transcription start site indicated with “+1”), i.e., SEQ ID NO: 118; in SEQ ID NO: 118, a uracil (“U”) replaces each thymine (“T”) of SEQ ID NO: 25.
-
+1 (SEQ ID NO: 25) ATTTTTCTGAGTTAGTGTGGCCTTCATCTGGTAATGTACTACCTGAGG GGGGAGGTGCCGCCTCTCTTTCAGCACCGTGCAACCATTCAAGGAGGG TGTGTTGTTCACCACATCTGCTTCCCACTGCCAAATCAGGCCTCAGAA AAGCTTTCTGGAAGTGACGCCAGCTTCAGGGACAAGGCCCAAGTTTCT AGGGGTCAACACCGTTCCATGGTTCCTGAAGAGATGGTAGACTATGGA ACGTAGGCGTTATGTTTTTGACCTATGTAACATGGTCCACTAACTCT +1 (SEQ ID NO: 118) AUUUUUCUGAGUUAGUGUGGCCUUCAUCUGGUAAUGUACUACCUGAGG GGGGAGGUGCCGCCUCUCUUUCAGCACCGUGCAACCAUUCAAGGAGGG UGUGUUGUUCACCACAUCUGCUUCCCACUGCCAAAUCAGGCCUCAGAA AAGCUUUCUGGAAGUGACGCCAGCUUCAGGGACAAGGCCCAAGUUUCU AGGGGUCAACACCGUUCCAUGGUUCCUGAAGAGAUGGUAGACUAUGGA ACGUAGGCGUUAUGUUUUUGACCUAUGUAACAUGGUCCACUAACUCU - In embodiments, the compound includes a nucleic acid that binds to the human miR-379 transcript including the upstream region of human miR-379 and the human miR-379 sequence. The sequence of the human miR-379 transcript including the upstream region of human miR-379 and the human miR-379 sequence is shown in SEQ ID NO: 119. The nucleic acid sequences of SEQ ID NOs: 21-24 hybridize to a region of human miR-379 transcript of SEQ ID NO: 26 (the transcription start site indicated with “+1”), i.e., SEQ ID NO: 119; in SEQ ID NO: 119, a uracil (“U”) replaces each thymine (“T”) of SEQ ID NO: 26.
- In embodiments, a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, or 98-99% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 hybridizes to a region of human miR-379 transcript of SEQ ID NO: 26, i.e., SEQ ID NO: 119; in SEQ ID NO: 119, a uracil (“U”) replaces each thymine (“T”) of SEQ ID NO: 26.
-
+1 (SEQ ID NO: 26) AGTCTTTCCAAGTTGACATGGCCTTCCTGGAGGAATTACCACTTAG GGTAGAGGCACCCCTTCCCCCATCAATGCCACTGCCCCACATTGGA GGAGGGGTTGTTTATGTTCACCATGTGCCTGCTTCCAATGCCAAAT CCAGCCTCAGAAAGCTTTCTGGAAGTGACGCCAACTTCAGGGGCAA GGCCCTGGTTCTGGGGTCAGCACCATTCCGTGGTTCCTGAAGAGAT GGTAGACTATGGAACGTAGGCGTTATGATTTCTGACCTATGTAACA TGGTCCACTAACTCT. +1 (SEQ ID NO: 119) AGUCUUUCCAAGUUGACAUGGCCUUCCUGGAGGAAUUACCACUUAG GGUAGAGGCACCCCUUCCCCCAUCAAUGCCACUGCCCCACAUUGGA GGAGGGGUUGUUUAUGUUCACCAUGUGCCUGCUUCCAAUGCCAAAU CCAGCCUCAGAAAGCUUUCUGGAAGUGACGCCAACUUCAGGGGCAA GGCCCUGGUUCUGGGGUCAGCACCAUUCCGUGGUUCCUGAAGAGAU GGUAGACUAUGGAACGUAGGCGUUAUGAUUUCUGACCUAUGUAA CAUGGUCCACUAACUCU - The consensus sequence of the mouse and human miR-379 transcript corresponds to a transcript of the consensus sequence provided in SEQ ID NO: 51.
- In embodiments, the compound includes a nucleic acid sequence that is 10 to 30 nucleobases in length. In embodiments, the compound includes a nucleic acid sequence capable of hybridizing at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases within a
RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript. In embodiments, the mammalian microRNA-379 transcript is a human microRNA-379 transcript. In embodiments, the compound includes a nucleic acid sequence capable of hybridizing at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases within the sequence of SEQ ID NO: 118 or 119. In embodiments, the compound includes a nucleic acid sequence capable of hybridizing at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases within 10-20, 10-30, 20-40, 20-50, 40-60, 40-70, 60-80, 60-90, 80-100, 80-110, 100-120, 100-130, 120-140, 120-150, 140-160, 140-170, 160-180, 160-190, 180-200, 180-210, 200-220, 200-230, 220-240, 220-230, 240-260, or 240-270 nucleobases downstream of the transcription start site (indicated with “+1”) of the transcript sequence of SEQ ID NO: 25 or 26 (i.e., transcript sequence SEQ ID NO: 118 or 119), a sequence including the transcript of SEQ ID NO: 25 or 26 (i.e., transcript sequence SEQ ID NO: 118 or 119), or a variation thereof. In embodiments, the compound includes a nucleic acid sequence capable of hybridizing at least 5 nucleobases within the sequence of 10-20, 10-30, 20-40, 20-50, 40-60, 40-70, 60-80, 60-90, 80-100, 80-110, 100-120, 100-130, 120-140, 120-150, 140-160, 140-170, 160-180, 160-190, 180-200, 180-210, 200-220, 200-230, 220-240, 220-230, 240-260, or 240-270 nucleobases downstream of the transcription start site (indicated with “+1”) of the transcript of SEQ ID NO: 25 or 26 (i.e., transcript sequence SEQ ID NO: 118 or 119). - In embodiments, the compound includes a nucleic acid sequence capable of hybridizing at least 5 nucleobases within a
RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript. In embodiments, the compound includes a nucleic acid sequence capable of hybridizing at least 5 nucleobases within a RNA sequence 10-20, 10-30, 20-40, 20-50, 40-60, 40-70, 60-80, 60-90, 80-100, 80-110, 100-120, 100-130, 120-140, 120-150, 140-160, 140-170, 160-180, 160-190, 180-200, 180-210, 200-220, 200-230, 220-240, 220-230, 240-260, or 240-270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript. - In embodiments, the present disclosure includes a compound including a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, or analogues or derivatives thereof.
- In embodiments, the compound includes a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal modified internucleotide linkage between nucleobases and/or terminal nucleobase analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- In embodiments, the compound includes a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or terminal nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence. In embodiments, the nucleobase analogs at the 5′- and/or the 3′ ends may be 2′-O-alkyl nucleobase, 2′-Fluoro nucleobase, or 2′-OMe nucleobase.
- In embodiments, the present disclosure includes a compound including a nucleic acid sequence having at least 90% sequence identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24.
- In embodiments, the compound includes a nucleic acid sequence having at least 90% sequence identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal modified internucleotide linkage between nucleobases and/or terminal nucleobase analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- In embodiments, the compound includes a nucleic acid sequence having at least 90% sequence identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence. In embodiments, the nucleobase analogs at the 5′- and the 3′ ends may be 2′-O-alkyl nucleobase, 2′-Fluoro nucleobase, or 2′-OMe nucleobase, and any combination thereof.
- In embodiments, the present disclosure includes a compound including a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24.
- In embodiments, the compound includes a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal modified internucleotide linkage between nucleobases and/or terminal nucleobase analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- In embodiments, the compound includes a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence. In embodiments, the nucleobase analogs at the 5′- and/or the 3′ ends may be 2′-O-alkyl nucleobase, 2′-Fluoro nucleobase, or 2′-OMe nucleobase, and any combination thereof.
- In embodiments, the present disclosure provides a complex of a compound including a nucleic acid sequence described in this disclosure hybridized to an
RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript or a microRNA-379 megacluster transcript. - In embodiments, the present disclosure includes a nucleic acid sequence of SEQ ID NOs: 1-20 hybridized to a region of mouse miR-379 transcript of SEQ ID NO: 25 (i.e., transcript sequence SEQ ID NO: 118) to form a complex. In embodiments, the present disclosure includes a nucleic acid sequence of SEQ ID NOs: 21-24 hybridized to a region of human miR-379 transcript of SEQ ID NO: 26 (i.e., transcript sequence SEQ ID NO: 119) to form a complex. In embodiments, the present disclosure includes a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, or 98-99% sequence identity with a continuous 10 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or analogues thereof, hybridized to a region of human miR-379 transcript of SEQ ID NO: 26 (i.e., transcript sequence SEQ ID NO: 119) to form a complex.
- In embodiments, the present disclosure includes a complex of a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10, 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence, hybridized to a
RNA sequence 10 to 270 nucleobase downstream of the transcription start site of microRNA-379 transcript. - In embodiments, the present disclosure includes a complex of a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10, 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence, hybridized to a RNA sequence transcript at 10-20, 10-30, 20-40, 20-50, 40-60, 40-70, 60-80, 60-90, 80-100, 80-110, 100-120, 100-130, 120-140, 120-150, 140-160, 140-170, 160-180, 160-190, 180-200, 180-210, 200-220, 200-230, 220-240, 220-230, 240-260, or 240-270 nucleobases downstream of the transcription start site of microRNA-379.
- The present disclosure provides a method of treating diabetic nephropathy in a subject in need thereof, the method including administering to the subject an effective amount of a compound of the present disclosure. The present disclosure includes a method of treating diabetic nephropathy in a subject by administering to the subject about 0.001 mg/kg to about 100 mg/kg of a compound of the present disclosure. In embodiments, a compound of the present disclosure inhibits renal glomerular podocyte death, glomerular mesangial expansion, glomerular hypertrophy, glomerular extracellular matrix accumulation, thereby treating DN.
- In embodiments, the method of treating diabetic nephropathy in a subject includes administering to the subject a compound or a pharmaceutical composition including a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10, 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, or analogues thereof.
- In embodiments, the method of treating diabetic nephropathy in a subject includes administering to the subject a compound or a pharmaceutical composition including a nucleic acid sequence having a nucleobase analog. In embodiments, the nucleic acid sequence includes Locked Nucleic Acid (LNA), 2′-O-alkyl, 2′ O-Methyl, 2′-deoxy-2′fluoro, 2′-deoxy, a universal base, 5-C-methyl, an inverted deoxy abasic residue incorporation, or any combination thereof. In embodiments, the nucleic acid sequence may include analogs with positive backbones; non-ionic backbones, modified sugars, and non-ribose backbones (e.g. phosphorodiamidate morpholino oligos).
- In embodiments, the present disclosure includes a method of treating diabetic nephropathy by administering a compound to a subject in need of such treatment, where the compound inhibits expression of a long non-coding RNA (lncMGC) in the subject. The method of treating diabetic nephropathy is by administering a compound to a subject in need of such treatment, where the compound inhibits expression of a long non-coding RNA (lncMGC) in the subject, which includes microRNA-376a, microRNA-299, microRNA-376c, microRNA-410, microRNA-494, microRNA-380-5p, microRNA-369-3p, microRNA-300, microRNA-541, microRNA-329, microRNA-381, microRNA-411, microRNA-134, microRNA-379, microRNA-154, microRNA-382, microRNA-376b, microRNA-496, microRNA-409-5p, microRNA-543, microRNA-377, microRNA-380-3p, and/or microRNA-495.
- In embodiments, the present disclosure includes a method of treating diabetic nephropathy by administering a compound to a subject, where the compound inhibits expression of a microRNA gene cluster. In embodiments, expression of the microRNA gene cluster that is inhibited for treating diabetic nephropathy is microRNA-379 gene cluster. In embodiments, the microRNA gene cluster expression of which is inhibited expresses microRNAs such as microRNA-376a, microRNA-299, microRNA-376c, microRNA-410, microRNA-494, microRNA-380-5p, microRNA-369-3p, microRNA-300, microRNA-541, microRNA-329, microRNA-381, microRNA-411, microRNA-134, microRNA-379, microRNA-154, microRNA-382, microRNA-376b, microRNA-496, microRNA-409-5p, microRNA-543, microRNA-377, microRNA-380-3p, and/or microRNA-495.
- The sequence of the nucleic acid that inhibits the microRNA for treating diabetic nephropathy is complementary to the microRNA sequence, or complementary to a transcript that includes the targeted microRNA and binds downstream of the transcription start site.
- Human microRNAs targeted for treating diabetic nephropathy are listed in Table 2.
-
TABLE 2 Human microRNAs Name Sequence SEQ ID NO: microRNA-376a UGCACCUAAAAGGAGAUACUA 83 microRNA-299-3p UAUGUGGGAUGGUAAACCGCUU 84 microRNA-376c UGCACCUUAAAGGAGAUACAA 85 microRNA-410 UGUCCGGUAGACACAAUAUAA 86 microRNA-494 CUCCAAAGGGCACAUACAAAGU 87 microRNA-380-5p AUGGUUGACCAUAGAACAUGCG 88 microRNA-369-3p AAUAAUACAUGGUUGAUCUUU 89 microRNA-300 UCUCUCUCAGACGGGAACAUAU 90 microRNA-541 AAAGGAUUCUGCUGUCGGUCCCACU 91 microRNA-329 UUUCUCCAAUUGGUCCACACAA 92 microRNA-381 UGUCUCUCGAACGGGAACAUAU 93 microRNA-411 GCAUGCGAUAUGCCAGAUGAU 94 microRNA-134 GGGGAGACCAGUUGGUCAGUGU 95 microRNA-379 GGAUGCAAGGUAUCAGAUGGU 96 microRNA-154 UAGGUUAUCCGUGUUGCCUUCG 97 microRNA-382 GAAGUUGUUCGUGGUGGAUUCG 98 microRNA-376b UUGUACCUAAAAGGAGAUACUA 99 microRNA- 496 CUCUAACCGGUACAUUAUGAGU 100 microRNA-409-5p AGGUUACCCGAGCAACUUUGCAU 101 microRNA-543 UUCUUCACGUGGCGCUUACAAA 102 microRNA-377 UGUUUUCAACGGAAACACACUA 103 microRNA-380-3p UAUGUAAUAUGGUCCACAUCUU 104 microRNA-495 UUCUUCACGUGGUACAAACAAA 105 - In embodiments, mouse microRNA targeted for inhibition are listed in Table 3.
-
TABLE 3 Mouse microRNAs: Name Sequence SEQ ID NO: microRNA-299-3p UAUGUGGGAUGGUAAACCGCUU 106 microRNA-376c UGCACUUUAAAGGAGAUACAA 107 microRNA-410 UGUCCGGUAGACACAAUAUAA 108 microRNA-494 CUCCAAAGGGCACAUACAAAGU 109 microRNA-380- 5p AUGGUUGACCAUAGAACAUGCG 110 microRNA-369-3p AAUAAUACAUGGUUGAUCUUU 111 microRNA-541 AAGGGAUUCUGAUGUUGGUCACACU 112 microRNA-329 UUUUUCCAAUCGACCCACACAA 113 microRNA-381 UGUCUCUCGAACGGGAACAUAU 114 microRNA-411 GCAUGCGAUAUGCCAGAUGAU 115 microRNA-134 UGUUUUCAACGGAAACACACUA 116 microRNA-379 GGAUGCAAGGUAUCAGAUGGU 65 microRNA-154 UAGGUUAUCCGUGUUGCCUUCG 66 microRNA-382 GAAGUUGUUCGUGGUGGAUUCG 67 microRNA-376b UUCACCUACAAGGAGAUACUA 68 microRNA-496 CUCUAACCGGUACAUUAUGAGU 69 microRNA-409- 5p AGGUUACCCGAGCAACUUUGCAU 70 microRNA-543 UUCUUCACGUGGCGCUUACAAA 71 microRNA-377 UGUUUUCAACGGAAACACACUA 74 microRNA-380-3p UAUGUAGUAUGGUCCACAUCUU 75 microRNA-495 UUCUUCACGUGGUACAAACAAA 76 miR-3072-5p AGGGACCCCGAGGGAGGGCAGG 77 miR-3072-3p UGCCCCCUCCAGGAAGCCUUCU 78 - In embodiments, the present disclosure includes a method of treating diabetic nephropathy by administering a compound of the present disclosure, which upregulates microRNA target genes and down-regulates expression of profibrotic genes. In embodiments, the compound of the present disclosure up-regulates and down-regulates in kidney mesangial cells.
- In embodiments, the compound of the present disclosure up-regulates target genes, for example, Tnrc6, CUGBP2, CPEB4, Pumillio2, BHC80 EDEM3, and any combination(s) thereof. In embodiments, the compound of the present disclosure down-regulates profibrotic genes, for example, pro-fibrotic genes Col1α2, TGF-β1, Col1α4, Plasminogen activator inhibitor-1 (PAI-1), fibronectin, connective tissue growth factor (CTGF), and any combination(s) thereof. In embodiments, the compound of the present disclosure treats diabetic nephropathy at an early stage of the disease. In embodiments, the diabetic nephropathy is characterized as having glomerular lesions including glomerular basement membrane thickening, mild mesangial expansion, severe mesangial expansion, nodular sclerosis (Kimmelstiel-Wilson lesions), or advanced diabetic glomerulosclerosis.
- The present disclosure provides a method of inhibiting expression of a mammalian microRNA-379, the method includes hybridizing a compound of the present disclosure to an
RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript. In embodiments, the method of inhibiting expression of a mammalian microRNA-370 cluster includes contacting a cell or tissue with a nucleic acid sequence of SEQ ID NOs: 1-24. In embodiments, the method of inhibiting expression of a mammalian microRNA-370 cluster includes contacting a cell or tissue with a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10, 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence. - In embodiments, the method of inhibiting expression of a mammalian microRNA-370 cluster includes contacting a kidney mesangial cell with a nucleic acid sequence of SEQ ID NOs: 1-24. In embodiments, the method of inhibiting expression of a mammalian microRNA-370 cluster includes contacting a kidney mesangial cell with a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10, 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- The present disclosure provides a pharmaceutical composition including a compound of the present disclosure and a pharmaceutically acceptable diluent, carrier, salt, and/or adjuvant.
- In embodiments, the pharmaceutical composition of the present disclosure includes a nucleic acid sequence of SEQ ID NOs: 1-24. In embodiments, the pharmaceutical composition of the present disclosure includes a nucleic acid sequence having 90-91%, 91-92%, 92-93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity with a continuous 10, 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, with internal internucleotide phosphorothioate linkage between nucleobases and/or nucleobase LNA analogs at the 5′- and/or the 3′-ends of the nucleic acid sequence.
- In embodiments, the present disclosure includes administering to an individual, a composition of a therapeutically effective amount of a compound including a nucleic acid sequence of SEQ ID NOs: 1-24, alone or in combination with a diabetic and/or diabetic nephropathic agent. The effective dose of the composition may be between about 0.001 mg/kg to about 100 mg/kg of compound. In embodiments, the compositions may have between about 0.1% to about 20% of the pharmaceutical composition. In embodiments, the compositions may include pharmaceutically acceptable diluent(s), excipient(s), and/or carrier(s).
- The composition of a compound including a nucleic acid sequence of SEQ ID NOs: 1-24 may be administered with a suitable pharmaceutical carrier. The administration can be local or systemic, including oral, parenteral, intraperitoneal, intrathecal or topical application. The release profiles of such composition may be rapid release, immediate release, controlled release or sustained release. For example, the composition may comprise a sustained release matrix and a therapeutically effective amount. Alternatively, a composition of a compound including a nucleic acid sequence of SEQ ID NOs: 1-24 can be secreted by genetically modified cells that are implanted, either free or in a capsule, at the gut of a subject. In embodiments, a composition of a compound including a nucleic acid sequence of SEQ ID NOs: 1-24 may be administered to a subject via subcutaneous route. In embodiments, the composition may be administered as an oral nutritional supplement.
- Oral compositions may include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral administration, a composition of a compound including a nucleic acid sequence of SEQ ID NOs: 1-24 can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the agent in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or agents of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, primogel, or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- In embodiments, a composition of a compound including a nucleic acid sequence of SEQ ID NOs: 1-24 in combination with another pharmaceutically active agent (small molecule or a large biological molecule) formulated for parenteral (including subcutaneous, intramuscular, and intravenous), inhalation, buccal, sublingual, nasal, rectal, topical, or oral administration for treating a viral infection, for inducing immune response, for treating neuroinflammation. The compositions may be conveniently presented in unit dosage form, and prepared by any of the methods well known to one skilled in the art.
- In embodiments, the composition of the present disclosure may be formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the individual to be treated; each unit containing a predetermined quantity of agent calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms are dictated by and directly dependent on the unique characteristics of the agent and the particular therapeutic effect to be achieved.
- The following examples are provided as illustrations of various embodiments of the disclosure but are not meant to limit the disclosure in any manner.
- RNA obtained from the glomeruli of streptozotocin (STZ) diabetic and control mice was profiled by miRNA-sequence and the Illumina sequencing data analyzed. In the diabetic mice glomeruli, a significant increase in the expression of several miRNAs was found (e.g. miR-379, -495, -377) (
FIG. 2B ) that are among the mega cluster of miRNAs within mouse Chr12 (FIG. 2A ). Genome organization showed that the miRNA mega cluster is hosted downstream of the lncRNA termed lnc-MGC, with another reported lncRNA, Mirg, present in this locus (FIG. 2A ). Lnc-MGC expression (5′ and 3′) was also increased under these diabetic conditions (FIG. 2B ), p<0.05. Furthermore, apart from the region upstream of lnc-MGC, no clear putative promoter was evident throughout the cluster, indicating that the miRNA cluster and lncRNA may be co-transcribed together as one unit, i.e., lnc-MGC may be induced under diabetic conditions and this up-regulates key miRNAs of the, cluster as one transcript, which encompasses a long ncRNA that functionally serves as host for the mega miRNA cluster. - Mouse MC (MMC) was treated with high glucose (HG, 25 mM), mannitol or TGF-β1 and several miRNAs within the cluster, (and lnc-MGC), was examined by amplifying these regions with specific PCR primers. TGF-β1 and HG significantly up-regulated the expression of miR-379 (the first miRNA in the cluster), miR-495 (in the middle) and miR-377 (downstream), as well as lnc-MGC (
FIG. 3 ), further supporting the sequencing and in vivo data (*, p<0.05) (NG=normal glucose, SD=serum depletion control for TGF-β1). miR-882 outside the cluster was unaffected. These results indicated that an miRNA mega cluster and its host lncRNA are concomitantly up-regulated in the glomeruli and MCs under diabetic conditions. - Small RNA (sm-RNA) sequencing was performed as previously described. Scatter plot of miRNAs in kidney glomeruli from control (CTR) and diabetic mice (STZ) were generated. The expression of each detectable miRNA in the form of log scaled reads was plotted with x-axis for CTR and y-axis for STZ. Each dot represents one miRNA. All the miRNAs in the miR-379 cluster were presented in red. Among them, the upregulated miRNAs with fold change ≥2) were highlighted with bigger size dots and labeled with the corresponding miRNA names. miR-882 was plotted in blue as a negative control (outside of miR-379 cluster). The expression of each detectable miRNA within the miR-379 cluster in the two samples (CTR and STZ) were ordered by
log 2 fold change from low to high, mean-centered and shown in the heatmap. Green represents lower than average expression in the 2 samples and red presents higher than average expression level. The expression of the detected miRNAs in this cluster was higher in STZ than CTR. The mouse miR-379 megacluster is located within the largest miRNA cluster currently identified in the genome. It maps within the DLK-DIO 3 genomic region (mouse chr 12, human chr14), which is home to several miRNAs and lncRNAs. TSS, transcription start site. miR-882 is located far-upstream of miR-379 cluster and not covered by lnc-MGC. All the miRNAs detected by smRNA-seq with at least 5 scaled reads in at least one sample are ranked bylog 2 fold change between STZ and CTR samples to generate ranked list and all the detectable miRNAs in cluster are considered as a gene set. Pre-ranked gene set analysis (GSEA) applied on the gene set using the ranked list of all the miRNAs revealed that miRNAs in the miR-379 cluster were significantly enriched within the miRNAs upregulated in the STZ diabetic mice, with normalized enrichment score of 1.56 (p=0.004). - To identify a putative promoter that could drive the genomic region, 5′ RACE experiments using primers from the miR-379 upstream region were carried out (
FIG. 4 ). Results revealed that this region has promoter-like features with TATA box and an initiator (INR) site. The binding sites for the C/EBP homologous protein (CHOP), a transcription factor (TF) associated with the ER and stress response, and an overlapping E-box was identified. Data for this promoter location was further supported by results showing that this region upstream of miR379 (lncMGC 5′ RACE (rapid amplification of cDNA ends)) is up-regulated in vivo in the glomeruli of diabetic mice (STZ-injected and db/db (the db/db mouse is a model of obesity, diabetes, and dyslipidemia wherein leptin receptor activity is deficient because the mice are homozygous for a point mutation in the gene for the leptin receptor)), and in vitro in MMCs treated with HG or TGF-β1 (*, p<0.05). These results identify the promoter of the lnc-RNA-MGC-miRNA cluster but also indicate that CHOP may be a key TF that regulates their coordinate expression. - Experiments were performed to test whether CHOP regulates this genomic region. Western blots showed that CHOP protein levels were up-regulated in the glomeruli of diabetic db/db and STZ-injected mice, compared to the respective controls. CHOP was also induced in MMCs treated with TGF-β1, HG or osmotic control, mannitol, indicating that diabetic conditions and cellular stress can upregulate CHOP which in turn, increases transcription of lncRNA-MGC and the miRNA cluster.
- CHOP Enrichment at the miR379 Promoter.
- Chromatin immunoprecipitation (ChIP) assays were performed to evaluate CHOP enrichment at the miR379 promoter. A significant increase in CHOP occupancy at the CHOP binding site of the miR-379 promoter (arrows) in MMCs treated with HG or TGF-β1, versus control normal glucose (NG) or serum-depleted (SD) was observed.
- Efficacy of CHOP siRNA (relative to a negative control siRNA, NC) for down-regulating CHOP in MMCs was evaluated. CHOP siRNA significantly attenuated HG- and TGF-β1-induced expression of miR-379 and lnc-MGC. Mir-495 and -377 expression were also inhibited. In addition to these miRNAs, similar trends were observed for 29 other cluster miRNAs that were tested, i.e. these 29 were significantly up-regulated in diabetic mice glomeruli and in response to TGF-β1, and increases of the most of them were inhibited by CHOP siRNA in MC. Cumulatively, these results indicate that CHOP is a key transcriptional regulator of the miRNA cluster and related lncRNA-MGC.
- miRNA target prediction algorithms predicted that numerous miRNAs in the mega cluster collectively targeted similar genes. Therefore, the 3′ UTRs of at least 25 genes were similarly targeted by 8-13 cluster miRNAs, with some genes having more than two miRNA target sites. Furthermore, it was found that these target genes had functions already related to DN, namely protein synthesis, ER stress, RNA binding proteins and protein translation (as determined by in silico GSEA (Gene Set Enrichment Analysis), IPA (Ingenuity Pathway Analysis), as well as Gene ontology analyses). This indicated that miRNAs in the mega cluster work in unison to alter the expression of groups of similar genes that can functionally modulate DN progression.
- Identification and Validation of Putative Targets of the miR-379 Cluster.
- Several potential targets of key cluster miRNAs that have functions relevant to DN were identified. These included RNA binding proteins and translational regulators (CUGBP2), Pumilio2, Tnrc6b, CPEB4, HuR, TFs and co-factors (Arid2, BHC80), Nf1a/b), an ER stress modulator (EDEM3), and the cell growth gene phosphatase and tensin homolog (Pten). To validate, down-regulation under diabetic condition was evaluated in the target genes. It was found that TGF-β1 or HG can reduce the mRNA expression levels of Tnrc6, CUGBP2, CPEB4, Pumilio2, BHC80 and EDEM3 in MCs in vitro, and in the glomeruli of diabetic mice in vivo (db/db and STZ), relative to controls (
FIG. 5 ; *p<0.05). These genes are known to regulate protein translation, protein synthesis, mRNA stability (e.g., CUGBP2) and miRNA processing (Tnrc6b). BHC80 interacts with histone deacetylases (HDACs) and the Ets TFs to promote chromatin condensation (86). Therefore, it is indicated that these targets mediate the downstream effects of the corresponding miRNAs in a cooperative and synergistic manner, to augment renal hypertrophy and fibrosis, and thereby enhance renal dysfunction in DN (FIG. 10 ). - CHOP siRNA treatment significantly prevented a key miRNA target (TNRC6) from being down-regulated by HG and TGF-β. Furthermore, in parallel, transfection of CHOP siRNA into MMCs also prevented increases in the TGF-β1 induced expression of key pro-fibrotic genes Col1α2, TGF-β1, Col1α4 and PAI-1 which are associated with DN. Consistently, CHOP siRNA also prevented TGF-β1 induced MC hypertrophy and protein content. These data indicate that inducing key mega cluster miRNAs can regulate MC genes and functions associated with DN pathogenesis through CHOP.
- miRNAs and siRNAs
- Oligonucleotide mimics and inhibitors of miRNAs, and siRNAs and corresponding control oligos were obtained from Integrated DNA technologies (IDT) or Thermo Fisher Scientific Inc. (Waltham, Mass.), as described. Wild-type (WT) MMCs (from WT C57BL/6 mice), MMC transfected with CHOP siRNA, and MMCs from CHOP-KO mice were treated with HG, mannitol and TGF-β1 as described. Briefly, cells (˜106/transfection) were transfected with siRNA or miRNA oligonucleotides using an Amaxa Nucleofector (Lonza, Basel, Switzerland) according to the manufacturer's protocols as described previously. siRNAs (double-stranded oligos of three pairs of sense (S) and antisense (AS) synthesized oligos,
-
S1 [SEQ ID NO: 59] rCrArUrCrUrGrCrUrUrCrCrCrArCrUrGrCrCrArArArUrCAG and AS1 [SEQ ID NO: 60] rCrUrGrArUrUrUrGrGrCrArGrUrGrGrGrArArGrCrArGrArUr GrUrG; S2 [SEQ ID NO:61] rUrCrArGrCrArCrCrGrUrGrCrArArCrCrArUrUrCrArArGGA and AS2 [SEQ ID NO: 62] rUrCrCrUrUrGrArArUrGrGrUrUrGrCrArCrGrGrUrGrCrUrGr ArArA; S3 [SEQ ID NO: 63] rCrUrUrCrArUrCrUrGrGrUrArArUrGrUrArCrUrArCrCrUGA and AS3 [SEQ ID NO: 64] rUrCrArGrGrUrArGrUrArCrArUrUrArCrCrArGrArUrGrArAr GrGrC; (r, ribose) against mouse upstream region of miR-379 were obtained from IDT. - Non-targeting siRNA controls were obtained from Thermo Fisher Scientific Inc. MMC were trypsinized and resuspended in Basic Nucleofection Solution at 1×107/ml. Subsequently, 100 μl of cell suspension (1×106 cells) was mixed with miRNA mimic, hairpin inhibitor oligonucleotides, or ON-TARGET plus siRNA or negative controls (Thermo Fischer Scientific Inc., Waltham, Mass.). Transfected cells were harvested for RNA and protein extraction. RNA was extracted from the cells and the expression of lncRNA-MGC, and all 40 miRNAs within the cluster were systematically examined using primers designed for each of the mature miRNAs. MMCs were transfected with oligonucleotide mimics, siRNAs of candidate miRNAs or negative control (NC) oligos to determine if manipulating their levels can influence TGF-β1 and HG responses. At 48-72 hr post-transfection, the expression of miRNA target genes, fibrosis and hypertrophy related genes, and proteins induced by TGF-β1/HG were determined by RT-qPCR and Western blotting using our published methods.
- EDEM3 as a Direct Target of miR-379
- Oligo mimics of miR-379 directly decreased the mRNA levels of its predicted targets Tnrc6b and EDEM3 in MMCs, whereas miR-379 inhibitor oligos (miR-379I) enhanced their mRNA levels in MMCs (
FIG. 6 ). Protein levels of EDEM3 were also decreased in MMCs treated with TGF-β1 or transfected with miR-379 mimic, indicating that direct effects of a key cluster miRNA (miR-379) on MC gene expression. - Whether EDEM3 is a direct target of miR-379 was tested. 3′UTR of mouse EDEM3 gene was cloned into psiCheck2 vector and co-transfected to MMC with miR-379 mimic. miR-379 inhibited luciferase activity of this reporter, which suggested EDEM3 is a direct target of miR-379. A potential target site of miR-200b/c was found in the 3′UTR of EDEM3. miR-200b inhibited the reporter activity. Because miR-200b/c are also known to be upregulated in glomeruli from diabetic mouse and MMC treated with TGF-β1, miR200 family and miR-379 cluster may collaborate to inhibit EDEM3 expression. Because miR-379 and miR-200b had no effect on the reporter with partial deletion of region which includes miR-379 and miR-200b/c sites from 3′UTR of EDEM3, those sites are real targets of miR-379 and miR-200b. Those results also suggest that miR-379 cluster and miR-200b upregulated in diabetic conditions induces DN through hypertrophy and fibrosis mediated by EDEM3 (ER stress).
- To confirm if ER stress is involved in the upregulation of miR-379 cluster, MMC was treated with tunicamycin (TM), a known ER stress inducer, and the expression of miR-379 cluster was tested. Initially, to test what dose of TM is best, the expression of HSPA5 (
heat shock 70 kDa protein 5), also known as GRP78 (glucose-regulated protein, 78 kDa), in MMC after treatment of TM (FIG. 15A ). 50 ng/ml was the minimum and significant dose to induce the expression of HSPA5 and similar induction of CHOP was observed (FIGS. 15A-15C ). - The expression of lncMGC and miRNAs in the cluster was increased by the TM (˜50 ng/ml) (
FIGS. 15D-15I ), suggesting that TM (ER stress) induces this cluster expression in MMC. Targets of miR-379 cluster including EDEM3, a target of miR-379, were decreased by TM as expected (FIGS. 15J-15R ). Faster migrating isoform of EDEM3 protein was detected in TM-treated cells by western blot while no such isoform was detected in MMC treated with TGF-β (FIG. 15K ). TM is an inhibitor of N-glycosylation and faster-migrating form is an un-glycosylated form of EDEM3 which loses the activity to protect the cells from ER stress (FIG. 15K ). TGF-β treatment decreased the expression of EDEM3 through induction of miR-379 and miR-200b (FIG. 15K ). Thus, there are two independent regulations of EDEM3, loss of N-glycosylation and decrease of expression through miR-379 (miR-200b) induction by TM treatment (FIGS. 15K-15M ). Other potential targets were down-regulated by TM (FIGS. 15N-15S ). Pro-fibrotic genes, such as Col1α2, Col4α1, FN and TGF-β1 were also upregulated by TM treatment in MMC (FIGS. 15T-15W ). These results suggest that TM (ER stress) induces miR-379 cluster expression and enhances ER stress and DN phenotypes (hypertrophy and fibrosis) by inhibiting the miR-379 cluster targets. - To inhibit the expression of lnc-MGC, a mixture of siRNAs to target lnc-MGC, which are located upstream of miR-379 was designed. Notably, transfecting this silnc-MGC into MMCs decreased both basal and TGF-β-induced expression not only of lncRNA-MGC, but also of the
key cluster miRNAs 379, -495 and -377, without affecting miR-882, located outside the cluster (FIG. 7 p<0.05). This indicated that silnc-MGC RNAs down-regulate lnc-MGC, and thereby down-regulate the component cluster miRNAs and their functions. - Genome-Wide miRNA Target Identification
- MCs were serum starved and tested with or without TGF-β1 for 24 hours. Cells were then UV crosslinked, sonicated and immunoprecipitated using an Ago2 antibody. Ago-associated RNA was purified then sequenced for RNA and miRNA on the Illumina Hiseq platform. The levels of 3′ UTR RNAs of the Col1α1 gene, which were enriched in control Ago2-IP samples (CTR), were decreased by TGF-β1. The results indicate that, under CTR conditions, Ago2 miRNA complexes bind to the 3′ UTR of Col1α1 RNAs. This is attenuated by TGF-β, which decreases specific miRNAs such as miR-29 to up-regulate Col1α1. These data suggest the feasibility of CLIP-seq experiments.
- To knockdown the expression of lnc-MGC in vivo (mouse kidney), four LNA-modified Gapmers (MGC1, MGC5, MGC8 and MGC10) were designed (
FIG. 16A ). GapmeRs were synthesized and obtained from Exiqon (Vedbaek, Denmark) according to the following design strategy: MGC1, TCAaaaacataacGCC [SEQ ID NO:55]; MGC5, CACggtgctgaaaGAG [SEQ ID NO:56]; MGC8, TGAaggccacactAAC [SEQ ID NO:57]; MGC10, ATTtggcagtgggAAG [SEQ ID NO: 58], (uppercase: LNA; lowercase: DNA, full phosphorothioate). LNA modification has several advantages, including less toxicity, lower dosing and efficient targeting. Basic design of these Gapmers is three LNAs at both 5′ and 3′ ends of oligonucleotides and backbone is phosphorothioated (FIG. 16B ). MMC were transfected with those Gapmers and the expression of lnc-MGC was examined. MGC10 consistently inhibited expression of lnc-MGC significantly at 48 hours after MGC10 transfection in two independent experiments although others did not with that consistency (FIGS. 16C-16D ). MGC10 also reduced the expression of lnc-MGC even after TGF-β treatment (FIG. 16E ). Some miRNAs in miR-379 cluster were confirmed to be reduced by MGC10 in MMC (FIGS. 16F-16H ). Several targets (EDEME3, Tnrc6b and Phf21a) of miR-379 cluster were also upregulated by MGC10 (FIGS. 16I-16L ) suggesting that down-regulation of miR-379 cluster restores the target expression. - Because MGC10 was effective to reduce the expression of miR-379 cluster in MMC in vitro, it was also tested in mouse kidney in vivo (
FIGS. 17A-17F ). Subcutaneous injection of 5 mg/kg MGC10 significantly reduced expression of lnc-MGC in the mouse kidney (24-72 hours) (FIG. 17B ). miRNAs in the cluster (miR-379, miR-495, and miR-377) were also reduced in the same samples (FIGS. 17C-F ). Those results suggest that MGC10 is effective in vivo in mouse kidney to reduce the expression of lnc-MGC and miR-379 cluster. To confirm the delivery of MGC10, the antisense in situ LNA modified probe was designed. Clear accumulation of MGC10 was observed in the kidney injected with MGC10 although very week background in the kidney injected with vehicle (PBS). Phosphorothioated oligonucleotides can be transported into nucleus by a protein complex (TCP1 complex). Because MGC10 is fully phosphorothioated, it may be efficiently transported into nucleus and cleaved lncMGC RNA and suppressed the expression of miR-379 cluster. - Next, MGC10 was tested in STZ injected diabetic mice. Five non-diabetic mice, five diabetic without injection, six diabetic mice with injection of negative control oligonucleotides and six diabetic mice with MGC10 injection were examined. lnc-MGC expression was higher in the kidney from diabetic mice than that from non-diabetic mice and interestingly, its expression was reduced in kidney from diabetic mice injected with MGC10, suggesting that MGC10 is effective even in diabetic mice. miRNAs in the miR-379 cluster behaved the similar patterns to lnc-MGC while no significant change of the expression of miR-882 (outside of miR-379 cluster) was observed. Targets (EDEM3, TRNC6B, CPEB4, Pumilio2) of miR-379 cluster were reduced in kidney from diabetic mice and it was restored in the kidney from diabetic mice injected with MGC10. Profibrotic genes, TGF-β1, Col1a2, Col4a1, CTGF, which were upregulated in the kidney from diabetic mice, were reduced in the kidney from diabetic mice injected with MGC10. These results show that MGC10 is effective to reduce the expression of lnc-MGC and miR-379 cluster miRNAs and restore targets and inhibits profibrotic genes even in diabetic mice.
- PAS staining showed mesangial expansion and increased glomerular size in diabetic mice compared to that in non-diabetic mice and those were reduced in diabetic mice injected with MGC10 (
FIGS. 18A-18C ). Those results suggest that MGC10 can prevent glomerular fibrosis and hypertrophy in diabetic mice. Regarding to ER stress, IHC of EDEM3, a target of miR-379, showed the significant decrease in kidney glomeruli from diabetic mice and that was restored in that from diabetic mice injected with MGC10 (FIGS. 18D-18E ). Those results demonstrate that MGC10 inhibits miR-379 and restore the EDEM3 and suppress the ER-stress in diabetic kidney. Serum profiling of those mice showed no significant difference in liver or kidney toxicity by MGC10 injection. - To test if miR-379 cluster is regulated by the same way even in human cells, human mesangial cells (HMC) was purchased from Lonza and treated with TGF-β or HG. Although genomic sequence of the miR-379 cluster region is conserved from human to mouse, because there are some minor mismatches in the genomic sequences, the expression of human version of lnc-MGC (hlnc-MGC) was examined in HMC by PCR using human specific primers. Similar to MMC, the expression of hlnc-MGC and miRNA-379 cluster miRNAs was increased by TGF-β or HG even in HMC although miR-882 (outside of miR-379 cluster) showed no significant difference. Decrease of some targets and increase of pro-fibrotic genes were confirmed in HMC.
- Because target sequence in human of MGC10 has two base mismatches, human version of MGC10 (HMGC10) was designed based on human sequence. Basic chemistry was the same as mouse version of MGC10. The condition of transfection was optimized and D33 was the best (regarding viability and transfection efficiency). hlnc-MGC and miR-379 cluster miRNAs were reduced by transfection of HMGC10 in HMC, suggesting that the same strategy can be useful to suppressed cluster miRNAs in human cells and may be useful to treat DN patients.
- Next, whether HMGC10 can inhibit the effects by HG or TGF-β in HMC was tested. Human lncMGC expression was significantly inhibited by HMGC10 even after TGF-β treatment (
FIG. 19A ). Similar trends were observed in the expression of miR-379, miR-495 and miR-377 but not miR-822 which is out of miR-379 cluster, suggesting that inhibition of hlncMGC (host RNA) by HMGC10 resulted in reduction of the expression of miRNAs in the cluster in HMC treated with TGF-β (FIGS. 19A-19B ). Targets (EDEM3, CPEB4, Pumilio2 and CUGBP2) of the cluster miRNAs were also examined and reduction of target expression was attenuated by HMGC10 treatment in HMC treated with TGF-β (FIGS. 19C and 19E ). Induction of profibrotic genes (TGF-b1, COL1A2, COL4A1, FN1 and CTGF) by TGF-β was also attenuated by HMGC10 in HMC (FIGS. 19D and 19F ). Those results suggest that reduction of hlncMGC by HMGC10 suppressed the expression of miR-379 cluster miRNAs and restored the expression of targets and also inhibited the expression of profibrotic genes in HMC even after treatment of TGF-β. Similar to TGF-β results, hlncMGC expression was significantly inhibited by HMGC10 in HMC treated with HG. The expression of miR-379, miR-495 and miR-377 but not miR-822 was inhibited by HMGC10 in HMC treated with HG. The reduction of target expression (EDEM3, CPEB4 and CUGBP2) was attenuated by HMGC10 treatment in HMC treated with HG. Induction of profibrotic genes (TGF-b1, COL1A2, COL4A1, FN1 and CTGF) by HG was also attenuated by HMGC10 in HMC. Again, those results suggest that reduction of hlncMGC by HMGC10 suppressed the expression of miR-379 cluster miRNAs and restored the expression of targets and also inhibited the expression of profibrotic genes in HMC even after treatment of HG. These results demonstrated that inhibition of lncMGC by Gapmer is useful also in human cells, which could be applied for human patient therapy. - Expression of miR-379 Cluster miRNAs in Human Kidney Tissue
- Glomeruli of patients with diabetic kidney disease were studied for cluster miRNA expression. Several cluster miRNAs were examined by qRT-PCR and small RNA-sequencing in RNA isolated from micro-dissected glomeruli of kidney biopsies from 46 Southwestern American (Pima) Indians with documented type-2 diabetes. Total RNA was isolated using spin-columns; miRNA expression was quantified using qRT-PCR performed using TaqMan Array Human MicroRNA Card (Applied Biosystems) and small RNA-sequencing. Samples were normalized to geometric mean of reference RNAs. Expression of miRNA precursors was determined in micro-dissected glomeruli of nephrectomy samples using Affymetrix Human Gene 2.1 ST 24-Array. The cluster miRNAs were expressed robustly in these diabetic patient samples with read frequency comparable to miR-192, which are highly enriched in the kidney and mediate important mechanisms in diabetic nephropathy (DN).
- In humans, DN is associated with glomerular hypertrophy, mesangial expansion and loss of podocytes leading to glomerulosclerosis. As described herein, increased expression of the precursors of some of the cluster miRNAs is associated with morphometric parameters of increased glomerular damage in micro-dissected glomeruli of human nephrectomy tissue samples that showed various stages of glomerular pathology similar to early stages diabetic glomerulopathy. These include decreased podocyte density and increased podocyte and glomerular volume as well as mesangial index, suggesting that cluster miRNA expression increases with glomerular damage. These associations suggest that inhibition of cluster miRNAs may also ameliorate human glomerular diseases including DN.
- The experiments in this example show that diabetic conditions (HG) induces TGF-β1 which upregulates miR-379 cluster targeting ER stress regulators and protein synthesis that resulted in hypertrophy and ER stress in mouse kidney related to DN (
FIG. 10 ). A host noncoding RNA (lnc-MGC) is regulated by CHOP which is activated by ER stress. The expression of miRNA-379 cluster depends on the expression of lnc-MGC from its promoter. CHOP siRNA inhibited the induction of lnc-MGC and miR-379 cluster miRNAs and the early features (ECM expression and cellular hypertrophy) of DN. miRNAs in this cluster target several groups of genes, transcription factors, RNA binding proteins regulating gene expression and protein synthesis and ER stress, which results in hypertrophy by increased protein synthesis and fibrosis by accumulation of ECM (profibrotic genes). Induction of those miRNAs was inhibited in the kidney from diabetic CHOPKO mice compared to those from WT mice. Similarly induction of those miRNAs and profibrotic genes by TGF-β was prevented in MMC from CHOPKO mice. A known ER stress inducer TM also induces lnc-MGC and miR-379 cluster miRNAs in MMC through reduction of N-glycosylation of EDEM3. Therefore, induction of lnc-MGC in diabetes may also be mediated by ER stress. Inhibition of those miRNAs by gapmer (MGC10) knocking down lnc-MGC ameliorated DN features (ECM accumulation and glomerular hypertrophy) in the early stage of mouse model of DN. This is the one of the critical mechanisms in DN and potential target to prevent DN. Gapmer inhibiting lnc-MGC (MGC10) can be developed as new drugs to prevent or treat the early stage of DN. - TGF-β or diabetic conditions (as well as ER stress) induce glomerular podocyte dysfunction and death. In order to determine whether MGC10 confers any protection on podocytes in diabetes, podocyte effacement and glomerular basement membrane (GBM) thickness using electron microscopy was assessed (summarized in the bar graph depicted in
FIG. 23A ). Clear protection from diabetes induced podocyte effacement and GBM thickening was observed in diabetic mice treated with the MGC10 compared to control oligo. Cell death measured by Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay was increased in glomeruli of diabetic mice compared to non-diabetic mice, which was attenuated by MGC10 (summarized in the bar graph depicted inFIG. 23B ). These results indicate that MGC10 is effective in reducing the expression of not only lnc-MGC and miR-379 cluster miRNAs in vivo in diabetic mice, but also restores the expression of the cluster miRNA target genes, inhibits profibrotic genes, and prevents glomerular fibrosis, podocyte death, and hypertrophy in diabetic mice. - Diabetes was induced in CHOP KO and control WT mice by administering STZ injections following standard protocols. CHOP KO mice developed diabetes at the same rates as WT mice. Four weeks after diabetes induction, mice were sacrificed. Diabetes-induced mice increased in the key cluster miRNAs, as well as in the lnc-MGC, which occurred in the glomeruli of WT mice, were abrogated in the glomeruli of diabetic CHOP KO mice (
FIG. 8 ). The expression of profibrotic genes Col1α2, Col4α1 and TGF-β1 were also attenuated in glomeruli from diabetic CHOP KO mice compared to diabetic WT mice. Histological analysis showed that PAS staining and glomerular hypertrophy were clearly reduced in diabetic CHOP KO mice compared to diabetic WT. Conversely, glomeruli of CHOP KO mice showed increased expression of key target genes of the cluster miRNAs compared to WT (FIG. 9 ). - MMCs were cultured from non-diabetic WT and CHOP KO mice, with or without TGF-β1. TGF-β1 induced increases in cellular hypertrophy were also ameliorated in MMCs from CHOP KO compared to WT mice. In addition, both the basal and TGF-β1 induced expression of fibrotic genes, Col1α1, Col4α1 and TGF-β1 (relevant to DN) were significantly decreased in MMC from the CHOP KO mice compared to WT. Under these conditions, both the basal and TGF-β1-induced increases in tree key cluster miRNAs and the lnc-RNA-MGC were also ameliorated in MMC derived from CHOP KO mice, compared to MMCs from WT mice.
- Use of TALENs (Transcription Activator-Like Effector Nuclease) to Target the Cluster miRNAs
- TALENs designed and generated to target and delete two genomic regions in the miRNA cluster are used. The first is knockout of miR-379 and the upstream promoter, aimed to interrupt both miR-379 and lnc-MGC expression. The second is to delete the entire mega cluster region. These TALENs are tested in vitro for their readiness to inject directly into mouse embryos, for the rapid and efficient generation of KO mice.
- Diabetic conditions lead to increased transcription of the promoter for the miRNA cluster and host gene lncRNA-MGC
- The CHOP binding sites are cloned and nearby regions of the promoter into luciferase reporters. These constructs are transfected into MMC and treated with or without HG (25 mM), mannitol (19.5 mM) and incubated for 24-72 hours; TGF-β (10 ng/mL is added, and is incubated for 6-24 hours). MMCs pre-treated with or without CHOP specific siRNAs or negative control siRNAs, or MMC from WT versus CHOP KO mice is treated with HG, mannitol or TGF-β1 to determine if losing CHOP reduces promoter transactivation. Chromatin immunoprecipitation (ChIP) assays with a CHOP antibody are used to evaluate CHOP occupancy at the promoter regions in response to TGF-β1 and HG in MMCs. ChIP-qPCRs amplify the desired promoter genomic region and an unrelated control region. Western blots are used to determine CHOP protein levels.
- Diabetic Conditions Increase the Expression of Multiple Mega Cluster Component Key miRNAs, and are Regulated by CHOP
- Wild type (WT) MMCs, MMC transfected with CHOP siRNA and MMCs from CHOP KO mice are treated with HG, mannitol and TGF-β1. RNA is extracted from the cells and the expression of lncRNA-MGC, and all 40 miRNAs within the cluster are systematically examined using primers designed for each of the mature miRNAs. This is supported by data indicating nearly 30 of the cluster miRNAs were induced in MMCs by TGF-β1 but inhibited by CHOP siRNAs.
- Chromatin Features of this Genome Region
- Known and novel transcripts, including miRNAs and many lncRNAs, can be identified by combining RNA-seq with ChIP-seq to identify domains marked with H3K4me3 (promoter mark), H3K36me3 (gene body), and enhancers (H3K4me1). Therefore, antibodies for these three chromatin marks are used to perform ChIP, and then use the ChIP-enriched DNA to sequence (ChIP-seq) this specific genomic region. The results verify whether the lncRNA and miRNAs within the cluster have their own promoters, or if they are transcribed as one unit. Initial observations indicate the presence of an H3K4me1 mark at the promoter start site, but nowhere else along the cluster, and lack of H3K4me3 marks, supporting the hypothesis, there is a single transcription unit. If the ChIP-seq data indicates potential intermediate promoters/transcription, it will be verified by cloning longer transcripts that include the majority of the miRNAs.
- Influence of the Host lncRNA-MGC
- MMCs are pre-treated with a mixture of siRNAs designed to target the lnc-MGC, and then treat them ±TGF-β1 or HG. Determining expression levels for all 40 miRNAs reveals if some or all are down regulated by the siRNAs.
- Validate Targets of miRNAs within the Mega Cluster that are Upregulated by TGF-β1 Predicted Computationally
- Putative target genes that are targeted by multiple miRNAs within the cluster and have functions related to DN include TNRC6B, CUGBP2, CPEB4, Pumilio2 (RNA binding proteins that regulate translation) and BHC80 (a transcription factor) and are common targets of multiple miRNAs including miR-379. Others, including HuR (RNA binding proteins), FoxP2, NF1A, Arid2 (TFs and co-factors) have binding sites in their 3′ UTRs for 9 to 18 of the cluster miRNAs. EDEM3, a protein related to ER-associated degradation, is a miR-379 target with interesting functions. Decreasing EDEM3 through miR-379 will cause unfolded proteins to accumulate resulting in glomerular hypertrophy. Hence ER stress may induce further ER stress through the miR-379-EDEM3 pathway (
FIG. 10 ). - 3′UTRs of the genes listed above are cloned downstream of a luciferase reporter gene. MMCs are transfected with the constructs (sense and antisense), and negative control oligos, and treated with or without TGF-β1, or with mimics or inhibitors of key selected miRNAs that target the genes discussed above (including miR-379, -377 and -495). It is expected that miRNA mimics will decrease, and inhibitors will increase, the luciferase activity of reporters that contain 3′-UTRs from bona fide target genes. The miRNA binding sites in the 3′ UTRs of targets identified experimentally are mutated to verify that the inhibitory effects of the mimics are lost. The protein and mRNA levels of these genes are also determined by Western blotting and RT-qPCR, respectively, as described.
- In Silico Analysis of the Biological Functions of the Predicted Targets of the Mega Cluster miRNAs
- Select candidate megacluster miRNAs is selected, whose expression, according to miRNA-seq, is increased at least 1.5-2-fold under diabetic conditions, e.g., the 28-30 miRNAs identified in the studies. mRNA expression profiles induced by TGF-β1 in MMCs is compared (transcriptome profiling by RNA-seq) with the micro RNA profiles, to identify genes whose mRNA expression patterns inversely correlate with miRNA expression. The 3′-UTRs of these mRNAs (in the USCS and ENSEMBLE genome browsers) is aligned with the differentially expressed miRNAs to identify potential targets. The results are compared with publically available miRNA target prediction sites in TargetScan, miRBase, PicTar and DIANA-microT 3.0. Targets predicted by two or more databases and conserved among rat, human and mouse species are pooled. Particular attention is paid to those miRNA, whose predicted targets have functions related to MC dysfunction and DN. These targets are imported into GO, Pathway analyses software (IPA) and GSEA to determine their potential biological functions, and changes they cause in functional disease networks, which are supported by initial data showing that multiple miRNAs target the same genes related to MC dysfunction.
- Ago-2-CLIP-Seq Based miRNA Target Profiling
- The ClIP-seq (HITS-CLIP) method can generate sequencing data for both miRNAs and their complementary (target) mRNAs bound to Ago2 in RISCs (RNA-inducing silencing complex), genome-wide. Ago2-CLIP-Seq coupled with bioinformatics is used to identify specific megacluster miRNAs and their targets bound to Ago2 in control and TGF-β1-treated MMC. The results reveal mechanisms of action and the in vivo functional roles of the miRNA cluster. MMCs are treated with and without TGF-β1 for 24 hours, then UV crosslinked and immunoprecipitated with Ago2 antibody. Ago2 associated mRNAs and miRNAs are isolated, transcribed into cDNAs, and libraries prepared for small and regular RNAs for sequencing (Iluminia). From the smRNA-seq CLIP data, the abundance of each mouse miRNA (miRBase v20) in each sample is determined by processing the raw reads. For target mRNA-seq CLIP data, reads in each sample are first aligned to the mouse genome assembly (NCBI GRCm38) using TopHat2.
- Ago2-binding clusters (containing reads that are significantly greater than background signal) are identified using the pooled, uniquely-aligned reads from all samples. Reads are summarized and normalized to obtain Ago2-binding cluster levels in each sample. Ago2 binding clusters across all the samples and replicates for each condition, and regions that differentially bind Ago2 between the two conditions are identified. The CLIP data and potential miRNA target sites predicted using base pair searches and existing tools like TargetScan are analyzed together to identify bona fide miRNA-mRNA interactions in control and TGF-β1-treated MCs.
- In addition, the abundance of each Refseq mRNA is determined by regular RNA-seq of the MC samples without IP, summarized, normalized and compared between the two conditions using Bioconductor package “edgeR.” The miRNA-mRNA interactions are integrated and identified by CLIP assays with the related changes in gene expression to further verify the interactions and reveal the potential effects of up-regulating cluster miRNAs on target gene expression levels. Furthermore, the potential functions of target mRNAs is determined with respect to DN using in silico analyses, including GO, WA, network and motif analysis of the identified targets. Mega cluster miRNAs whose expression was co-modulated, or mega cluster target genes that contain multiple, closely related miRNA binding sites, are also identified by comparing data obtained under the two conditions. The expression levels of target mRNAs and corresponding proteins is assessed by qPCR and Western blots respectively.
- Functional Roles of Candidate Megacluster miRNAs tat Respond to TGF-β1/HG and their Targets in MC Dysfunction
- “Gain of function” and “loss of function” approaches are used. MMCs are transfected with oligonucleotide mimics, inhibitors of candidate miRNAs (miR-379, -495, -377), or NC oligos to determine whether manipulating the levels of their putative target genes can influence TGF-β1 and HG responses. At 48 to 72 hours post-transfection, the expression of miRNA target genes, fibrosis and hypertrophy related genes and proteins induced by TGF-β1/HG is determined by RT-qPCR and Western blotting. Cellular hypertrophy, oxidant and ER stress markers are assayed. Similarly, the gain and loss of function of key target genes (including EDEM3, CUGB2, Tnrc6, BHC80) are tested.
- Role of CHOP and lncRNA-MGC on the Expression of miRNA Targets
- The down-regulating of target genes, which augments DN pathogenesis is tested by determining that CHOP and lncRNA-MGC drive the expression of the miRNA cluster. The effect of CHOP siRNA and lncRNA-MGC siRNAs on the expression of the same miRNA targets, and potential new targets identified by CLIP-seq is determined in control and TGF-β1-treated MMCs. Targets are also examined in glomeruli and MMC derived from CHOP KO and WT mice.
- Dysregulation of key megacluster miRNAs and their targets in mouse models of DN
- miRNAs and their targets identified in MCs in vitro are regulated in mouse models of T1D- and T2D-associated DN in vivo using: 1) STZ-injected T1D mouse models of DN in which increases in
expression f 30 of the cluster miRNAs was observed, 2) Male T2D leptin receptor deficient db/db mice (Strain BKS. CG-m+/+lepr db/J) at 10-14 weeks of age (101-103). db/db mice are obese, insulin resistant and diabetic by 6-8 weeks, and develop renal dysfunction by 10-12. After confirming hyperglycemia (glucose >300 mg/dL), db/db mice are compared with age-matched controls (db/+, glucose <150 mg/dL). 3) Akita T1D mice in the DBA2J background, which develop features of DN that are more overt than the STZ model. 4) Mice diet-induced obese (DIO) mice (C57BL/6J) on 14 week high fat diets (60 kcal percent fat), and controls on standard diets. DIO mice are insulin resistant, have mild hyperglycemia, elevated triglycerides and fibrosis/inflammation in glomeruli. Blood pressure, changes in physiology (blood glucose, urinary protein, albumin, creatinine), and the histology and morphology of the renal cortex are monitored regularly and at sacrifice. At the end of the indicated time periods, kidneys are dissected from all the mice, and cortical tissues and glomeruli isolated, then either flash frozen for RNA/protein extraction, or used to prepare MMCs. RT-QPCR is used to compare the basal levels of the miRNAs and their candidate target genes in glomeruli. - Reduced Levels of Mega Cluster miRNAs and Lnc-MGC in CHOP-KO Mice; Protection (CHOP KO Mice) from DN Development
- CHOP KO mice and their controls are made diabetic by STZ injections. At 4, 12 and 16-20 weeks post-diabetes development, key features of DN are assessed in these mice. The expression levels of fibrotic genes, TGF-β1, 40 of the mega cluster miRNAs, and lnc-MGC, in glomeruli are determined at each time point. At least 10 mice per group are studied per time point and experiments are performed in triplicate.
- Treating T1D Mice with LNA Anti-miR-379 Alters Course of DN, and LNA-Gapmers that Target the Lnc-MGC
- LNA modification has several advantages, including less toxicity, lower dosing and efficient targeting. LNA-modified anti-miR-379 is designed, and the control LNAs target miR-239b, which is expressed in Caenorhabditis elegans. To target lnc-MGC in vivo Gapmer technology is adopted/used. LNA™ longRNA GapmeRs are newly available antisense oligos that are used to functionally analyze mRNAs and lncRNAs. They contain a central stretch (gap) of DNA monomers flanked by blocking of LNA-modified nucleotides (http://www.exiqon.com/gamper). The LNA blocks increase the oligos' target affinity and nuclease resistance and the DNA gap induces RNase H cleavage of the target RNA after binding. The gapmers are 14-16 nucleotides in length and are fully phosphorothioated. Exiqon's advanced design algorithms design the most potent LNA™ longRNA GapmeRs that have minimal off-target effects and high success rates. LNA-anti-miR-379 or LNA-anti-lnc-MGC are injected subcutaneously twice weekly into control and STZ-injected DBA2J mice, which develop more sever DN than C57BL6 mice. The progression of key structural, histological and molecular features of DN is followed for up to 20 weeks as described. The anti-miR-379 and anti-lnc-MGC are evaluated in these in vivo translational studies.
- To study the function of miR-379 in vivo, miR-379 knockout (KO) mouse was generated. The genome editing using the RNA-guided Cas9 nucleases from the microbial CRISPR (clustered regularly interspaced short palindromic repeat)-Cas systems was used to generate gene knockout mouse. A paired nickase strategy was used for engineering a system to ameliorate off-target activity. Paired nicking method can reduce off-target activity by 50- to 1,500-fold in cell lines and to facilitate gene knockout in mouse zygotes without sacrificing on-target cleavage efficiency.
- A double nickase strategy was used to delete mouse miR-379 genomic region with less off-target. Five guide RNAs, three sense (S1, S2, and S3) and two antisense (AS1 and AS2) were designed (shown in
FIG. 11B ). Positions and actual sequences of oligonucleotides to construct expression vectors (e.g., PX461, EGFP; PX462, or Puromycine (PX461 and PX462 are plasmid names; the double strand DNA made from designed and synthesized sense and antisense oligos were cloned into the plasmid vectors. The guide RNAs are expressed from the plasmids. PX461 has EGFP gene to monitor the transfection by GFP. PX462 has Puromycine resistance gene to select the cells by drug (Puromycine) resistance) are listed below. - Potential Targets
-
S1 (SEQ ID NO: 27) CCTGAAGAGATGGTAGACTATGG S1S (SEQ ID NO: 28) CACCgCCTGAAGAGATGGTAGACTA S1AS (SEQ ID NO: 29) AAACTAGTCTACCATCTCTTCAGGc S2 (SEQ ID NO: 30) GATGGTAGACTATGGAACGTAGG S2S (SEQ ID NO: 31) CACCgGATGGTAGACTATGGAACGT S2AS (SEQ ID NO: 32) AAACACGTTCCATAGTCTACCATCc S3 (SEQ ID NO: 33) TGTTTTTGACCTATGTAACATGG S3S (SEQ ID NO: 34) CACCgTGTTTTTGACCTATGTAACA S3AS (SEQ ID NO: 35) AAACTGTTACATAGGTCAAAAACAc AS1 (SEQ ID NO: 36) CCTATGTAACATGGTCCACTAAC AS1S (SEQ ID NO: 37) CACCgGTTAGTGGACCATGTTACAT AS1AS (SEQ ID NO: 38) AAACATGTAACATGGTCCACTAACc AS2 (SEQ ID NO: 39) CCACTAACTCTCAGTATCCAATC AS2S (SEQ ID NO: 40) CACCgGATTGGATACTGAGAGTTAG AS2AS (SEQ ID NO: 41) AAACCTAACTCTCAGTATCCAATCc - In the above sequences, S1 is one of the target sequences. S15 is synthesized oligonucleotides for sense strand with extra 5′ overhang (CACC) for cloning. S1AS is synthesized oligonucleotides for antisense strand with extra 5′ overhang (AAAC) for cloning. S1S and S1AS are complimentary and annealed double strand DNA (S1S/S1AS) has 5′ overhang for cloning. Small “g” is transcription start site in the expression vector. Likewise, in the remaining target sequences listed above.
- Using TCMK cells (mouse kidney cell line) in vitro, activity of genome editing at miR-370 locus was tested with several combinations of those guide RNAs (sense and antisense). Since the combination S2 and AS1 showed the best activity, this combination was injected into fertilized eggs to make mutant mice.
- Two strategies are used to inject guide RNAs. First, guide RNAs are injected into pronuclei of fertilized eggs with plasmids expressing guide RNAs and nickase. Second, the guide RNA is transcribed in vitro and nickase RNA is injected into cytoplasm of fertilized eggs. The first strategy required injecting the same plasmids used for cell line transfection in vitro. For the second strategy, T7-transcribed guide RNAs were made. For this purpose, guide RNA part in the plasmids was amplified with primers with T7-promoter and reverse primer for guide RNA (below).
-
T7-S2 (SEQ ID NO: 42) TTAATACGACTCACTATAGGGATGGTAGACTATGGAACGT T7-AS1 (SEQ ID NO: 43) TTAATACGACTCACTATAGGGTTAGTGGACCATGTTACAT gRNA-R (SEQ ID NO: 44) AAAAGCACCGACTCGGTGCC - The amplified PCR products were used as template for in vitro transcription of guide RNAs using T7 in vitro transcription kit. Seven mice were obtained from plasmid injection and fourteen mice were obtained from RNA injection experiments. The short deletion of miR-379 genomic region was tested by fragment analysis in the PCR fragment amplified from tail DNA.
- Deletion found in 8F was 36 bp at miR-379 locus.
FIG. 20A-B shows the 36 base-pair deletion in the miR-379 locus of a mouse generated using the CRISPR/CAS9 system described in this disclosure. - A colony of mice possessing the 8F deletion was generated by crossing heterozygotes to produce homozygotes. The colony was expanded and mice were used for characterization of miR-379 knockout as well as for experiments of
type 1 diabetes (STZ-induced) and high fat diet (HFD). Kidney mesangial cells (MC) from three miR-379 KO mice were cultured in vitro and expression of miR-379 was significantly reduced compared to MC from wild type mice (FIG. 21A ). One of the targets of miR-379 was confirmed significantly increased in miR-370K0 mice compared to MC from wild type mice (FIG. 21B ). These mice were also used for in vitro experiments in diabetic conditions (high glucose, TGF-β, and other treatments. - Another method to stop the transcription of lnc-MGC (miR-379 cluster) was also established, as depicted in
FIG. 22 . For replacement of miR-379 region with poly(A) signal sequence, ˜200 bases oligonucleotide was designed (below) which includes 5′ and 3′ homologous sequences to miR-379 region (underline) and minimum BGH poly(A) sequence in the middle (italics). DNA ligase inhibitor (SCR7) was also used to enhance recombination. - Minimum bGH polyA (52 Bases)
-
[SEQ ID NO: 72] GTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTA GGTGTC
Any available poly(A) sites from any of the mammalian transcripts can be used as well. -
- For the replacement, ˜100 eggs were injected with Cas9 nickase mRNA, two guide RNAs (S2 & AS1) and SCR7 (ligase inhibitor inhibiting end joining and enhancing replacement). Twenty two (22) mice were born and twenty-one (21) mice survived. By PCR screening, five founders were identified as four full insertion (7F, 9M, 10M, 18M) and one partial insertion (8F). These mice were crossed with wild-type B6 mice and confirmed replacement. The line with partial insertion was designated as 51536 and full insertion was S1543. These lines were expanded for further experiment. The method to insert poly(A) signal are applicable to stop any kinds of transcripts (coding or noncoding) if guide RNAs are designed for specific targets.
- Because the disclosed CRSPR-CAS system works to delete (inhibit) miR-397 cluster in mouse tissue, miR-379 cluster in human patients is inhibited by the same strategy. Therefore, human versions of guide RNAs for miR-379 region were designed (below). Six guide RNAs (4 sense (S) and 2 antisense (AS)) were designed. Positions and actual sequences of oligonucleotides for guide RNAs on human miR379 [SEQ ID NO: 79] are shown below:
- Design of Human miR379 guide RNAs
- Sequences of potential targets (e.g., 51 below) and sequences of oligos for cloning (e.g., S1S and S1AS) are listed below (the oligos for cloning are listed below the target sequences):
-
[SEQ ID NO: 80] S1: TTCCGTGGTTCCTGAAGAGATGG [SEQ ID NO: 120] S1S: CACCgTTCCGTGGTTCCTGAAGAGA [SEQ ID NO: 121] S1AS: AAACTCTCTTCAGGAACCACGGAAc [SEQ ID NO: 27] S2: CCTGAAGAGATGGTAGACTATGG (same as mouse S1) [SEQ ID NO: 28] S2S: CACCgCCTGAAGAGATGGTAGACTA [SEQ ID NO: 29] S2AS: AAACTAGTCTACCATCTCTTCAGGc [SEQ ID NO: 30] S3: GATGGTAGACTATGGAACGTAGG (same as mouse S2) [SEQ ID NO: 31] S3S: CACCgGATGGTAGACTATGGAACGT [SEQ ID NO: 32] S3AS: AAACACGTTCCATAGTCTACCATCc [SEQ ID NO: 82] S4: GATTTCTGACCTATGTAACATGG [SEQ ID NO: 122] S4S: CACCgGATTTCTGACCTATGTAACA [SEQ ID NO: 123] S4AS: AAACTGTTACATAGGTCAGAAATCc [SEQ ID NO: 81] AS1: CCGTGGTTCCTGAAGAGATGGTA [SEQ ID NO: 124] AS1S: CACCgTACCATCTCTTCAGGAACCA [SEQ ID NO: 125] AS1AS: AAACTGGTTCCTGAAGAGATGGTAc [SEQ ID NO: 27] AS2: CCTGAAGAGATGGTAGACTATGG (same target as S2) [SEQ ID NO: 126] AS2S: CACCgCCATAGTCTACCATCTCTTC [SEQ ID NO: 127] AS2AS: AAACGAAGAGATGGTAGACTATGGc - S1, S2, S3, S4, AS1, and AS2 are sequences of potential targets. Sequences of oligos for cloning are under the each target sequences. For example, S1S is sequence of sense oligo for S1 and S1AS is sequence of antisense oligo for S1. They are designed for constructing expression vectors for miR-379 target genes (e.g., PX461, EGFP; PX462, or Puromycine (PX461 and PX462 are plasmid names; the double strand DNA made from designed and synthesized sense and antisense oligos were cloned into the plasmid vectors. The guide RNAs are expressed from the plasmids. PX461 has EGFP gene to monitor the transfection by GFP. PX462 has Puromycine resistance gene to select the cells by drug (Puromycine) resistance). Possible combinations include: S1-AS2, S2-AS1, S3-AS1, S3-AS2, and S4-AS2. Additional sets of possible combinations include S1S-S1AS, S4S-S4AS, AS1S-AS1AS, AS2S-AS2AS. Delivery of plasmids expressing these guide RNAs and CAS9 nickase (or other CAS9 derivatives, for example, fusion with repressor) into human kidney reduces human lnc-MGC and miRNA-379 cluster and prevents DN.
- While the disclosure has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the disclosure following, in general, the principles of the disclosure and including such departures from the present disclosure within known or customary practice within the art to which the disclosure pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the appended claims.
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/985,779 US20200407721A1 (en) | 2015-05-26 | 2020-08-05 | Compounds of chemically modified oligonucleotides and methods of use thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562166533P | 2015-05-26 | 2015-05-26 | |
US15/163,816 US10787664B2 (en) | 2015-05-26 | 2016-05-25 | Compounds of chemically modified oligonucleotides and methods of use thereof |
US16/985,779 US20200407721A1 (en) | 2015-05-26 | 2020-08-05 | Compounds of chemically modified oligonucleotides and methods of use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/163,816 Division US10787664B2 (en) | 2015-05-26 | 2016-05-25 | Compounds of chemically modified oligonucleotides and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200407721A1 true US20200407721A1 (en) | 2020-12-31 |
Family
ID=57397167
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/163,816 Active US10787664B2 (en) | 2015-05-26 | 2016-05-25 | Compounds of chemically modified oligonucleotides and methods of use thereof |
US16/985,779 Pending US20200407721A1 (en) | 2015-05-26 | 2020-08-05 | Compounds of chemically modified oligonucleotides and methods of use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/163,816 Active US10787664B2 (en) | 2015-05-26 | 2016-05-25 | Compounds of chemically modified oligonucleotides and methods of use thereof |
Country Status (1)
Country | Link |
---|---|
US (2) | US10787664B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210310000A1 (en) * | 2018-08-17 | 2021-10-07 | City Of Hope | Compounds of chemically modified oligonucleotides and methods of use thereof |
CN112111491A (en) * | 2020-08-27 | 2020-12-22 | 中国科学院生物物理研究所 | Increasing mitochondrial RNA interference using mitochondrially targeted Argonaute proteins |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015063081A2 (en) * | 2013-10-29 | 2015-05-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Micrornas modulating the effect of glucocorticoid signaling |
US20210310000A1 (en) * | 2018-08-17 | 2021-10-07 | City Of Hope | Compounds of chemically modified oligonucleotides and methods of use thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
FR2588189B1 (en) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
WO2003056030A2 (en) * | 2001-11-08 | 2003-07-10 | The Johns Hopkins University | Methods and systems of nucleic acid sequencing |
WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US20070155685A1 (en) * | 2004-02-27 | 2007-07-05 | Karl-Hermann Schlingensiepen | Pharmaceutical composition |
JP2008501693A (en) * | 2004-06-03 | 2008-01-24 | アイシス ファーマシューティカルズ、インク. | Double-stranded composition with individually regulated strands for use in gene regulation |
US8178503B2 (en) * | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
JP5473594B2 (en) * | 2006-04-13 | 2014-04-16 | アルコン リサーチ, リミテッド | RNAi-mediated inhibition of histamine receptor H1-related conditions |
-
2016
- 2016-05-25 US US15/163,816 patent/US10787664B2/en active Active
-
2020
- 2020-08-05 US US16/985,779 patent/US20200407721A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015063081A2 (en) * | 2013-10-29 | 2015-05-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Micrornas modulating the effect of glucocorticoid signaling |
US20210310000A1 (en) * | 2018-08-17 | 2021-10-07 | City Of Hope | Compounds of chemically modified oligonucleotides and methods of use thereof |
Non-Patent Citations (5)
Title |
---|
Crooke et al. 2008. Mechanisms of Antisense Drug Action, an Introduction. Chapter 1 in Antisense Drug Technology: Principles, Strategies, and Applications, 2nd ed, S.T.Crooke, ed. Boca Raton, FL: Taylor and Francis (Year: 2008) * |
Kanwar et al. 2011. A Glimpse of Various Pathogenetic Mechanisms of Diabetic Nephropathy. Annu. Rev. Pathol. Mech. Dis. 6:395–423 OF RECORD ON IDS (Year: 2011) * |
Roberts et al. 2020. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 19: 673-694 (Year: 2020) * |
Soifer et al. 2011. Chapter 25: Silencing of Gene Expression by Gymnotic Delivery of Antisense Oligonucleotides. Pp. 333-346 in Functional Genom. Method Protocol 2nd edition, M. Kaufmann and C. Klinger, eds. Methods in Molec. Biol. Vol. 815. NY, NY: Humana Press (Year: 2011) * |
Villeneuve and Natarajan. 2010 The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol 299:F14–F25 (Year: 2010) * |
Also Published As
Publication number | Publication date |
---|---|
US10787664B2 (en) | 2020-09-29 |
US20160348105A1 (en) | 2016-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012322788B2 (en) | Micrornas in neurodegenerative disorders | |
JP5971948B2 (en) | Treatment of vascular endothelial growth factor (VEGF) -related diseases by suppression of natural antisense transcripts against VEGF | |
KR101722541B1 (en) | Treatment of tristetraproline(ttp) related diseases by inhibition of natural antisense transcript to ttp | |
KR101865433B1 (en) | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua | |
JP5923306B2 (en) | Treatment of tumor suppressor gene-related diseases by suppression of natural antisense transcripts against tumor suppressor genes | |
JP2021513861A (en) | CAMK2D antisense oligonucleotide and its use | |
JP5978203B2 (en) | Treatment of fibroblast growth factor (FGF21) fibroblast growth factor FGF21) related diseases by inhibition of natural antisense transcripts against FGF21 | |
EP2516647B1 (en) | Molecule for treating an inflammatory disorder | |
KR20120047268A (en) | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) | |
CN102712927A (en) | Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1 | |
SG190355A1 (en) | Microrna inhibitors comprising locked nucleotides | |
CN102482672A (en) | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene | |
TW201202418A (en) | Treatment of Methionine Sulfoxide Reductase A (MSRA) related diseases by inhibition of natural antisense transcript to MSRA | |
TW201209163A (en) | Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3 | |
US20200407721A1 (en) | Compounds of chemically modified oligonucleotides and methods of use thereof | |
WO2013134403A1 (en) | Method of treating neurodegenerative diseases with microrna regulators | |
EP2663323B1 (en) | Methods targeting mir-128 for regulating cholesterol/lipid metabolism | |
US20210310000A1 (en) | Compounds of chemically modified oligonucleotides and methods of use thereof | |
EP2608812A2 (en) | Methods targeting mir-33 micrornas for regulating lipid metabolism | |
WO2022026648A1 (en) | Inhibition of incexact1 to treat heart disease | |
KR20170058979A (en) | Allele-specific therapy for huntington disease haplotypes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: CITY OF HOPE, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NATARAJAN, RAMA;KATO, MITSUO;REEL/FRAME:064061/0037 Effective date: 20150630 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |